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Variation-aware algorithms for cancer genome
analysis
Eric T. Dawson
In this thesis, I explore variation-aware algorithms for analyzing cancer genomes. The
scientific community has extensively catalogued millions of mutations present in cancer
cells. This information is rarely used during read alignment and variant calling because
of a lack of algorithms for doing so. Rediscovering these variants wastes significant
computational time and negatively impacts the sensitivity of detection, motivating the
development of new solutions.
The variants in malignant cells can arise from a number of genetic and environmental
sources. In the years after the Chernobyl nuclear disaster, thousands of individuals in
areas where radionuclides were deposited developed thyroid cancer. The excess relative
risk of thyroid cancer has been estimated to be between fifteen and thirty fold higher
following 131I exposure. In Chapter 2, I analyze more than 300 thyroid cancer cases
from children and young adults exposed to ionizing radiation from increased levels of
131I originating from Chernobyl. I characterize the mutational landscape of these tumors
across the variant size spectrum and compare it to sporadic thyroid cancer cases. I
investigate possible signs of radiation exposure in the genome, especially large balanced
structural variants and small indels.
In Chapter 3, I develop methods for working with structural variants in variation
graphs. Variation graphs have been shown to reduce reference bias and improve alignment
to variant sites, though previous work has primarily focused on variants less than fifty
base pairs in size. I describe the tradeo s of various representations of large variants in
the graph. I then develop several methods for genotyping and calling large variants in
graphs. I construct graphs of both germline and somatic variation and describe how to
work with these structures. I develop a method for fast structural variant genotyping
using graph mappings and show that this significantly outperforms standard structural
variant callers for certain types of variation. I describe how to locate structural variant
mismapping signatures on variation graphs and how variation graphs can improve calling
of structural variants.
Lastly in Chapter 4, I demonstrate a new application of an alignment-free algorithm
for genome analysis. I describe a MinHash toolkit for viral coinfection analysis and its
application to Human Papillomavirus (HPV) samples. This toolkit is able to classify
iv
individual reads from multiple sequencing technologies and accurately detect clinically-
relevant HPV coinfections. Finally, I dicuss how these approaches can be applied in other
genomic analyses.
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Chapter 1
Introduction
Cancer is a disease of the genome, and in comparison to normal human cells the cancer
cell population harbors significant amounts of variation and heterogeneity. This variation
remains di cult to analyze, in part because of our reliance on the linear reference genome.
Structural variants remain particularly di cult to analyze because of their size. While
other fields are transitioning to data structures that can encode population variation and
the reference together as a pangenome, cancer genomics has largely lagged behind.
In this thesis, I describe new methods for improving our understanding of genomic
variation in cancer genomes, especially large-scale genomic alterations, by adapting
and extending data structures and algorithms from analogous problems in other fields.
Chapter 2 of this thesis is devoted to the analysis of hundreds of papillary thyroid
carcinoma samples from the Chernobyl Tissue Bank. It is known that radiation induces
double-strand breaks in DNA and that radiation exposed tumors often carry large
structural variants and other genomic markers of radiation exposure. I discuss methods
for detecting structural variation using variation graphs in Chapter 3. Variation graphs
provide a succinct encoding of both a reference genome and variation, which often comes
from previous studies. In Chapter 4, I discuss a toolkit for detecting viral coinfections
that uses a variation-aware exact kmer matching strategy.
In this chapter I provide background for my work. I cover the human genome and
the many mutations found in cancer genomes. I will discuss structural variation and
challenges in detecting large variants. I describe how variation-aware algorithms can
improve genomic analyses and discuss the use of one type of variation-aware algorithm,
the graph genome, in detail. I describe mixtures of genomes. Lastly, I discuss radiation-
associated papillary thyroid carcinoma in the context of the Chernobyl nuclear disaster.
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1.1 The Cancer Genome
The word cancer comes from the Greek word for crab, highlighting the crustacean-like
appearance of a solid tumor invading surrounding tissue using finger-like projections. A
state of malignancy is characterized by a cellular population having achieved su cient
evolutionary advantage to invade and outcompete normal tissues. Much like Darwinian
evolution in organismal populations, somatic mutations are acquired randomly and then
filtered via natural selection to increase the allele frequency of modifications conferring
higher fitness [5]. Such changes arise in the genome and alter cellular processes by
modifying RNA and protein expression and function. Malignancies may acquire changes
that can increase the mutation rate (e.g., by increased genomic instability) or confer a
selective advantage, such as increased metabolism. Changes may either be a gain-of-
function, in which case the a ected gene is termed an "oncogene," or loss-of-function, in
which case the a ected gene is termed a "tumor suppressor."
Cancer a icts many eukaryotic organisms, although the remainder of this work will
focus on cancer in Homo sapiens. Evidence of cancer in humans has been recorded in
literature for at least 3000 years [6]. Our understanding of it as a genomic disease has
only emerged in roughly the last four decades, though the idea that it originates in the
genome was proposed over 100 years ago [7, 8].
Since the advent of short-read sequencing, cancer genomes have become common
subjects of sequencing studies. While sequencing has largely remained within the research
space, clinical sequencing has become a major priority for health organizations both for
hereditary cancer predisposition screening and for targeted precision medicine. Such
sequencing may well become routine within the next ten years.
When searching for disease-relevant mutations, short sequencing reads are mapped
to the human reference genome. Di erences between this reference and the reads are
determined through a process known as variant calling. These variants are then assessed
to determine whether they may be contributing to disease. This makes understanding the
underlying genome crucial to inferences about how the variants within a tumor contribute
to the cancerous state.
1.1.1 Reference genomes
Reference genomes fulfill several essential functions that enable contemporary genomic
analysis. Most importantly, a reference provides a common coordinate system for genomes
from the same species. In the same way, a linear haploid reference provides a sequence
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context for variation. This implies a set of states that define variants, such as "reference"
and "non-reference." Together, these two roles allow the description of intra- or inter-
organismal variation in a concise and consistent manner using a single grammar. Next,
a reference genome serves as a representative for its species of origin when comparing
genomes of di erent species. This simplifies processes such as homolog comparison.
Lastly, a reference genome provides a basis for further study of organisms within a species.
Genome assembly of every individual has historically been prohibitively expensive. A
reference genome provides a prior which may be used to sca old assemblies, align reads,
and call variants via resequencing rather than de novo assembly.
1.1.2 The Human Genome
The human genome is composed of approximately three billion basepairs organized into
23 pairs of chromosomes. This karyotipic structure is largely conserved among healthy
humans. Each individual carries twenty-two pairs of autosomes and one pair of sex
chromosomes. By the middle of the 19th century these structures were observable with
microscopy, although only the gross structure was discernable. By the middle of the
20th century changes in chromosome structure were implicated in disease, such as the
canonical Philadelphia chromosome (a reciprocal translocation t(9;22)(q34;q11)) observed
in chronic myelogenous leukemia [9] and the complete or near-complete duplication of
chromosome 21 in Down Syndrome [10].
Techniques such as chromosome painting, multicolor flourescence in-situ hybridization
(mFISH), and spectral karyotyping (SKY) later provided increased cytogenetic resolu-
tion, allowing the detection of events smaller than chromosome arms. Flourescence in
situ hybridization followed from early experiments which tagged DNA with radioactive
labels. The technique allowed tagging of specific sequences within a chromosome with a
flourescent tag visible by microscopy. mFISH expanded this technique by using multiple
flourescent color tags. The use of multiple tags enables the detection of intrachromoso-
mal translocations or inversions when multiple tags fall on the same chromosome and
interchromosomal events when they fall on separate chromosomes. This approach was
combined with a defined band multiplexing scheme in spectral karyotyping, which allows
detection of multiple kinds of cytogenetics events. However, these methods cannot detect
changes much smaller than several hundred kilobases. Such a coarse-grained picture
hides a vast array of genomic modifications that vary dramatically in both size and e ect.
The development of sequencing technologies (specifically the Maxam-Gilbert [11]
and Sanger [12] methods) enabled examination of genomes at basepair resolution over
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longer stretches of DNA. Maxam-Gilbert relied on base-specific cleavage of the DNA. The
Sanger method used termination of DNA chain extension by incorporation of ddNTPs;
the Sanger method would become the dominant technique over the next twenty years
largely because it was easier to scale and required fewer hazardous chemicals. These early
techniques were automated and commoditized heavily by the mid 1990s. Adaptations
in the chemical processes, particularly the invention of removable base terminators and
pyrosequencing, led to the development of high throughput short-read shotgun sequencing.
Shotgun sequencing would be used to complete the majority of the human genome.
The first draft of the human reference took thirteen years and three billion US dollars
to complete [13]. A "complete" version containing 99% of euchromatic sequence (but
with many gaps) was announced in 2003. It was decided early on in the study that the
reference would be a composite of several individuals so that no individual would be the
"gold-standard" human being. In total, sequence from many donors was used to create the
reference, though nearly 70% came from a single individual [13]. It was also decided that
the reference should be haploid, representing only one-half of the chromosomal material
in a typical human cell. This made the reference a standard unit of comparison with
only one allele per site and has made it easier to write algorithms against a simpler data
structure [14]. However, it also means the reference represents neither the full genome of
a single individual nor an average of humanity.
1.1.3 Human genome resequencing studies
The second generation of human genome studies leveraged the human reference to help
characterize the diversity present within and between human populations, predominantly
focusing on single-base substitution variants. The International HapMap Project began
in 2002 with the goal of characterizing small variants in genomes of individuals from
diverse populations and coordinating the deposit of these into a public database [15].
In total, the project reported over one million single-nucleotide polymorphisms (SNPs)
from 269 people of Yoruban, European, Han Chinese, or Japanese descent. HapMap
specifically targeted SNPs with a minor allele frequency > 5% in specific populations as
well as those in linkage disequilibrium (LD), where specific alleles of SNPs are linked
into short blocks between recombination breakpoints. These blocks, called haplotypes,
are composed of runs of SNPs in LD and are often population-specific. SNPs in LD tend
to carry a predictable set of alleles; knowing one or a few marker SNP(s) within the
haplotype block allows one to impute the remaining alleles. With the confirmation of
linkage disequilibrium in the human genome and a catalogue of haplotypes and SNPs,
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the HapMap project enabled researchers to begin assessing which SNPs were associated
with traits and disease phenotypes.
Genome-wide association studies became popular in the mid-2000s as a way to
correlate genomic regions and specific SNPs to phenotype. Although HapMap relied
on the sequenced human reference genome, the individuals in the study were not fully
sequenced. Instead, microarrays were designed that assessed genotypes at specific common
SNPs at regular intervals in the genome. In the case of Phase 1, this interval was 5kb;
Phase 2 dramatically expanded the array to genotype roughly 4.6 million SNPs [16].
HapMap provided a useful if incomplete picture of human genetic diversity, successfully
categorizing the majority of SNPs at > 5% allele frequency [17]. The study could only
assess specific alleles at specific sites because it relied on arrays rather than sequencing.
While sites in-between could be imputed, this process was not as accurate as sequencing
every base. In addition, the HapMap dataset came from only 269 individuals from four
populations. While ambitious for its time, the arrival of a ordable high-throughput
sequencing and a need for more diversity precipitated the need for further studies.
The 1000 Genomes Project used low-coverage sequencing of thousands of individuals
to catalogue a much greater number of variants than HapMap [18]. The use of sequencing
rather than arrays allowed the assessment of more complex variation. In addition to SNPs
the project characterized multi-base insertion-deletion (indel) variants, multi-nucleotide
polymorphisms, and structural variants. The initial release of the 1000 Genomes data in
2012 reported 38 million SNPs, 1.4 million indel variants, and more than 14,000 long
deletions from 1,092 individuals. A later release in 2015 greatly increased this number,
providing a public database of 84 million SNPs, 3.6 million indels, and almost 70,000
structural variants [19, 20].
Multiple projects have extended the pioneering work of HapMap and 1000 Genomes in
surveying human genetic diversity. The Simons Genome Diversity Project sequenced 300
individuals from 142 ethnic groups to find unique variants within these populations [21].
gnOMAD analyzed data from almost 20,000 whole genomes and 200,000 exomes at high
depth by combining data from many studies and processing it in a single workflow [22].
This produced calls for millions of small variants and hundreds of thousands of structural
variants that are polymorphic in human populations [22, 23]. Sequencing studies of
hundreds of thousands of individuals are already underway. The 100,000 Genomes Project
has sequenced 100,000 genomes from 85,000 individuals in the UK. This study focused
on sequencing probands with rare diseases and their families. The UK Biobank study
catalogued genotyping arrays from 500,000 individuals along with rich health information.
1.1 The Cancer Genome 6
Over the course of the next five years, the National Institutes of Health All of Us program
aims to sequence 1 million individuals from diverse backgrounds.
Since its initial release, over 300 million single-nucleotide variants [24], tens of millions
of small insertions and deletions, and around half a million larger structural variants [23]
that di er between individuals and the haploid human reference have been characterized.
We have also determined that significant portions of an individual’s DNA may be absent
from the reference [25, 21] and that our understanding of human genetic variation, while
much improved, remains incomplete. The di erences in our DNA explain much of the
variation in human phenotypic traits as well as the underlying cause of many diseases.
Today, sequencing human-scale genomes has become routine, taking less than a day and
costing roughly $1000. The dramatic drop in the cost of sequencing has led to exponential
growth in the number of genomes sequenced worldwide. This, in turn, has dramatically
improved our understanding of human genetic variation. Despite the reference genome
portraying it as a simplistic, fixed model, our genome is a highly mutable object at both
the individual base level and in its large-scale structure.
1.1.4 Cancer sequencing studies
Cancer resequencing studies began shortly after the completion of the human reference
genome in 2003 [26]. By 2008, multiple groups had published results from whole-
genome sequencing of individual tumors and matched normal tissue [27, 28]. Techniques
for purifying and amplifying the coding DNA of the genome (i.e., the exome) and
improvements in sequencing technology greatly reduced the cost of performing such
analyses for the portions of the genome thought to be most important in cancer. Cancer
sequencing studies also sought to obtain molecular data types not used in population
studies. This included information about methylation, mRNA, miRNA, and protein
abundance.
Major resequencing and multi-omics studies of cancer began around 2008 [29, 30].
The Cancer Genome Atlas sequenced over 11,000 patients during its ten-year timeframe.
The International Cancer Genome Consortium combined this dataset with that of the
UK’s Cancer Genome Project and dozens of other research nodes to generate a set of over
25,000 exome-sequenced somatic pairs. The next generation of studies would focus on
analyzing tumors from across many cancer types, often using whole genome sequencing.
The Pancancer Analysis of Whole Genomes is the largest of these to date, combining
more than 2,800 whole-genome sequenced samples processed on standardized analysis
pipelines [31].
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The cancer sequencing projects of the last twenty years provided valuable insights into
the genomic and molecular signatures of many cancer types. Results from these studies
were collected into databases. The Catalog of Somatic Mutations in Cancer provides an
overview of individual somatic mutations seen across thousands of samples [32]. The
National Cancer Institute’s Genomic Data Commons provides mutation information as
well as raw sequencing data for thousands of samples including those of The Cancer
Genome Atlas project, while the International Cancer Genome Consosrtium maintains
its own data portal with tens of thousands of samples. Together, these studies have
provided invaluable insight into the spectrum of mutations present in the cancer genome,
from single-base substitutions to complex structural variants.
1.2 Mutations in cancer genomes
The mutations observed in cancer cells highlight the genetic plasticity of the human
genome as well as that plasticity’s role in oncogenesis. Germline mutations are present in
all cells of an individual and are passed on between generations. In addition, mutations in
the germline occur in humans at a rate of about 1 ≠ 2 ◊ 10≠8 mutations per basepair per
generation, resulting in tens to hundreds of mutations between the genomes of o spring
and their parents [33].
Cells in the body also acquire mutations relative to the genetic background of the
individual over time [34, 35]. Such mutations are termed "somatic" as they are present
in only a subpopulation of cells in the individual and are not passed on to future
generations via the germline. Both germline and somatic mutations may contribute to
cancer development and span a broad spectrum of size and complexity.
1.2.1 Germline mutations in cancer
The role of germline mutations in cancer was established using pedigree studies. Li
and Fraumeni first described a pattern of inherited cancer predisposition in 1969. Li
and Fraumeni observed four families each with pairs of o spring that had developed
cancer among a collection of nearly 700 medical records. A ected families appeared to
show autosomal dominant patterns of transmission for various cancers of soft tissues.
Such familial cancer patterns strongly supported the notion that cancer is a disease of
the genome as DNA is the molecule of heredity. Later, this inherited cancer syndrome
would be attributed to mutations in P53, a potent tumor suppressor gene. Mutations in
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P53 allow proliferation of cells with acquired genomic instability; over time, these cells
may become neoplastic. The autosomal dominant inheritance pattern of Li-Fraumeni
Syndrome can be attributed to the fact that even individuals heterozygous for loss of
P53 are at increased risk for development of cancer.
Hereditary cancer predisposition need not travel in an autosomal dominant inheritance
pattern, though this is the most common form of inheritance. Xeroderma pigmentsosum
is caused by autosomal recessive mutations in the genes XPC, ERCC2, POLH; the
disease is characterized by extreme sensitivity to UV light and a significantly increased
risk of certain skin cancers. Fanconi anemia provides another example of autosomally-
inherited cancer predisposition where mutations in several genes of the FA DNA repair
pathway lead to increased risk of several types of cancer over patients’ lifetimes.
Mutations in almost 200 genes have since been implicated in hereditary cancer
syndromes [36, 37]. While the vast majority of these are tumor suppressors, there are
proto-oncogenes that may be mutated in hereditary cancer syndromes (e.g. ret in MEN2
syndrome) [38]. Genes may harbor many such predisposition mutations. Of roughly
25,000 mutations cataloged in the BRCA1 and BRCA2 genes, over 4,000 are associated
with a significantly increased lifetime risk of breast or ovarian cancer development
[39]. These mutations are frequent targets of genetic screening because of their high
contribution to increased risk.
Hereditary cancers due to a highly-penetrant germline mutation account for 5-10% of
all cancer cases. Familial clustering without a known predisposition mutation is observed
in as many as 10-15% of other cases [40, 41]. These familiar patterns may not adhere to
strict Mendelian inheritance patterns. Such patterns may be the product of mutations
with low penetrance, interactions caused by similar lifestyles and exposures, or simply
chance clusterings of cancer occurrences.
1.2.2 The interaction between germline and somatic mutation
A model for the interplay between germline and somatic mutations in the genesis of
cancer was proposed by Knudson in 1971 [42]. Knudson observed distinct patterns of
disease in retinoblastoma patients. Retinoblastoma occurrence could skip generations,
suggesting an autosomal recessive model of inheritance. Patients with a family history of
retinoblastoma also presented earlier and often with bilateral disease, but patients with
no family history never displayed bilateral tumors. Knudson assumed that retinoblastoma
was due to the inactivation of a single recessive gene and would require loss of both copies
for retinoblastoma development. In Knudson’s data, bilateral disease fit a model in which
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only a single mutation needed to occur for a patient to acquire retinoblastoma. Unilateral
disease best fit a model requiring two mutations to occur. This prompted Knudson to
propose what became known as the two-hit hypothesis, wherein a second mutation is
acquired somatically and the first may be either somatically acquired or inherited via
the germline. The two-hit hypothesis provided the mathematical foundation for models
of cancer predisposition inheritance via recessive mutation of tumor suppressor genes
followed by somatic inactivation of the remaining functional gene copy.
A set of eight "Hallmarks of Cancer" have been used to describe when a population
of cells has become malignant [43]. The basis of all of these hallmarks lies in genomic
instability (i.e. mutation) of the underlying cellular population. Hanahan and Weinberg
proposed an initial six characteristics that helped provide a framework for understanding
the neoplastic state. Sustained proliferative signaling allows cancer cells to grow unre-
stricted. At the same time, evasion of growth inhibitors prevents suppression of this
unsustained growth. Cancer cells can acquire resistance to cell death signals, meaning that
individual cells may persist longer in the neoplastic state. Cells may exhibit replicative
immortality, producing daughter cells for many generations beyond typical programmed
senescence. Lastly, in a search for resources, cancer cells may invade surrounding tissues
and induce the creation of new blood vessels.
The hallmarks of cancer provide a cell biology framework that facilitates a more
clear-cut definition of neoplastic state. In addition, the hallmarks can often be linked to
specific genomic alterations that promote or inhibit relevant processes. Mutations which
actively contribute to the cancer phenotype are often called "drivers" of the neoplasm.
Much as the driver of a car determines the direction of travel, driver mutations determine
the evolutionary trajectory of the cancer cell population by participating in one or several
of the hallmarks directly.
Cancer cells may harbor hundreds of thousands of mutations compared to the germline
background from which they originate [44]. Mutation rates di er by orders of magnitude
across cancer types and between tumors of the same organ. Pediatric tumors may harbor
only a single clone of cells with less than a dozen mutations [45], while certain melanomas
and breast cancers may harbor multiple subclones with dozens of mutations per megabase.
Some of these populations will harbor multiple driver mutations either in a single clonal
population or across multiple subclones within the tumor [46]. The mutation rate of a
tumor is not an e ective predictor of its growth; however, a higher mutation rate does
increase the risk of treatment resistance and cancer recurrence [47].
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Only a small minority of mutations in cancer cells confer selective advantage. Though
the number varies across tissue of origin, on average approximately five mutations within
a tumor are under positive selection [48, 49]. An even smaller proportion (less than one
per tumor, on average) are under negative selection while the remainder are selected
neutrally. All of these mutations arise randomly due to genomic instability, errors in
repair, or exposure to mutagens [50]. In principle, mutations may occur at any site in
the genome, though mutations at some sites (e.g. those which disrupt essential genes)
are not tolerated by cells. As only 1-2% of the genome encodes protein sequences [51],
mutations will most often fall in non-coding regions.
Mutations which do not confer selective advantage either on their own or in concert
with other mutations have been termed "passengers" to distinguish them from "driver"
mutations which contribute to the cancer phenotype. The total number of passenger
mutations in a given cancer mutation catalog is often two or three orders of magnitude
greater than the number of drivers [49]. It is important to note that under this definition
a mutation need not be su cient or necessary for tumor formation to be considered a
driver. Because neutral passenger mutations may be present in clones with positively-
selected drivers, such mutations may rise in frequency within a given tumor without
conferring a selective advantage. The probability of seeing the same neutrally-selected
mutation at high frequency across tumors from di erent patients is very small, however,
and so observing the same mutation multiple times across a number of tumors is often
considered evidence in favor of that mutation being a driver.
1.2.3 Single nucleotide variants
Single nucleotide variants (SNVs) are common cancer driver mutations and are the
best characterized of the mutational classes. Most single nucleotide driver mutations
reported in previous studies are in coding regions. Single nucleotide substitutions may
be activating or inactivating. The BRAF V 600E mutation is a single-nucleotide change
that is an established driver across many cancer types. BRAF is a protein kinase that
is important in the MAPK signaling pathway, which controls a broad array of cellular
functions involving growth and proliferation. A substitution of glutamic acid for valine at
codon 600 in the protein causes constitutive activation, leading to constitutive signaling
in the downstream MAPK pathway. BRAF V 600E is a primary driver of thyroid cancer,
malignant melanoma, and carcinomas of the lung and colon [52].
There are examples of non-coding SNVs that drive tumorigenesis. Mutations in
the promoter of the TERT telomere reverse transcriptase gene are found across cancer
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types but are especially present in hepatocellular carcninomas. These mutations are the
most frequent genetic alteration in these neoplasms and confer a significant immortality
advantage by preventing telomere shortening. In thyroid cancer, promoter mutations in
the TERT gene are associated with more aggressive tumors but are insu cient to generate
a malignant state [53]. Such mutations, which are insu cient to drive tumorigenesis on
their own but which contribute to more aggressive disease, are sometimes referred to as
"backseat drivers" to distinguish them from the primary driver of a tumor (Gad Getz,
private correspondence).
1.2.4 Indels and multinucleotide variants
Small variants a ecting more than one nucleotide are also common in cancer. Indel
variants are common somatic mutations and can act as drivers. Most tumors will harbor
approximately 1 somatic indel for every 10 somatic SNVs [44]. However, tumors with
mutations leading to microsatellite instability and those with other mutations a ecting
DNA repair can have higher ratios of indels to SNVs [54, 55]. Indels in short tandem
repeats have been implicated as drivers when they occur in specific genes [56].
Indel variants are more di cult to detect than SNVs. This is partially because
alignnment algorithms often penalize gaps more than mismatches, though parameter
tuning can help alleviate this e ect. This is further exacerbated by the fact that indels
are most often located in repetitive regions. Long reads improve indel calling since they
can span the entire repetitive region, though homopolymer runs still present challenges.
Multinucleotide variants (MNVs), in which multiple adjacent bases are substituted but
not inserted or deleted, also occur. Often, one of these variants will be protein-altering
and the second mutation will revert the codon to produce the original amino acid. MNVs
have been shown to occur at roughly 1-3% of the SNV rate in the germline [57]. Somatic
MNV rates vary across cancer types, with lung and skin cancers having five times the
rate of other cancers due to the e ects of tobacco- and UV-induced DNA adducts [58].
MNVs are often deleterious in genes associated with developmental disorders [59] and
can form driver mutations at well known cancer hotspots such as BRAF V 600E [58].
1.2.5 Mutational signatures
Mutations in cancer may arise from a number of mutagenic processes, both exogenous
and endogenous. Some mutagens act through distinct mechanisms which leave defined
patterns of mutation in the DNA. Chemicals such as those in tobacco smoke are well-
1.3 Structural variation 12
established mutagens. So too are energetic particles such as UV light or ionizing radiation.
DNA repair processes, whether acting normally in response to stimulus or when aberrated,
may induce mutations in the cell endogenously.
Many of these processes produce specific mutational profiles, or signatures, in the
genome. Understanding the signature produced by a mutagen can help inform clinicians
about any exposures that may have led to oncogenesis. Mutational signatures may also
be indicators for specific clinical treatments. While more than eighty signatures have
been deciphered many of these have not yet been attributed to an exposure or endogenous
process [44]. There has been significant interest in new methods for detecting signatures
and attributing them to specific mutagens in the last ten years.
Mutational signature extraction relies on dimensionality reduction techniques such as
non-negative matrix factorization [60]. These algorithms are used to generate vectors
that approximately model the mutational patterns of a given exposure (the signature)
and the amount of that signature seen in the genome (the amplitude or dosage). Most
signatures examined so far have been on the 96 trinucleotide contexts of the genome.
Many mutagens leave signatures in these contexts, and they are easy to interpret while
limiting the number of features in the model.
Signatures have been found in higher-order (e.g. pentanucleotide) contexts as well
as by examining features based on microhomology, strandedness, and length of indels
and characteristics of structural variant breakpoints. Today, several dozen signatures
are commonly observed across a range of cancers, many of which can be attributed
to a particular exposure [44]. In addition, an increasing amount of evidence points
to signatures or combinations of signatures caused by non-linear interactions between
mutagens [61]. Signatures for exposure to particular environmental agents have now been
established in human cell lines [62], and as our ability to create single-exposure systems
through gene editing improves we will likely gain even more insight into how mutational
signatures manifest in the genome. Mathematical advances, such as the introduction of
denoising and sparsity-enforcement techniques from the field of signal processing should
also provide improved methods for detection.
1.3 Structural variation
Structural variants are typically defined as any changes in the genome larger than 50
basepairs in size. This definition encompasses one- or multi-breakpoint events as well
as chromosomal abnormalities such as chromothripsis. On average, structural variants
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a ect a much larger number of basepairs within a given individual than do small variants
[19, 63, 64]. Although large structural variants are easily visible by microscopy and were
described early in genomic history, they have not been as well characterized as SNVs
and indels in the modern era. This is largely due to their size relative to sequencing
reads, forcing them to be called heuristically by mismapping signals rather than directly
as small variants are. Reads overlapping either breakpoint of a variant are either
softclipped or split-mapped, and often have lower mapping quality versus reads mapped
in invariant regions. Structural variants also tend to be present in repetitive regions,
further frustrating read mapping and discovery.
1.3.1 Simple structural variants
Simple structural variants (i.e. those that are formed from relatively few breakpoints) can
be divided into several classes. Balanced events do not produce a change in copy number.
Breakpoints may be reciprocal (i.e., DNA strands on either side of the breakpoint are
evenly exchanged) or portions of the genome may be lost during the event. Unbalanced
structural variants produce a change in copy number. Unbalanced structural variant
types include deletions, foreign sequence insertions, and duplications. These vary greatly
in size and aetiology. Foreign sequence insertions such as ALU element movements are
highly polymorphic in human populations.
Balanced events include inversions and translocations. Inversions, while rare in
the general population, occur at a much higher rate in somatic variation [65, 66, 54].
Translocations may place distant parts of the same chromosome together to form new
subchromosomal structures. They may also place portions of sequence from two or
more di erent chromosomes together. These events are again quite rare in the general
population but have been identified frequently in cancer and other diseases.
1.3.2 Chromoanagenesis and multibreakpoint events
Beyond the simple structural variant forms, many tumors exhibit large and complex
structural changes. These may involve one or many chromosomes and may be accompanied
by a high local substitution rate. Such dramatic changes in the chromosomal structure
have collectively been labeled chromoanagenesis [67].
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Fig. 1.1 Types of complex structural variant events, reproduced directly from Figure 3 of
reference [1].
Several distinct patterns of chromoanagenesis have been described in cancer. Reference
[1] describes these in detail and an overview of common patterns is reproduced from
their paper in Figure 1.1.
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Localized SNV hypermutation, or kataegis, may occur within chromothripsis regions.
While not considered a structural variant event, kataegis is a common pan-cancer pattern
and can be an important marker for genomic instability [68]. Mutations in TP53 are
associated with kataegis. Hotspots often reflect the activity of the APOBEC family of
cytidine deaminases as well. While common across cancers, bladder carcinomas display a
much higher rate of kataegis than other cancer types [68].
Chromothripsis was first described in 2011 and is characterized by apparent chro-
mosomal shattering and repair. This generates a series of what may be more than 100
clustered events on one or a few chromosome arms. All types of non-insertion simple
event (i.e., deletions, translocations, and inversions) can be present and are often present
at similar ratios. A defining characteristic of chromothripsis is locally oscillating copy
number over the event’s span.
Chromoplexy was first observed in prostate tumors by Baca et al. [69]. Chromoplexy
is characterized by the involvement of multiple chromosome arms in a series of inter-
chromosomal translocations [1]. These are most often balanced and copy-neutral. The
total number of composite events is usually much less than in chromothripsis, and events
most often form a complete cycle (or "closed-chain") among the breakpoints of a ected
chromosomes [69]. It has been proposed that chromoplexy is caused by erroneous repair
of double-strand breaks in the DNA.
Other well-defined patterns of hypermutation have been described. Fold-back inver-
sions are present in roughly one-sixth of pancreatic tumors [70]. These events are defined
by a duplicated DNA portion with everted (i.e. outward-facing) read pairs at the break-
point. Fold-back inversions are hypothesized to be a product of breakage-fusion-bridge
cycles, first described by McClintock in 1941 [71]. Mutations in genes involved in the
DNA homologous repair pathway (such as BRCA1 and BRCA2) can generate high rates
of copy-number altering events at the structural variant scale as well as in small indels.
L1 retrotransposition can lead to insertion of the L1 retrotransposon sequence at novel
locations in the genome. Lastly, viruses such as Human Papillomavirus can insert into
the genome and induce localized duplications near the integration site.
1.3.3 Structural variants in cancer
Structural variants are well established as important contributors to disease. Structural
variants have been implicated as disease drivers in schizophrenia [72, 73], Down Syndrome
[10], epilepsy, hemophilia, pancreatitis, and numerous disorders of the nervous system
[72, 74–76]. Many structural variants, acting as either passengers or drivers, have been
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characterized in cancer. Because of their complexity and size, structural variants may
impact the cancer phenotype in diverse ways.
Structural variants were perhaps the first genomic abnormality to be described in
cancer. Theodore Boveri first hypothesized that chromosome abnormalities visible by
light microscopy might lead to cancer development in 1914 [8]. One of the earliest
descriptions of a structural variant as a driver was made by Nowell and Hungerford in the
1960s. A specific chromosomal abnormality was identified by microscopy in patients with
chronic myelogenous leukemia. This abnormally small, recurrent chromosome was termed
the Philadelphia Chromosome [9]. As cytogenetic techniques improved, the genomic
portions involved were located to chromosomes 9 and 22 and it was determined that a
reciprocal translocation generated the Philadelphia Chromosome. Later, the mechanism
of action was discovered to be generation of a gene fusion product, BCR ≠ ABL, which
leads to constutive activation of the JAK/STAT and MAPK pathways and unchecked
cellular expansion.
Structural variants may impact the copy number of genomic regions. Unbalanced
variants which alter the copy number of genomic portions may directly a ect gene dosage.
Loss of tumor suppressor genes such as P53 in the genome allows cells to proliferate
uncontrollably. Genomic loss in the short arm of chromosome 22 is an apparent pan-cancer
backseat driver mutation, although specific genes that contribute to this phenotype have
not been described. Loss of heterozygosity, which may be caused by imperfect replication
or partial chromosome loss, can result in loss of functioning gene products in the a ected
region. Duplication of oncogenic regions can increase gene dosage. This mechanism is
commonly seen among genes in the RAF-RAS signaling pathway, including MY C, RAF ,
and RAS [77].
Structural variants may remove or join functional domains of proteins by altering the
exonic sequence of the DNA. Large deletions of inhibitory domains can cause a ected
genes to become constitutively active. A deletion of six exons in BRAF between exons 2
and 8 has been associated with increased resistance to treatment [78]. This mutation
causes deletion of the RAS-binding domain and constitutive activation of the gene
product, leading to constant signaling in the RAF ≠ RAS pathway. Structural variants
may also form activating fusions involving multiple gene partners. Gene fusion drivers
are common across cancers. In thyroid cancer, RET ≠ PTC fusions occur between the
RET receptor tyrosine kinase and one of several gene partners in roughly 15% of sporadic
thyroid cancers. The most common RET ≠ PTC fusion (RET ≠ CCDC6) is driven by
a multi-megabase inversion on chromosome 10, while other fusion partners form after
1.3 Structural variation 17
interchromosomal translocation events. In lung cancer, the ALK ≠ STRN fusion drives
a significant portion of tumors. This specific fusion is also targetable by therapy, however,
and treatment to deactivate the fusion protein proves e ective for many patients.
1.3.4 Di culties in structural variant discovery
Large, simple structural variants are easily detected by microscopy. Large inversions and
translocations are often genotyped using flourescence in-situ hybridization techniques.
The original FISH protocol was invented by Rudkin and Stollar in 1977 [79]. Today,
multicolor FISH and spectral karyotyping techniques provide e ective methods for
analyzing variants. In these methods, flourescent genomic probes are hybridized to
targeted DNA sequences. Di erences in expected banding patterns can be used to discern
normal from abnormal chromosomes. Spectral karyotyping combines the use of multicolor
FISH probes with a defined chromosomal color banding scheme to look at events across
the genome. However, the minimum event size for intrachromosomal events in either
of these approaches is still roughly 1 mbp [66]. Interchromosomal exchanges are easier
to detect as they are not size-dependent. These methods represent the current state of
the art for assaying radiation-associated structural events [80, 81]. Structural variants,
particularly inversions and translocations, have been noted as stable, long-term markers
of radiation exposure. Smaller events have also been noted in individuals exposed to
large amounts of medical radiation [54].
Structural variant detection with short next-generation sequencing reads relies on
identifying imperfect read mappings to the reference and translating these signals into
structural variant calls. The earliest short read structural variant callers relied on
discordant paired-end fragment length and soft clipping of reads to detect where they
overlapped structural variant breakpoints [82–84]. Over time tools would improve
detection of all event classes by incorporating these signals together [85, 86]. Other
tools utilized assembly-based approaches to detect the full spectrum of events, with a
particular advantage in detecting insertions [87].
Several new technologies have led to renewed interest and ability in assaying structural
variation over the past decade. Oxford Nanopore and Pacific Biosciences (PacBio) have
both released sequencing platforms capable of producing reads as long as one megabase.
Such remarkably long read lengths allow the capture of whole structural variant alleles
in a single read. Mapping these reads required the development of new read mapping
algorithms and structural variant callers [88]. The cost of such length is that both
technologies have per-base error rates as high as 12%, though these are continually
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improving [89] and, in general, read length rather than basepair accuracy is more
important for structural variant detection. Algorithmic improvements to read mapping
and variant calling were required to make analyzing such data feasible, though it now
outperforms short read data for detecting most classes of events [88]. Linked-read
technologies, such as those from 10X Genomics and Moleculo, have also enabled better
resolution by providing information about the larger molecules of DNA from which
sequencing reads originate [90]. Lastly, Hi-C, optical mapping, and other technologies
have allowed phasing large chunks of chromosomes including when structural variants are
present, especially when combined with long reads [91]. These advances in technology
have highlighted that structural variation plays key roles in both healthy individuals and
disease.
Structural variants present unique challenges in resequencing and assembly compared
to small variants, mostly due to their size relative to sequencing reads. Small variants are
often recurrent and can be easily defined by a single position in the genome. Procedures
for producting consistent representations of individual small variants are well-defined
[92].
Normalizing variant representation for large variants remains an unsolved problem
in the field. While structural variants often generate similar genomic structures or
transcript products it is di cult to normalize variant calls in a consistent manner. The
same structural variant may vary in its breakpoints by thousands of basepairs. Variants
may also overlap, be composed of multiple breakpoints, or be fully nested within other
variants. The RET ≠CCDC6 (PTC) fusion is a good example of a structural variant that
produces a recurrent, well-characterized gene fusion product with relatively consistent
breakpoints. The individual breakpoints of the fusion still vary over several hundred
basepairs in the introns of RET ≠ CCDC6. Non-coding variation is more di cult to
classify as recurrent or non-recurrent given that there is not necessarily a consistent
genomic product and breakpoints may therefore not be under functional selection.
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Fig. 1.2 An overview of discordant read signatures induced by structural variants. Dupli-
cated directly from figure one from [2]. Columns represent di erent types of short-read
evidence for a structural variant based on read count (RC), read pair (RP), split read
(SR), and assembly (AS) methods for (A) a deletion, (B) a novel sequence insertion, (C)
an inversion, and (D) a tandem duplication.
Short-read technologies have dominated the era of resequencing due to their cost
advantages. The relative size of these reads compared to structural variants means that
individual reads (and read pairs) often fail to span both sides of a variant’s breakpoints.
When a read spans a single breakpoint, it can still be di cult to map across the break
as the portions on either side will be small; this is further confounded by the fact that
structural variants are often present in repetitive regions or in regions of microhomology
at the breakpoints.
In addition, small-variant calling algorithms are not well suited for locating structural
variants, and the two classes of variation have traditionally been analyzed separately
even though they often occur together. Structural variant calling pipelines often use a
consensus step to harmonize calls among many structural variant callers and produce
a higher-specificity callset. Consensus pipelines have been shown to improve both
sensitivity and specificity over running individual tools [93]. Running multiple algorithms
and merging structural variant calls adds significantly to the computational and analytical
burden presented by such data. Such pipelines can be prohibitively expensive and di cult
to manage for smaller studies.
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Long read technologies produce reads that are often of su cient length to fully
span many smaller structural variants and provide anchoring sequence to breakpoints.
Linked reads provide many of the same advantages and can yield useful information
about molecule of origin. However, both of these technologies introduce computational
challenges. Linked reads rely on special software to incorporate Unique Molecular
Identifier information for mapping, variant calling, and phasing; without this, they are
essentially just standard short Illumina reads. Long reads require new algorithms for
e ective mapping due to their length and error rate, though this is improving with greater
read fidelity. Nonetheless, the process of aligning long reads remains slow and expensive.
For long reads, read error rates confound structural variant calling. Homopolymer
runs have proven especially hard to sequence, meaning repeat expansions/contractions
are di cult to genotype. Sequencing errors also frustrate read alignment and small
variant calling, though the random or pseudo-random nature of long-read errors (outside
of homopolymers) means that this error can be e ectively scrubbed given su cient depth.
This still adds to the complexity and expense associated with calling such variation.
Further confounding structural variant comparison is the lack of a common format
for variants. While the Variant Call Format has special syntax designed for structural
variation calls, many callers produce values for the SVLEN, SVTYPE, or END fields
that deviate from the description in the specification. Complex events in "breakend"
format are often not convertable back to the more human-readable SVTAG format. The
required information fields are not always clearly defined in the specification. There is
also no notion of left-alignment and trimming — as there is for small variants — that
minimizes the e ects of variable positon and imprecise representation. Representation
and naming of complex events is especially challenging given that they may span many
VCF records.
1.4 The rediscovery problem
The standard practice for analyzing new genomes is known as resequencing, in which the
genome of interest is shotgun-sequenced, its reads are mapped to the reference genome
of its species, and variant locations are called against the reference. Whether the variant
has been seen in the population before is ignored at this stage; recurrent variants in the
population are "rediscovered" in the individual as if they were novel. A common next
step in analysis is to annotate variants from resequencing with allele frequencies and
impacts from population and functional genetics studies.
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This circular process wastes considerable computational e ort, though it is still
significantly more cost-e ective than performing whole-genome assembly with current
practices in sequencing and computing. While every new genome will di er by 3-5 million
SNVs and indels as well as millions of bases a ected by structural variation, many of
these variants are likely to have been previously observed. In diseases such as cancer,
only a very small proportion of variants, perhaps even a single one, drive the disease
phenotype. Such variants are highly recurrent and have in general been well-cataloged.
Modern genomic pipelines were largely designed in the mid 2000s and fail to make
use of prior knowledge of population variation before the annotation stages. Sample sizes,
however, have grown exponentially over the past decade. Large institutes now regularly
sequence more samples in a month than were sequenced in the first 15 years of the field.
At the same time, the data point for each individual sequenced grows richer with longer
reads and new technologies. Even at the largest research centers it has become di cult
to maintain su cient computing infrastructure to process the ever-increasing amounts of
data; because of this, traditional high-performance compute systems are being phased
out and replaced by commodity cloud systems. While computing power has increased
in exponential fashion according to Moore’s Law, the cost of analysis has not dropped
concurrently with the cost of sequencing.
1.4.1 Costs and limitations of computing at scale
Genomic data sizes have grown dramatically over the last twenty years. Initially, com-
putational power and cost of storage kept pace with sequencing rates. In 2007 this
trend reversed, with sequencing costs dropping roughly 2-3 times as fast as storage cost
due to the introduction of massively-parallel shotgun sequencing approaches. A typical
30X short-read human genome now costs roughly $1000. Sequencing studies with tens
to hundreds of thousands of participants are common, and studies with over a million
individuals are underway.
Shortly after the introduction of the 454 and Illumina-Solexa sequencing machines it
became apparent that smaller genomics centers would not be able to provision su cient
IT infrastructure fast enough to keep up with the amount of data being produced. This
led some in the community to advocate for moving genomics data to the cloud, rather than
local high-performance computing (HPC) environments which up until this point had
been the dominant location for genomic analysis [94]. However, it would take many years
for this transition to take place because of the regulatory and technological challenges
such an undertaking presented. Many major studies, including the Pancancer Analysis of
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Whole Genomes, have now been processed in the cloud, often seeing significant savings
in cost and time [31].
For power users, HPC has been the preferred option for genomics data processing.
Traditional HPC environments provide local storage and fast, on-demand compute running
on bare-metal servers. Typically, job management is performed using a scheduling
program, and user authentication is handled by SSH, sometimes accompanied by a
firewall or VPN to prevent unwanted incursion to the server and its data. When
performing genomic analyses, data is downloaded from collaborators or central repositories.
Processing can then be done using any number of programming languages or licensed
commercial software instances. Most academic centers maintain local compute clusters
with teraflops of compute and several petabytes of storage.
While the cloud o ers nearly-limitless compute and storage it brings with it a number
of notable di erences from the familiar architectures of HPC. Compute in the cloud is
performed on virtual machines rather than bare metal servers. These must be provisioned
and destroyed by users, and there is often no scheduler to handle such provisioning
automatically. Installation of custom scripts on the cloud often falls to the user, whereas
system administrators have typically performed this role in on-premise computing centers.
Billing from the cloud is often much more transparent than from HPC centers; this can
lead to sticker shock when users see the per-unit price without considering that local
HPC is often heavily subsidized and its costs amortized over many years of operation.
New technologies o er some solutions for managing these challenges. Containerization,
where software is packaged inside a runtime and can be distributed independently of
a physical server, allows users to share code without sharing access to servers or data.
In doing so, the new paradigm has become movement of code to data, rather than the
copying and transfer of data to code on local compute. This dramatically improves
reproducibility and lowers the barriers to entry for computing on the cloud. It also reduces
data duplication across large studies. Most cloud providers support containers, and their
performance is comparable to cloud virtual machines. In some use cases containerization
is being replaced by managed services, where cloud computing companies provide access
to highly-abstracted analysis pipelines through externally exposed APIs. These services
reduce the development burden on users at the cost of transparency and flexibility.
An alternative approach for reducing the gap between compute capability and se-
quencing data influx is to develop algorithms that are more e cient. Algorithms designed
to operate on subsets of data or which use heuristics to avoid excess work can signif-
icantly improve throughput. Examples of sublinear algorithms include the MinHash
1.4 The rediscovery problem 23
implementation in [95] and [96]. Succinct data structures [97] may also be used to reduce
the amount of memory needed to process data; these have been applied in several recent
tools [98, 99]. Reference-based compression functions similarly and significantly reduces
file sizes for aligned NGS data [100]. More e cient data structures and algorithms enable
the use of smaller units of computing for analysis. This can make such analyses accessible
to groups which might not be able to a ord them otherwise. It also opens up new areas
for remote research, such as real-time analysis at point-of-care or in environments that
are not amenable to internet connection or compute infrastructure.
1.4.2 Variation-aware algorithms
A more e cient method for resequencing would be to align reads in a manner that
incorporated prior population genetic information and genotype variation directly. Such
alignment algorithms are "variation-aware," in that they are able to incorporate prior
knowledge about genomic variation. Variation-aware algorithms also include kmer-
matching algorithms which genotype known variants [96]. By incorporating prior infor-
mation, variation-aware algorithms can significantly reduce runtime and provide better
sensitivity. However, because they are only as good as their prior, variation-aware
algorithms do not provide any benefit over other approaches when analyzing novel
variation.
Significant interest has arisen around research into methods that can decrease the
amount of reference bias in resequencing studies. Modified references containing alter-
native alleles have been used to improve population-specific studies [101]. Others have
explored replacing all variant alleles in the reference with the major alleles in an e ort to
reduce population bias in the reference [102]. Disease-specific and personal references
have been shown to improve read alignment and downstream analyses [103]. E orts
such as these seek to undo some of the decisions made for the sake of simplicity during
the generation of the human reference and to create reference structures that are more
representative of human populations.
Several methods exist for mapping reads in a variation-aware manner, though none
have achieved widespread acceptance. HiSat2 [104] uses a set of hierarchical graph FM
indexes to align reads to tiling graphs of small genomic regions containing variation.
This has been shown to improve RNA-seq analysis as well as HLA typing and analysis of
DNA fingerprinting [105]. The variation graph toolkit implements similar algorithms and
has been shown to reduce reference bias when aligning to population variation [99]. In
theory it should be possible to align reads to known variants, perform calling of known
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and novel variants, and retrieve allele frequency and other annotations in a single process.
Though no implementation of such a pipeline exists, it is reasonable to assume it could
save significant amounts of time and money compared to current alignment, calling and
annotation pipelines.
The common coordinate system provided by the reference genome is a major advantage
of resequencing over genome assembly. The ability to refer to a variant by reference
version, contig and position enables a consistent language for referring to variants and
was a primary goal of the Human Genome Project. This enabled the generation of a
massive body of genome annotations that is persistent and consistent across individuals,
saving significant amounts of computational e ort over personalized genome assembly
and annotation.
Alternative data structures have also been proposed and are generating significant
interest as possible replacements for the linear reference. Graph-based representations
of genomes have become the most-common of these, and have been shown to reduce
reference bias while still permitting usage of the reference-based coordinate system
[106–109]. Graphs have been used in RNASeq analysis, small variant detection and
structural variant typing and have consistently been shown to improve read mappings
overall, though further analysis of variation to include in the graph is required.
1.5 Graph representations of genomes and pangenomes
Graph genomes are a type of variation-aware data structure that are under active
development within the genomics community. The linear reference has multiple issues of
representation, as discussed in subsection 1.1.1 and section 1.4. It is desirable to instead
have a reference that represents collections of genomes. Such a collection is referred to as
a "pangenome." A pangenome may contain genomes from the cells of a single individual,
many individuals from a single species, or a metagenome from a collection of many
species together. Pangenomes have been previously implemented and have provided
novel insights in a variety of fields. Metagenome indexes are perhaps the most explored
implementation of pangenomes, though read collections and MinHash sketch databases
are other examples of such structures [110–112].
Genome graphs provide an alternative to the linear reference for representing the
reference sequence and reference relative variation in a single common data structure
[113]. A graph GV,E is defined by a set of nodes V and a set of edges E. In most graphs,
nodes define objects and edges define relationships between nodes. Graph data structures
1.6 Genomic mixtures, subclones, and uneven heterogeneity 25
are common in network analysis, and research into graph data structures has increased
















Fig. 1.3 A variation graph containing five substitution variants. The model used in vg
automatically generates edges for all possible haplotypes when incorporating a variant.
Many types of graph have been used to represent genomes. Assembly algorithms
have historically used de Bruijn graphs or overlap graphs to represent the contiguous
relationships between short reads [114–116]. The string graph has been used as a more
generic model for genome assembly and variant calling [117]. A general model, the
sequence graph, is used by [99] and [108] to represent population variation called against
a reference genome. Several implementations of the variation graph have been used for
graph alignment, query, and variant calling. Graphs have also been utilized to represent
partial order alignments of both DNA bases and amino acids and splicing within RNA
transcripts [118–122].
In a genome graph, genomic sequence is represented along with relationships between
those sequences. The most common representation is the variation graph, in which nodes
contain genomic sequences and edges represent relationship between nodes;alternative
representations placing the sequence on edges do exist [108]. Annotations in a variation
graph are overlaid via paths, which describe collections of nodes and edges that share
attributes. Haplotypes trace paths along nodes and edges in the graph. The variation
graph toolkit vg provides one such implementation of this structure, and it has been
shown to reduce reference bias and improve read mappings [99]. Tools for producing and
operating on graphs remain nascent and there is ample opportunity for improvements in
both theory and practice in the field.
1.6 Genomic mixtures, subclones, and uneven het-
erogeneity
It is exceedingly rare that an individual genome is sequenced on its own. Historically, it
has been di cult to isolate a single cell for sequencing, though techniques for doing so
are now routine and commoditized [123, 124]. Many organisms are multiploid and store
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multiple homologous copies of DNA within even a single cell. These copies may be hard
to distinguish computationally. As genome assemblies are typically presented in a linear
fashion, only one haplotype is chosen to be representative. This process is imperfect and
haplotigs are often merged in assemblies. Techniques for binning reads using trio data
have demonstrated that assembly of individual haplotypes is possible and genetically
informative [125, 126]. Techniques for separating haplotypes and removing haplotigs
post-assembly and without the use of trios are under active development [127, 128].
1.6.1 Metagenomics
There has been significant interest in studying mixtures of genomes as next-generation
sequencing costs have fallen and DNA barcoding techniques have improved. The field
of metagenomics deals with such studies. Metagenomics is a broad field, ranging from
sampling of the human microbiome [129] to collection and analysis of samples from the
oceans [130] and the International Space Station [131]. Common goals of metagenomics
studies include sampling of cryptic diversity from the environment [130] or detection of
specific traits such as antibiotic resistance [132].
Deconvoluting mixtures of genomes is computationally expensive, and recent research
has focused on data structures and algorithms for accelerating the process. Reference
[110] describes Kraken, a high-performance tool which uses a large database of kmers to
lowest common ancestor of all genomes containing each kmer to accurately identify species
within a sample at the genus level. This tool improved significantly on the performance
of BLAST, one of the most widely-used algorithms for querying a sequence against
many known sequences [133]. Reference [95] used the MinHash locality-sensitive hashing
scheme to compare genomes in time sublinear to the total sequence length by taking a
representative "sketch" of each genome. This process has been used to approximately map
long reads as well to perform overlapping for genome assembly [134]. Such approaches
have made metagenomic analyses feasible for very large databases of known sequences.
Reference [112] used Sequence Bloom Trees to make comparison of read sets to all known
viral and bacterial sequences feasible using contemporary computing hardware.
1.6.2 HPV16 lineages and sublineages
Metagenomic analysis of HPV16 infections is of major interest to cancer researchers.
Human papillomavirus (HPV) is a DNA virus responsible for over half a million cervical
cancer cases each year and an estimated 239,000 deaths worldwide [135]. Persistent
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infection with one of the carcinogenic HPV types is necessary for invasive cervical cancer
development, and accounts for a large proportion of other anogenital and oropharyngeal
cancers [136]. There are more than 200 papillomavirus types known to infect humans,
with each type defined on the basis of at least 10% sequence di erence in the L1 gene
(major capsid protein) sequence. Not all HPV types contribute equally to infection or
disease risk. Approximately a dozen of the more than 200 HPV types are considered
carcinogenic, with just two types, HPV16 and HPV18, accounting for approximately
75% of cervical cancer cases worldwide [137].
HPV infection is not mutually exclusive to a specific type [138]. Concurrent infection
with multiple HPV types is common, occurring in 20-50% of HPV infections [138–141].
One study reported nine distinct HPV types simultaneously in a single patient [142].
Co-infections appear to be random assortments of types with no evidence to support
clustering of types or viral interactions between types [139].
Within each HPV type there are variant lineages which di er by 2-10%, and as little
as 1% for sublineages, in their L1 gene sequence from other variants of the same type,
and these also vary in risk for cervical precancer and cancer [143, 144]. For HPV16, the
most common and carcinogenic type, there are four main variant lineages (A, B, C, and
D) and ten sublineages (A1, A2, A3, A4, B1, B2, C, D1, D2, and D3) that are roughly
correlated with their geographic distribution. HPV16 sublineages show strong di erences
in histology-specific cervical precancer and cancer risks, with relative risks exceeding 100
for specific sublineages (D2, D3 and A4) associated with adenocarcinoma [4].
Mirabello et al. [4] used phylogenetic methods and lineage-specific SNP genotyping
to detect HPV16 lineages. While able to accurately determine the dominant lineage,
Mirabello et al. were not able to assess whether samples were infected with multiple
lineages. There is little known about the epidemiology of co-infections with multiple
HPV16 variant lineages, though this is clinically relevant given the significant di erences
in risk associated with each lineage.
1.6.3 Tumor heterogeneity and clonal hematopoesis
Tumors often contain significant amounts of heterogeneity [46]. In many cancer types
the primary tumor may have multiple subclones with independent driver mutations.
Subclones may also harbor resistance mutations and it has been shown that targeted
deep-sequencing of tumors has the potential to improve patient care by providing a better
overall picture of tumor genomic architecture [145, 146].
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Subclonal expansions are common in cancer and normal cells. Reference [147] found
evidence for subclonal expansion in all metastases and 94.7% of tumors they examined.
Even without the presence of high-fraction subclones, the tumor itself is a population of
cells. It is well established that normal cells acquire clonal mutations over time [148, 149].
These mutations appear to be under neutral or slightly positive selection [48]. These
same patterns hold for normal tissue, where it has been shown that clones with mutations
conferring growth advantages colonize epithelial tissues such as the skin and esophagus
[149].
Somatic clones can also colonize the blood. Mutations in several genes are known to
lead to clonal hematopoesis, in which a single hematopoetic stem cell lineage produces
a substantial portion of mature blood cells [150]. This phenomenon is associated with
later development of hematologic cancers as well as heart disease and ischemic stroke
[151]. DNMT3A, TET2, ASXL2, JAK2, SF3B1 SRSF2, and TP53 are commonly
mutated in clonal hematopoesis [152]. These genes had previously been identified as
drivers in acute myelogenous leukemia and myelodysplastic syndrome.
Clonal expansion plays an essential role before and during early tumorigenesis [153].
Mutations can be induced by exposure to mutagens [154, 62] and by predisposing germline
mutations [45, 38]. Driver mutations are acquired by chance and subsequently rise in
clonal fraction because they confer a fitness advantage over wild-type cells [155]. Clones
with driver mutations in cancer genes colonize surrounding tissues and are under positive
selection [149, 48]. It can take many decades for an initial clonal lineage to become
malignant, and many will never do so [151, 155]. Clonal expansion in normal tissue
therefore provides an early indicator of possible precancerous state.
1.7 Radiation-associated papillary thyroid carcinoma
1.7.1 The 1986 Chernobyl Nuclear Disaster
The Chernobyl Nuclear Disaster is one of the largest releases of radiation into the
environment to date. During a planned test at roughly 01:23 Moscow Time on April
26, 1986, two explosions occurred in the number 4 reactor of the Chernobyl Nuclear
Power Plant. These explosions led to dispersal of radioactive fuel, fuel byproducts, and
irradiated graphite control rods into the immediate area, as well as structural damage
and fires in the plant complex. Hundreds of firefighting personnel were sent in and many
were exposed to high levels of radiation. A subsequent graphite fire released significant
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amounts of radionuclides, particularly 131I, 90Sr, and 137Cs. This fire would burn for
two weeks before being extinguished, during which time it would continue to release
radionuclides into the atmosphere.
The disaster had lasting impacts across a wide geographic region. Radionuclides
were spread throughout the Northern Hemisphere including large portions of Europe
[156, 157]. The triggering of radiation detectors as far away as Sweden, Norway and
the United Kingdom was the first warning many nations received that a nuclear release
had occurred. One hundred and thirty four first responders received su ciently high
doses of radiation to display symptoms of acute radiation sickness [158]. Approximately
thirty people were killed immediately due to the initial explosions or from acute radiation
poisoning.
Within four years a major increase was seen in the number of adolescent thyroid
cancer cases in areas of Belarus, Russia, and Ukraine, particularly in the areas directly
north of the Chernobyl site [159, 160]. While the short half-life of 131I prevents direct
measurement of where it was deposited, estimates can be gleaned from measurements of
137Cs, which has a much longer half-life. High exposure to 131I is strongly associated
with subsequent risk for thyroid cancer [161]. The total number of thyroid cancer cases
reported in the a ected areas among people who were adolescents during the incident
is roughly 5,000. It is estimated that the Chernobyl incident likely contributed to an
excess of up to 4,000 - 10,000 cancer-releated deaths in those exposed, though the exact
numbers are di cult to precisely estimate and political controversies over these numbers
continue over thirty years later.
The Chernobyl Tissue Bank, an international program, was established to preserve
and catalog blood and tissue from individuals that were exposed to radionuclides from
the disaster. The Chernobyl Tissue Bank holds roughly 5,000 samples from individuals
aged less than 19 years of age at the time of the incident who later developed thyroid
cancer. These individuals come from either of two hospitals in Ukraine or the Russian
Federation. Some combination of tumor and normal thyroid tissue (either fresh-frozen
and formalin-fixed para n-embedded) and normal blood are available for each individual.
All samples are reviewed by an international team of expert pathologists.
While 131I has a half-life of only 8.4 days, the half-lives of 137Cs and 90Sr are both
approximately thirty years. Areas impacted by fallout of 137Cs and 90Sr will remain
measurably contaminated for centuries. Agricultural countermeasures are still required
to avoid introduction of radioactive products into the food supply [158]. While there
is no evidence for an increase in solid cancer prevalence (with the exception of thyroid
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cancers), there is evidence that rates of leukemia may be elevated in cleanup workers.
While direct health e ects have impacted perhaps tens of thousands of individuals, the
total human costs of the disaster have been much greater. Approximately 300,000 people
were evacuated permanently from the area surrounding Chernobyl and Pripyat and a 35
kilometer exclusion zone now exists around the plant. Millions experienced psychological
trauma as a result of the disaster, and depression and suicide rates for those a ected
have remained significant [162].
The international response to Chernobyl has provided invaluable information regarding
radiation dosimetry, management of contaminated areas, and the health e ects of
environmental radiation. The response to the 2011 Fukushima nuclear accident, including
the use of caesium binders in livestock feed, was informed by the international research
collaborations built after the Chernobyl disaster [158, 157]. Chernobyl has also provided
insights into the long-term e ects of exposure from nuclear testing, where accurate
dosimetry is not always available [163]. Continued studies of survivors and the valuable
resources of the Chernobyl Tissue Bank will provide essential knowledge for responding
to any future disasters.
1.7.2 Thyroid cancer
The most notable public health outcome of the Chernobyl disaster was a dramatic
increase in thyroid cancer rates among adolescents in irradiated areas. Thyroid cancer
accounts for 1-2% of all cancer cases each year. Though this varies significantly between
sexes and continents, in general the rate of occurrence in women is roughly three times
that in men.
In contrast to most cancer types, the incidence of thyroid cancer has been increasing
over time [164, 165]. The total number of thyroid cancer cases diagnosed per year has
doubled since 1970 [164]. This increase remains significant even when accounting for
improved detection methods. Thyroid neoplasms tend to be diagnosed earlier than most
cancers, with a median age at diagnosis is 46 years of age compared to 67 years for all
cancers [161]. Overall mortality from thyroid cancer has declined during this period, and
survival rates exceed 95% for follicular and papillary subtypes [161].
Biological sex is among the only factors that appears to explain major di erences
in thyroid cancer rates [161]. Thyroid cancer is roughly three-times more prevalent in
women than in men, though the reason for this di erence is not well understood. Thyroid
neoplasms represent roughly 7% of cancer cases in women in Latin America each year
but only 1-2% of cancer cases in men [165].
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There are multiple thyroid cancer subtypes that display histologic and epidemiologic
di erences. The most common subtype is papillary thyroid carcinoma (PTC), which
accounts for anywhere from 60 to 90% of cases. Prognosis for the papillary subtype
is good with five-year survival rates over 95%. The follicular subtype is composed of
well-di erentiated cells (like papillary cases) but prognosis is slightly worse [161, 166].
Follicular cases account for roughly 10-15% of diagnoses. Medullary tumors account for
5-10% of tumors. Approximately 25% of medullary cases display familial inheritance
due to mutation in the MEN2 gene. Prognosis for the medullary subtype is again quite
good, with survival rates in the range of 80%. Anaplastic subtypes account for the
remainder of cases (1-2%) and are associated with significantly worse prognosis compared
to papillary cases, with many patients not surviving more than six months after diagnosis.
All non-papillary cases are associated with greater age at diagnosis. Overall, thyroid
cancer survival rates are higher for any other cancer type except non-melanoma skin
cancer, largely due to the high number of papillary and follicular type tumors compared
to the rarer, more aggressive types [165].
Exposure to radiation is a well-established risk factor for thyroid cancer development.
Exposure in adolescence presents a greater risk of cancer development than during
adulthood [167]. Iodine deficiency also predisposes one to a greater risk of thyroid cancer
[168]. This is primarily for the follicular and anaplastic subtypes in sporadic cases,
however, and not for the more common papillary subtype. It has been hypothesized
that su cient dietary iodine can reduce uptake of radioactive iodine isotopes. Ron et al.
found that iodine supplementation with potassium iodide was associated with a three-
fold reduction in risk of thyroid cancer at one gray of exposure to 131I and that iodine
deficiency was associated with a three-fold increse in risk for the same exposure. Iodine
supplementation is often used as prophylaxis in populations at risk due to environmental
exposure.
1.7.3 Ionizing radiation and its e ect on the genome
Ionizing radiation is a powerful carcinogen [169]. High-energy particles can induce both
single- and double-stranded breaks in the DNA, and radiation is known to act as both a
mutagen and a clastogen [170, 81].
The impact of exposure to radiation is dependent on its source [169]. As an ionized
particle passes through tissue it transfers energy. The amount of energy transferred per
unit distance is known as the Linear Energy Transfer (LET). X rays and gamma rays
have low LET while alpha particles are high LET; beta emissions fall somewhere between
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these. The quality of a radioactive source is the factor by which an exposure must be
multiplied to produce a normalized measure of biological damage, e ectively converting
an absorbed dose in gray to one of biological risk in Sieverts. Robustness is a measure of
cells’ sensitivity to exposure from a particular radiation source.
Though a full discussion of radiation quality and e ective dose is beyond the scope
of this thesis, it is important to consider that the samples in the Chernobyl Tissue
Bank received very di erent exposures than tumors receiving medical radiation. These
doses were received primarily from deposited radionuclides through consumption of
contaminated vegetables or milk. In the case of 131I, most of the energy transferred is
through beta emissions. Medical doses may come from X-ray, gamma ray, alpha or beta
sources. Total doses for medical regimens may be as high as 30 Gy, although this dose is
usually fractionated to minimize damage to cells [171]. Previous studies have most often
focused on exposure of cell lines or medical samples to gamma, X-ray, or alpha particles.
Direct comparison of studies of medical radiation and those of individuals exposed from
environmental radiation should be done with care.
Cornforth et al. provide a lengthy review of their own published research on fibroblasts
and lymphocytes exposed to di erent radiation sources in [81]. Cytogenetic profiling
by mFISH was used to look for chromosomal aberrations and the number and types of
aberrations were used as a measure of dose response. It is well-established that such
cytogenetic abnormalities are markers of radiation exposure [172]. Overall, all types of
radiation examined (heavy ion, alpha particles, X rays, and gamma rays) produced a
linear or curvilinear response to exposure.
Large inversions and complex translocations are markers of radiation exposure in
cytogenetics [81, 172, 66]. These changes are stable across cellular generations and can be
used for biodosimetry. In general, the ratio of complex interchanges (i.e. those involving
three or more breakpoints) to simple ones is highly dose-dependent for low-LET radiation
[81]. No such relationship exists for high-LET radiation. Workers from nuclear weapons
plants harbor long-term signatures of exposure in their cytogenetic profiles [80]. Hande et
al. found a strong association between dose received and the number of intrachromosomal
rearrangements in former radiation workers from the Soviet Union. These balanced
events are signs of induced double strand breaks [170, 54]. Cytogenetics-based methods
have been shown to be sensitive to exposures as low as 0.3Gy [172] and stable cytogenetic
markers of exposure persist for decades [80].
Cytogenetics has long been the gold standard of biodosimetry metrics and chromo-
somal events visible by mFISH are clearly associated with radiation exposure. The
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resolution of such techniques is much lower than that of next-generation sequencing,
however. [54] examined twelve radiation-associated tumors from individuals exposed to
medical radiation. These tumors were whole-genome sequenced and compared to 319
radiation-naive tumors processed through the same pipeline.
Radiation-exposed samples harbored a greater number of small deletions compared to
radiation-naive tumors, consistent with non-homologous end joining creating erroneous
DNA repair products. These deletions were small (Æ100 bp), well below the detection
threshold of cytogenetic techniques. Deletions were distributed randomly across the
genome, whereas deletions caused by other known carcinogens are often in distinct regions
or motifs. In addition, radiation-exposed tumors were significantly enriched for balanced
inversions. These mutations are relatively rare in cancer samples not exposed to radiation.
Large inversions like those found in [54] are consistent with reports of intrachromosomal
translocations and inversions in radiation-exposed cells using mFISH [66, 172, 80].
Behjati et al. demonstrated that next-generation sequencing of radiation exposed
tumors could detect two genomic markers of radiation exposure. The study was limited
to only twelve radiation-exposed tumors. In this thesis I analyze approximately 300
radiation-exposed samples, though at much lower doses than those of Behjati et al.
While still insu cient to detect novel radiation sensitivity mutations in the germline this
number is su cient to obtain valid calculations of significance. Results and discussion of
this analysis follow in Chapter 2.
1.8 Structure of the remainder of this thesis
In Chapter 2, I describe a cloud-based analysis of over 1,000 whole-genome samples from
the Chernobyl Tissue Bank. These were analyzed as somatic pairs, either tumor - normal
blood or tumor - normal thyroid tissue; a total of 393 tumor - normal pairs were initially
included. Normal blood was chosen over normal thyroid tissue as a germline background
when available. These pairs were analyzed for somatic SNVs, indels, structural variants,
and telomere length, as well as small variants in the germline. These results were
examined in the context of phenotype data including radiation dosimetry estimates, as
well as in comparison to cases of sporadic thyroid cancer.
In Chapter 3, I discuss variation graphs and structural variation.







After the 1986 Chernobyl nuclear disaster a pronounced rise in pediatric thyroid cancer
cases was observed in regions north of the site. A concerted international e ort was made
to catalogue blood and tissues from individuals presenting with thyroid cancers in these
regions. This resource, called the Chernobyl Tissue Bank, now holds approximately 4,500
samples from Ukraine and Russia. A portion of these samples come from individuals
that developed pediatric thyroid cancer but who were not exposed to radiation, allowing
comparison between cases and controls which are age- and population-matched.
Over the course of three years we received 1,307 samples from the Chernobyl Tissue
Bank (Table 2.1). These samples came from indivduals which had a thyroid tumor that
had been labeled by pathology as papillary thyroid carcinoma (PTC). In addition to
pathology data we received phenotypic data on sex, age at exposure, age at surgery,
dosimetry estimates, and geographical information for each individual.
To be included in our study we required that individuals have a thyroid tumor sample
and at least one normal tissue sample (either blood or non-tumor thyroid) which was
whole genome sequenced and passed stringent quality controls. In total, 998 samples met
these criteria from a total of 381 individual patients. However, 21 of these samples had
tumors with low purity (Æ20%) or tumor-normal pairs that appeared flipped (i.e. where
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Tissue Type Received WGS Sequenced Passing QC
Thyroid tumor 491 400 381
Normal Blood 331 252 252
Normal Thyroid 483 382 365
Metastasis 2 2 0
Total 1307 1036 998
Table 2.1 Counts of samples delivered from the Chernobyl Tissue Bank. 1,036 samples
in total were sent for whole genome sequencing. Of these, 998 passed quality control
metrics at the sample level and were used in the analytic set.
normal thyroid tissue showed evidence of malignancy) based on somatic analysis. These
samples are excluded from some analyses where the inability to detect their full mutation
spectrum might skew results. The distribution of samples available per individual is
shown in Figure 2.1 (subsection 2.1.2).
In addition to the somatic pairs from the Chernobyl Tissue Bank we received fifty
sporadic whole genome sequenced PTC cases from The Cancer Genome Atlas THCA
study [53]. These were sequenced on a platform with slightly shorter reads and lower
depth. All fifty of these samples were included in our analysis.
I examined the mutational landscape of these samples, including somatic single-
nucleotide variants, indels, and structural variants; germline small variants; and muta-
tional signatures. I compared the results between exposed cases and unexposed cases
from both this study and [53]. Results from whole genome sequencing analysis were
corroborated with SNP array and RNA data where possible. While data from a variety of
assays was available this work relies primarily on analysis of the whole genome sequencing
data.
2.1.1 Collaboration and publication notes
The work in this chapter was performed in collaboration with others. The Chernobyl
Tissue Bank provided samples and phenotype data. Nationwide Children’s Hospital
provided whole genome sequencing of our samples. The Cancer Genome Research
Laboratory at the National Cancer Institute provided some RNA sequencing as well
as nucleotide array data, methylation array data, and a relative telomere length assay.
I designed the germline and somatic calling pipelines with Dr. Chip Stewart and Dr.
Gad Getz of The Broad Institute of Harvard and MIT, largely based on their work in
[53]. Jaegil Kim from the Broad Institute helped devise early versions of the mutational
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signature analyses. I worked with Dr. Danielle Karyadi and Dr. Stephen Hartley at
NCI on manual quality control and variant annotation. Dr. Karyadi performed extensive
manual review of the small variants as well. Dr. Mia Steinberg, Dr. Jieqiong Dai, and Dr.
Joe Boland performed the mRNA- and miRNA-Seq analyses, which I used as validation
for the results in WGS. Dr. Lindsay Morton was essential to study design, quality control,
and statistical analyses. The work is currently being prepared for submission. I have
noted where individual analyses or tools have been made available publicly.
2.1.2 Quality control and study design
The tissue samples in the Chernobyl Tissue Bank are a unique and precious resource
and radiation-related incidents attract significant amounts of public attention. As
an international collaboration across multiple centers there were also major logistical
challenges in managing data and sample transfer. Due to these factors and possible
regulatory implications of our results, I implemented stringent quality control pipelines to
ensure the integrity of our data. This ensured that genomic data matched the phenotype
data across all platforms analyzed. This was corroborated with extensive manual review.
We received some combination of whole genome sequencing, mRNA and miRNA
sequencing, an Illumina OmniX SNP array, an Illumina EPIC methylation array, and a
relative telomere length assay data for each sample. For each assay, I coordinated the
individual laboratory information management system identifiers with the sample code
from the sequencing center and the identifier from the Chernobyl tissue bank. This was
used to generate a study-unique identifier for each sample on each assay. This global
identifier facilitated cross-assay comparison later on.
Each sample was quality checked individually on each assay. QC thresholds were
established by exploratory data analysis and then applied programatically. When a
sample failed a scripted QC threshold we only removed it from the study after manually
reviewing and verifying any inconsistencies.
Whole-genome data was checked for contamination, purity, ploidy, sex concordance
(both between samples and with phenotype data), depth of sequencing, and estimated
driver detection sensitivity. We required a median depth of 60X in the tumor sample
and 20X in the normal. Most of our samples were sequenced to >90X for tumors and
>40X for normal blood and normal thyroid tissues.
The majority of samples in our dataset had a ploidy of exactly two. I examined the
WGS copy number aberration (CNA) plots of any samples that received a ploidy of less
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than 1.99 or greater than 2.01 according to allelicCAPSEG [173]. All of these samples
passed review.
We examined WGS contamination using verifybamid [174], GATK version 4.0 [175],
and ContEst [176]. Any samples with contamination above 2% were flagged and manually
reviewed. All samples flagged as Ø 2% contaminated were subsequently removed from
analysis.
We examined WGS tumor purity using ABSOLUTE [173] and an allele-fraction (AF)
based metric (developed by Dr. Stewart and Dr. Karyadi). ABSOLUTE relies on somatic
copy number alterations to determine purity. In many of our thyroid tumors there was
little or no SCNA activity. While purity estimates from ABSOLUTE and the AF purity
metric were highly correlated, in the cases where the two methods disagreed the AF
purity estimate provided a more accurate estimate of purity. These metrics were also
compared against tumor purity estimates from the CTB pathology board.
Based on the AF purity, I calculated the approximate heterozygous mutation calling
sensitivity for a given tumor-normal pair. I defined sensitivity to be the probability of
observing more than three reads from the tumor which support a heterozygous alternate
variant, assuming a binomial distribution. Where necessary, individual mutations were
examined to give a manual estimate of tumor purity based on allele frequency. Any
tumor with less than 80% sensitivity (corresponding to approximately 20% purity) was
flagged during downstream analysis.
We also examined normal thyroid tissue samples for signs of clonal expansion or
secondary tumors by running a flipped somatic pipeline where normal tissue samples were
called against the somatic background of the tumor. The presence of somatic mutations
in the normal thyroid tissue that are not present in the tumor would indicate clonal
expansion of the tumor or a second malignant focus in the normal tissue. This could
impact downstream variant calling, reducing the apparent mutational burden and our
ability to detect driver mutations. Any normal tissue samples which were labeled by
pathology review as containing tumor foci or which contained >50 somatic mutations
compared to the tumor were removed from analysis.
Sex concordance was assayed by calculating the ratio of reads covering the Y chro-
mosome and those covering the X chromosome. The software package for calculating
this metric is available at https://github.com/edawson/check-sex. Sex-chromosome read
ratios were plotted against the labeled sex from phenotype data to establish cuto s. In
addition, sex estimates from whole genome sequencing were compared to those from
the OmniX array and phenotype data from the Chernobyl Tissue Bank. Samples which
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were labeled with a particular sex but which did not cluster with that sex were reviewed
manually, and any found to be discordant were removed from subsequent analysis.
Samples were initially screened to have come from the same individual by comparing
OmniX results. Many samples were not sent for sequencing as it could not be ascertained
that the samples were actually from a single individual. Samples were further fingerprinted
across WGS, OmniX, and EPIC methylation arrays using shared sites across the three
platforms. WGS BAM files from tumor and matched normal(s) were fingerprinted
using BAM-matcher [177]. Any samples which were not reported with high confidence
as coming from the same individual were reviewed. Several samples were flagged as
discordant between tumor and normal due to significant copy number alterations but
were deemed to be from the same individual upon manual review (see subsection 2.6.4).
Fig. 2.1 An upset plot of the data available for 381 patients with a tumor and at least
one matched normal. The majority (236 of 381) of individuals remaining after quality
control have both normal blood and normal thyroid tissue. One hundred and twenty
nine have only normal thyroid tissue; sixteen have only normal blood.
After sample-level QC, somatic pairs were matched to assess which individuals had
samples available for study. An upset plot of available samples per somatic pair is
available in Figure 2.1. For individuals with two normal samples I chose normal blood
over normal thyroid tissue for somatic analysis. The secondary normal was used for
validation and for analyses not presented in this work. Any individual without a tumor
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or without a matched normal that was not considered high-quality was removed from
the analytic set.
2.1.3 Phenotypic overview of analyzed somatic pairs
In total, 381 somatic pairs met criteria for inclusion. Among the 381 individuals available
from the Chernobyl Tissue Bank dataset, 303 received a non-zero estimated raditation
dose. Seventy-eight individuals were born at least one year after the Chernobyl nuclear
event and are estimated to have received no radiation exposure. I refer to the full sample
set of 381 patients as REBC (Radiation Epidemiology Branch - Chernobyl). Unexposed
cases are labeled "REBC-Unexposed," whereas "REBC-Exposed" is used to distinguish
samples which received a non-zero radiation dose. The fifty matched whole genome
sequenced cases from [53] are collectively labeled "THCA" (the name of the TCGA
Thyroid Carcinoma study which produced them). Counts of samples in each sample set












































Fig. 2.2 Summary data for phenotype variables in our dataset. (A) Counts of somatic
from each of the REBC-Exposed, REBC-Unexposed, and THCA sample sets. (B) Age
at surgery for each of the sample sets. There is a significant di erence in age between
any pairwise combination of the three sets (p < 0.01). (C) The proportion of individuals
of each sex for the sample sets.
Chernobyl-associated PTC cases are significantly younger than THCA cases
Thyroid cancer risk peaks in the fifth decade of life, with most cases occuring between
age 40 and 60 [161, 178]. The THCA cases in our dataset fit within this age range (mean
= 51.9, median = 49, range = [17, 85]). Both the unexposed and exposed portions of the
REBC sample set di er significantly from the THCA sample set in mean age at onset (p
< 0.01, Figure 2.2B). Exposed cases have a mean age of onset of 29 (median 30, range =
[13, 45]); unexposed cases have a mean of 20 (median = 21, range = [10, 29]). These age
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Dose Range (mGy) Number of samples
0 < Dose < 200 mGy 235
200 Æ Dose < 500 mGy 37
500 Æ Dose < 1000 mGy 14
1000 mGy Æ Dose 17
Table 2.2 Summary of estimated radiation doses for exposed cases.
di erences are again significant (p < 0.01, Figure 2.2B). Statistically, there is a ceiling
to attained age since sampling for the unexposed individuals was stopped at a fixed
timepoint roughly thirty years after the accident. Some of these may also be sporadic
cases that were caught early due to enhanced screening after the Chernobyl disaster.































































































Fig. 2.3 (A) Geographic region of samples in the REBC-Exposed and REBC-Unexposed
sample sets. (B) Number of exposed samples within each exposure category. (C) Summary
of doses within each dose category.
For other phenotypic variables we see no significant di erence among the three
datasets. REBC-Exposed, REBC-Unexposed, and THCA show identical sex distributions
with roughly three times as many female cases as male ones (Figure 2.2C). This di erence
in rates between the two sexes is well established [161]. The two REBC sample sets are
also drawn from the same geographical regions at roughly the same rates (Figure 2.3A).
Seventy-five percent of our exposed samples received an estimated dose of less than
200mGy (Figure 2.3B and C, Table 2.2). This is significantly less than medical doses like
those seen in [54], which can approach 30Gy of total absorbed dose.
All analysis for this study was performed in the FireCloud, a cloud-based platform
hosted by the Broad Institute. DNA was extracted at Nationwide Children’s Hospital
and sequenced at the Broad Institute on the Illumina X10 platform. Sorted and indexed
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BAM files of aligned reads were provided by the Broad GDAC team through FireCloud.
FireCloud uses a workflow description language called WDL to manage analyses [179].
All WDL scripts used in this text which could be made public are available on FireCloud
and at GitHub.
For both small variants and structural variants we implemented consensus-calling
pipelines that used the intersection of multiple tools to improve sensitivity and specificity.
This has been shown previously to improve variant calling results over the use of a single
caller [180, 31].
2.2 Simple somatic variants
I analyzed somatic SNV and indel variants (collectively simple somatic variants or SSVs)
using two linked consensus pipelines. Single nucleotide variants were called using Mutect1
[181], Mutect2 (via GATK version 3.8) [175], Strelka [182] and Strelka2 [183]. Indel
variants were called using Mutect2, Strelka1, Strelka2, SvABA [87] and Snowman, an
older version of the SvABA algorithm that was used in the Pancancer Analysis of Whole
Genomes [184]. SvABA and Snowman results were pulled from the structural variant calling
pipeline. The remaining algorithms were part of the SSV pipeline. The outputs of these
variant callers were converted from VCF into a common tab-separated format. This
file was then annotated by Oncotator [185] to convert this to a MAF-like format which
includes information such as gene name, variant context, and variant impact. These calls
were then annotated with two panels of normal samples, one from this study and one
from the Pancancer Analysis of Whole Genomes [31].
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3. OxoG filter
4. Tumor read count filter
5. Normal read count filter
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Fig. 2.4 Diagram of somatic calling pipeline.
This pipeline produced a union of roughly four million raw SSV calls among the
four callers. These were first filtered using a consensus voting scheme. Each variant
caller received one vote; however, callers using the same algorithm (i.e. Strelka1/2 and
SvABA/Snowman) could contribute a maximum of one vote between the two of them.
I required an SSV to receive at least two votes to remain in the set. Any SSV seen in
either the panel of normals from this study or from [31] was removed. Any variant seen
in dbSNP was labeled but not removed. Variants annotated as OxoG artifacts were
removed [186]. Lastly, calls which relied on fewer than 5 tumor alt-supporting reads or
where the normal sample had two or more alt-supporting reads were removed.
2.2.1 REBC PTC cases carry a comparatively low mutational
burden
Across the entire study, there were approximately 350,000 SSVs after filtering (per sample
mean = 920, median = 742, range = [12, 49910]). One sample exhibited a hypermutator
genotype, with roughly ten times the number of calls compared to the next highest tumor
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(shown in Figure 2.5A, but not within scale in Figure 2.5B or C.). Several tumors also
exhibit a very small number of variant calls (<100); many of these were flagged during
QC as low-purity tumor samples. The hypermutator sample was analyzed separately
where necessary to prevent distortion of overall statistics. Any tumors with purity less
than 20% were excluded from the calculation of summary statistics as well. With these
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D
Fig. 2.5 Overview of SSV counts for REBC samples. (A) The log10 mutation counts for
all 381 samples, with samples with more than 4,000 or fewer than 100 SSVs highlighted
in orange. Samples with low tumor purity are in light blue. (B) The number of SSVs
per megabase, excluding one SSV hypermutator sample. (C) The total SSV count per
sample. (D) The SSV count, per sample, broken down by variant class. Samples with
low purity are marked with a grey tick. The hypermutator sample exceeds the plot scale
and marked with a goldenrod tick.
The median number of mutations per megabase across all 360 REBC samples with
purity above 20% (and excluding the hypermutator) was 0.25. This was lower than
in the THCA sample set, which had a median of 0.35 mutations per megabase (per
sample mean SSV count = 1128, median = 1367, range = [54, 3832]). The REBC sample
set has among the lowest coding SSV counts per sample of any cancer type in The
Cancer Genome Atlas (Figure 2.6) [187]. However, the number of SSVs per sample is of
comparable magnitude to other thyroid studies [44, 53].























































































Fig. 2.6 A comparison of coding SSV counts between REBC and TCGA sample sets.
2.2.2 Somatic SSV counts increase with age
A low mutational burden is somewhat expected given that thyroid cancer has an age
at onset between that of pediatric and adult cancers. Pediatric cancers tend to have
mutation rates of 0.01 to 0.5 mutations per megabase [45]. The mutation counts in
REBC fall within this range.
There is a significant correlation between age and SSV burden across all of our samples
(p < 0.01, r2 = 0.51, Figure 2.7). It is well established that mutations accumulate with
age in both cancerous and normal cells [34]. I attempted to correct for the e ects of age
by fitting a linear model relating SSV counts to age at surgery across all three sample sets
and then examining the residuals between the observed and expected SSV counts. The
distribution of residuals is plotted against age at surgery in Figure 2.8. The randomness
of the residuals and the consistency of their medians across sample sets indicates that
much of the di erence in SSV count between groups can be explained by di erences in
the age of individuals within each sample set.
No di erence in SSV burden was seen between male and female cases (Kolmogorov-
Smirnov test p-value = 0.5). Nor was the number of SSVs signficantly correlated with




















Fig. 2.7 The number of SSVs generally increases with age across all three sample sets.
Samples flagged for low purity tend to have lower SSV counts regardless of which sample
set they belong to.
REBC−Exposed REBC−Unexposed THCA












Fig. 2.8 Residuals of predicted and observed SSV counts plotted against age at surgery.
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continuous radiation dose (Pearson’s test, p = 0.14). When examining dose categorically,
a significant di erence in mean SSV count was observed between dose groups (one-way
ANOVA, p = 0.006, Figure 2.9). However, this is likely due to the large di erences in
dose group size and having few samples (Æ20) in most of the dose groups. The medians
of the groups are approximately the same (Figure 2.9). For a linear model predicting
the number of mutations based on age at surgery, dose category, and sex, only age at
surgery was a significant predictor (p < 0.001, adjusted r2=0.247). The same was true
of a model which used the same age and sex variables but continuous dose rather than














Fig. 2.9 Number of SSVs plotted per dose group.
Overall, the substitution SSV mutation spectrum of our dataset is consistent with
those of previous studies on sporadic thyroid cancer. Thyroid cancer in general carries a
relatively small number of somatic SSVs and more closely resembles pediatric cancers
than those of adulthood in its SSV burden. There is a significant positive correlation
between SSV burden and age at surgery. No other phenotypic factors we tested were
associated with increased SSV burden. In addition, SSV hypermutation is rare, with
only a single sample exhibiting an order of magnitude more SSVs than the median count
per sample.
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2.2.3 MAPK genes are significantly mutated in papillary thy-
roid carcinoma
Next, I applied several methods to look for significantly mutated genes across our REBC
data sets. MutSig2CV [188] is designed to detect genes which have more mutations than














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2.10 Significantly mutated genes from MutSig2CV.
MutSig2CV reported nine significantly-mutated genes in the REBC samples. Four
of the nine genes are part of the MAPK pathway, which is mutated in the majority of
adult sporadic thyroid cancers, especially the papillary subtype [53, 189]. BRAF was
the most commonly mutated gene. Most of the BRAF mutations in our dataset are
the common BRAF V 600E thyroid and pan-cancer driver mutation. 140 / 291 (47%) of
exposed samples harbored a BRAF mutation, of which 134 (97%) were BRAF V 600E.
Three tumors had BRAF K601E mutations. One tumor had an in-frame insertion at
position 598 (BRAF 598_599insIDF GLA); one other tumor had an in-frame deletion at
BRAF 600_601V K>E. All of these alternative mutations likely have similar activating
e ects to BRAF V 600E.
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Protein Change Sample Set Number
p.V 600E REBC-Exposed 135
p.V 600E REBC-Unexposed 32
p.V 600E THCA 10
p.K601E REBC-Exposed 3
p.600_601V K > E REBC-Exposed 1
p.598_599insIDFGLA REBC-Exposed 1
Table 2.3 Overview of BRAF mutations in the three sample sets.
Three RAS genes (NRAS, HRAS, and KRAS) were the next most frequent sig-
nificantly mutated genes reported by MutSig2CV. These MAPK pathway genes are
well-established thyroid cancer drivers [53]. Mutations in the RAS genes are almost al-
ways mutually-exclusive with BRAF mutations. We observed this pattern in our samples,
with only one case harboring a mutation in BRAF K601E and KRASG12D. Mutations
in di erent RAS genes were mutually exclusive. Across sample sets, the individual
proportions of HRAS, KRAS, and NRAS mutations were similar.
2.2.4 Thyroid genes are frequently mutated in papillary thy-
roid carcinoma
Two genes essential for thyroid function —thyroglobulin (TG) and thyroid stimulating
hormone recepter (TSHR) —were reported as significantly mutated across sample sets
by MutSig. While both genes were mutated in a su cient number of samples to reach
study-wide significance, the mutations observed in TG appear to be the result of lineage-
specific mutational patterns. TG is the most highly expressed gene in follicular thyroid
cells and the TG protein is essential for production of thyroid hormones [190].
We found a high number of non-coding intronic indel mutations in TG, consistent with
a lineage-specific hypermutation pattern described by [191]. The ratio of noncoding to
coding mutations in TG was approximately 17:1, while the same ratio in well-established
PTC drivers (BRAF , NRAS, HRAS and KRAS) ranged from 1:2 to 1:20. The majority
of mutations in established drivers were primarily missense substitutions rather than
indels. While [191] reported this pattern in lineage-specific genes from multiple cancers
(including TG in 20-40% of thyroid tumors), they could not definitively conclude whether
the high frequency of these mutations was due to positive selection or a novel lineage-
specific mutational process which may be acting on highly-transcribed genes in open
chromatin. We note that the majority of TG mutations occurred along with mutations
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in other established PTC driver genes such as BRAF and NRAS, HRAS, and KRAS,
suggesting that mutations in TG are not su cient as oncogenic driver mutations on
their own. None of the mutations we observed were reported previously in COSMIC,
although the database does contain roughly 1000 other previously reported SSVs in TG
and specific mutations in TG are associated with enlarged thyroid, goiter, and other
clinical symptoms [192–195]. Given this evidence, we do not consider TG to be a primary
driver of papillary thyroid carcinoma.
MutSig reported TSHR (thyroid stimulating hormone receptor) as significantly
mutated in the REBC sample sets. Activating mutations in TSHR are found in approxi-
mately 4% of thyroid nodules [196]. MutSig reported TSHR mutations in 2% (6 / 381)
of the REBC samples (4 Exposed, 2 Unexposed) and 1 THCA sample. The patterns
observed in TSHR di ered from those observed in TG. The ratio of noncoding:coding
mutations in TSHR was 4:1 and the majority of mutations were substitutions rather than
indels, suggesting that TSHR is not subject to the same mutational process a ecting
TG. Four of seven samples with a TSHR mutation had at least one primary driver
mutation. Two samples had known driver mutations in BRAF and NRAS and one
had a whole-genome CNA pattern; the remaining TSHR mutant sample was the SSV
hypermutator. Considering the presence of other drivers and the relatively low number
of mutations across the sample sets it is unlikely that TSHR is a primary driver of
papillary thyroid carcinoma, though the possibility that it may be contributing to the
cancer phenotype cannot be ruled out from whole-genome data alone.
DICER1 was also reported as significantly mutated by MutSig. Three samples
harbored a coding DICER1 mutation, with two samples each possessing two indepen-
dent mutations. DICER1 codes for an endoribonuclease that is essential to microRNA
processing. Germline mutations in DICER1 are associated with predisposition to en-
docrine cancers and pleuropulmonary blastoma, a condition known as DICER1 Syndrome
[197, 198]. Somatic mutations in DICER1 tend to occur at known hotspots in trans with
germline hits to produce a second hit. All three samples with reported protein-altering
mutations in DICER1 were not exposed to radiation.
2.2.5 Pancancer drivers and frequently mutated genes
Three other genes were reported by MutSig as significantly mutated. AKT1 is a well-
established pan-cancer driver with clear oncogenic properties [199, 200] and was reported
as mutated (though not significantly) in sporadic thyroid cancer cases [53]. Three
mutations were found in the AKT1 tumor supressor gene, though all of these samples
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also contained mutations in other genes. Two genes, CR2 and DHX30, were reported
as significantly mutated but are likely not drivers. CR2 encodes a membrane receptor to
which Epstein-Barr virus binds to lymphocytes. Two of the three observed CR2 mutations
were predicted to be protein damaging by CADD and PolyPhen2 [201]. DHX30 encodes
a DEAD box protein that is a putative RNA helicase. None of the mutations we observed

































































Altered in 238 (62.47%) of 381 samples.
Fig. 2.11 Oncoplot of frequently mutated genes for SSVs in the REBC sample set.
In addition to significantly mutated genes I looked for genes that were mutated
frequently (but not necessarily reported as significant by MutSig) using maftools [202].
BRAF ; NRAS, HRAS and KRAS ; TG; TSHR; AKT1 ; and DICER1 were again reported
among the most frequently mutated genes. Other known thyroid cancer related genes
were reported as well. RET mutations were reported in four samples. RET is a well-
established fusion partner in both sporadic and radiation-associated thyroid cancer,
where activating fusions drive oncogenesis [189]. Activating mutations in RET are also
associated with the Multiple Endocrine Neoplasia family of familial cancer syndromes
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[203, 38]. RET K1007N was predicted to be damaging by CADD, SIFT and POLYPHEN;
RET R163Q, RET A26V , were predicted to be benign; and RET R67C was predicted to be
benign by all tools but POLYPHEN, which gave it a "possibly damaging" categorization.
Frequent mutations in TTN, PIEZO2 and many other genes were likely due to their size





























































































Fig. 2.12 SSV counts in genes, restricted to SSVs which overlap sites previously reported
as mutated in COSMIC.
I then examined mutations in frequently-mutated genes which overlapped variants
in the COSMIC database, broken down by sample set (Figure 2.12). Notably, all of
the DICER1 mutations in our dataset come from the unexposed cases. Three exposed
samples and one THCA sample had DICER1 mutations.
Mutations in other cancer-related genes were reported. There were no TP53 mutations
in the unexposed samples. TP53 is the most-commonly mutated gene across all cancers
[187]. TP53 mutations in thyroid cancer are associated with the more aggressive low
di erentiated subtypes [204]. Mutations in PIK3CA, APC, NOTCH1 and MEN1 were
also reported.
2.3 Insertion and deletion spectra
I next examined the insertion and deletion (collectively indels) spectra of samples. Indels
have been implicated as a possible result of radiation exposure in the genome [54]. For
these analyses, I chose to exclude the SSV hypermutator sample as well as any samples
deemed to have less than 20% purity, as these would not provide an accurate overview
of the total number of indels. It is also important to note that the THCA samples
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were sequenced using reads that are roughly fifty basepairs shorter than the sequencing












































Fig. 2.13 Insertion / deletion counts per sample
The number of indels per sample varied slightly across sample sets. THCA had a
median indel count per tumor of 64. REBC-Unexposed samples carried a median of 35
while REBC-Exposed samples carried a median of 49. REBC-Exposed carried a median
36 deletions (mean = 38, range = [2, 216]) and a median 13 insertions (mean = 13, range
= [2, 77]). THCA carried a median 53 deletions (mean = 5, range = [9, 119]) and 16
insertions (mean = 20, range = 1, 82). The REBC-Unexposed set carried a median 26
deletions (mean = 26, range = [2, 53]) and 10 insertions (mean = 11, range = [2, 53]).
2.3.1 Indel burden increases with age
Both SNVs and indels accumulate randomly with age even in normal cells [35, 34]. The
number of indels per tumor and age at surgery were significantly correlated across all
samples in our study (r2 = 0.54, p Æ 0.001, Figure 2.14).
When restricting the dataset to only REBC-Exposed and REBC-Unexposed samples,
this correlation was weaker but still significant (r2 = 0.32, p Æ 0.001). When excluding
low purity samples, r2 was slightly higher, indicating that purity may impact the ability
to call indels (r2 = 0.35).



























Fig. 2.14 Indel SSV burden generally increases with age. Low-purity samples also appear
to have lower-than-expected indel counts.
2.3.2 The indel to substitution ratio is correlated with radia-
tion dose
[54] reported that deletion events were the main signatures of radiation exposure, though
they examined only twelve samples which were exposed to high levels of medical radiation
(up to 30 Gy). The 303 REBC-Exposed samples were exposed to much lower amounts of
radiation, with most being exposed to less than 100 mGy (Table 2.2).
One metric reported by [54] to be indicative of radiation exposure was the ratio of
indels to substitution variants. [54] used the indel:substitution ratio as a method for
correcting for the age-related accumulation of mutations, analogous to comparing the
residuals of predicted indel burden based on age versus observed indel counts.
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Fig. 2.15 The number of indel SSVs generally increases with the number of substitution
SSVs.
After excluding the SSV hypermutator and low-purity samples, I assessed the in-
del:substitution ratio as a predictor of radiation dose. Figure 2.15 shows that the number
of indels increases with the number of substitution SSVs. Both indel count and substitu-
tion count are correlated with age at surgery (indels: r2 = 0.53; substitutions: r2 = 0.48;






























Fig. 2.16 The indel:substitution ratio, broken down by dose category and sample set.
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I first examined dose broken down categorically into five groups. Across dose groups,
the indel:substitution ratio increases with increasing dose Figure 2.16. A one-way ANOVA
test indicates that the means of these groups are not the same (p < 0.001). Unexposed
samples have roughly the same indel:substitution ratio across all sample sets.
I next examined dose as a continuous predictor for the indel:substitution ratio
(Figure 2.17A). Excluding samples that received an estimated dose of zero, the in-

















































Fig. 2.17 (A) The indel:SNV ratio plotted against estimated radiation dose and (B) IREP
probability of causation.
Last, I looked at how the indel:substitution ratio responded to the IREP-estimated
probability of causation (Figure 2.17B). IREP was developed to estimate the probability
that a radiation exposure of known dose caused an individual’s cancer. The model
incorporates attained age as part of its calculation and produces both an estimate
and a confidence interval for the predicted probability a given case was caused by
radiation. I used the 50th percentile estimate for the IREP value. There was a significant
correlation between the IREP POC 50th percentile estimate and the indel:substitution
2.3 Insertion and deletion spectra 56
ratio (Pearson’s test p-value < 0.001, r2=0.39). When examining IREP as a discrete set
of groups, there is a positive relationship with the indel:susbtitution ratio.
2.3.3 The deletion to insertion ratio is correlated with radia-
tion dose
In addition to the indel to substitution ratio, [54] reported that the ratio of genomic
deletions to insertions was correlated with exposure to radiation. Reference [54] found that
radiation-associated deletions occurred randomly across the genome, in sharp contrast
to deletions and insertions not caused by radiation. Reference [54] also reported high
rates of microhomology at deletion breakpoints, indicative of microhomology-mediated

















Fig. 2.18 The DEL:INS ratio.
In REBC-Exposed samples, there was a significant positive correlation between
continuous dose and the deletion:insertion ratio (r2 = 0.12, p = 0.036). However, dose
was a better predictor of the indel:substitution ratio than the deletion to insertion ratio.
The mean deletion:insertion ratio was not significantly di erent between dose groups
(one-way ANOVA, p = 0.05).
It is di cult to explain why the insertion:deletion ratio is not a strong responder to
increasing dose in the REBC sample set. The REBC study had relatively low insertion
and deletion counts in general which makes statistical inference di cult. It is possible
that the inflation in the number of deletions due to radiation exposure in this sample set
is insu cient to see an e ect.
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2.3.4 The deletion to substitution ratio is a better predictor of
exposure than the indel:substitution ratio
I next tested whether the deletion:substitution ratio might be a better measure of radiation
exposure than the indel:substitution or deletion:insertion ratios. The deletion:substitution
ratio was significantly correlated with continuous dose (r2 = 0.48, p < 0.001). The
strength of this correlation is slightly higher than that between the indel:substitution


















Fig. 2.19 The deletion:substitution ratio. This ratio generally increases with increase
radiation dose.
A one-way ANOVA indicated that the mean deletion:SNV ratio di ered between dose





























Fig. 2.20 The DEL:SNV ratio.
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The deletion:SNV ratio is a slightly better response variable to radiation exposure
than the indel to SNV ratio. This is in line with the findings of [54] that deletions, and
not insertions, are the primary small-variant indicator for exposure to radiation.
2.4 Somatic mutational signatures
Next, I applied the SignatureAnalyzer framework to look for substitution mutational
signatures in our sample sets. Signature analyzer uses non-negative matrix factorization
(NMF) to estimate mutational signatures of exposures and their corresponding amounts
based on counts of mutations in the 96 trinucleotide contexts. SignatureAnalyzer attempts
to automatically choose the best number of signatures for decomposition using a Bayesian
sampling approach.
As sample selection can significantly influence mutational signature detection, I
performed mutational signature decomposition using specific combinations of the data. I
first applied the method to all samples (THCA, REBC-Exposed, and REBC-Unexposed),
excluding the hypermutator and low purity samples.










































































































































































































































Mutation Signatures in REBC.THCA.noHyper.noLowPurity
Fig. 2.21 Signatures detected in THCA and REBC (excluding SSV hypermutator and
low purity samples).
The model converged to four signatures in the majority of its runs, though Signa-
tureAnalyzer reported five signatures as the best fit in two of its ten runs. However, the
five-signature model shows higher similarity to the well-defined signatures from COSMIC
2.4 Somatic mutational signatures 59


















































































Fig. 2.22 Five extracted mutational signatures from THCA and REBC samples (excluding
the SSV hypermutator and low purity samples) compared to COSMIC V3 SBS signatures.
I compared the mutational signatures found in our dataset(s) to the catalog described
in COSMIC v3 which were first described in reference [44]. This catalog contains
significantly more signatures than the COSMIC v2 signatures [32], and several of the
older signatures have been better resolved into multiple constituent new signatures.
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2.4.1 Evidence of APOBEC activity in PTC
Signatures W1 and W5 most resemble COSMIC signatures SBS13 and SBS2, respectively.
Both of these signatures are associated with APOBEC cytidine deaminase activity [60]
and have been previously reported in thyroid carcinoma as well as other cancers [44].
The activity levels of signatures W1 and W5 vary across tumors in our sample set, with
some tumors harboring many more mutations attributable to the underlying mutational
processes. This is consistent with unequal APOBEC activity among tumors.
2.4.2 Clock-like signatures predominate in raPTC
Signature W2 closely resembles SBS5, with relatively high similarity to SBS3 and SBS40
as well. All three of these signatures have relatively flat profiles and high similarity to one
another. SBS5 is seen in all cancers and is associated with signature SBS1 in some cancer
types [44]; both SBS1 and SBS5 are sometimes referred to as "clock-like" due to the
accumulation of associated mutations with age in both tumors and normal cells. While
aetiologies for SBS5 and SBS40 have not yet been established, both are correlated with
patient age in some cancers. SBS3 is related to deficiency in homologous-recombination
based DNA repair. Manual inspection and the presence of signature SBS1 (described
below) suggest that signature W2 is SBS5.
Signature W3 closely resembles SBS1, which is associated with an endogenous muta-
tional process. SBS1 has previously been reported in thyroid cancer. Overall, signatures
W1, W5, W2 and W3 reflect previously established mutational patterns in thyroid
cancer. These signatures were well-defined by the five-signature NMF model but not the
four-signature model. The remaining signature of the five-signature model (W4) most
closely resembles SBS22 and SBS25. SBS22 is associated with aristocholic acid exposure
and SBS25 is associated with exposure to chemotherapy, though neither signature has
been reported previously in thyroid cancer. Signature W4 is distributed relatively evenly
across our samples. Given this evidence, it is likely that W4 is an artifact of overfitting.
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Fig. 2.23 Signature activity in THCA and REBC (excluding SSV hypermutator and low
purity samples).
Signature activities vary across samples in our dataset, though some trends exist.
THCA samples tend to have more mutations attributable to W3 (SBS1). These samples
are significantly older, which may partially explain this di erence. Most mutations in
the dataset are attributable to Signature W2 (SBS5).
The SSV hypermutator sample was excluded from signature analysis because it had
an order of magnitude more mutations than any other sample. Single-base substitution
context proportions for this sample are shown in Figure 2.24. This profile resembles
COSMIC signatures SBS1 and SBS5 as well as components of several signatures proposed
to be the result of defects in DNA repair and mutations in DNA polymerase genes
(including SBS6, SBS14, SBS15, SBS20, SBS21). Defective DNA repair mechanisms
might help explain the high burden of mutations in this tumor. While this tumor had
multiple single hits in DNA repair genes and proofreading polymerases, no mutations
that could su ciently explain its hypermutator status were found in either its somatic or
germline catalogs. Further integrated analysis including expression and methylation data
will be required.
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Fig. 2.24 Trinucleotide mutational context proportions for the SSV hypermutator sample.
The profile of the mutational context proportions shows the characteristic peaks of SBS1
in C>T base changes. The large proportion of C>A base changes resembles a number of
SBS signatures related to DNA repair deficiency combined with mutations in proofreading
polymerases (including SBS14 and SBS20).
Overall, these results recapitulate established mutational signatures in thyroid carci-
noma and do not suggest the existence of a radiation-related mutational pattern in the
96-context substitution model. It is possible that longer substitution contexts might yield
evidence for a radiation exposure signature. However, the findings of [54] indicate that
an indel mutational signature for radiation exposure would be more likely. Additionally,
most of the variation in substitution SSV burden is attributable to age (Figure 2.8). If
radiation is inducing substitutions in the REBC-Exposed samples, those mutations are
accumulating at a rate below the sensitivity of SignatureAnalyzer to detect signatures in
this dataset.
2.4.3 Indel signatures are associated with radiation exposure
Reference [54] previously reported an increase in the number of small deletions, particu-
larly those longer than 2-3bp and with with microhomology at the breakpoint, within
radiation-exposed tumors. We found a significant association between the number of
small deletions and increasing radiation dose by examining the indel:substitution ratio in
the REBC sample set (see subsection 2.3.2). Our analysis, however, examined deletions
globally and did not take into account the length of the event or local sequence context
around the indel.
2.4 Somatic mutational signatures 63
Reference [44] used 83 di erent indel categories, or features, to generate indel mu-
tational signatures in more than 2,000 tumors from the Pancancer Analysis of Whole
Genomes study. These features incorporate information about the length of the indel,
the deleted base (for single-base indels), and whether the indel lies within a repeat or has
microhomology at its ends. Current versions of SigProfiler [205, 44] can take as input a
count matrix of these features and extract indel mutational signatures.
I calculated counts of indel features using https://github.com/edawson/presig, which
takes a MAF file as input and outputs a SigProfiler-compatible indel feature counts
matrix. I then performed NMF-based signature extraction using SigProfiler (python



































































































































































Fig. 2.25 De novo extracted indel (ID) signatures from SigProfiler for REBC samples.
Signature A resembles COSMIC ID8, a putative radiation signature. This signature
contains a major component of large deletions in repetitive elements and with microho-
mology. Signature B is highly similar to COSMIC ID1, a background mutational process
ubiquitous in almost all samples. There is strong evidence of remaining convolution in
both signatures; nearly all of the indel features that are not characteristic of ID1/ID8
are shared between Signature A and Signature B.
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The suggested solution reported by SigProfiler was for two signatures (shown in
Figure 2.25). Signature A resembles COSMIC ID8. ID8 was also reported in signature
decomposition performed automatically by SigProfiler (shown in Figure 2.26). It has
been suggested that COSMIC ID8 is associated with defective repair of double-strand
breaks, possibly induced by radiation [44]. The second signature reported (Signature
B) was enriched for insertions of a single base in cytosine homopolymers greater than
five basepairs in length (COSMIC SBS1). This signature has been attributed to slippage
during DNA replication and is found in almost all cancer samples.
Fig. 2.26 COSMIC indel signature ID8. ID8 is composed of mosly large deletions, often
within repeats or with small portions of microhomology (dark red and purple portions).
Roughly fifteen percent of all indel mutations in the REBC sample sets were attributed
to Signature A (3,166 of 20,257 total indels). I next assayed whether there was a correlation
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Fig. 2.27 (A) A beeswarm plot of the number of ID8-associated indel mutations per
sample, broken down by dose category. The number of ID8-associated indels increases
with increasing dose category. (B) The number of ID8-attributable indels plotted with
continuous radiation dose. There is a signficant association between the number of
ID8-attributable indels and increasing radiation dose (shown here with values over 1000
mGy truncated to minimize the e ect of outliers).
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The amount of ID8-attributable indels generally increases with increasing dose category
(Figure 2.27A). There was a signficant association between these indel features and
radiation dose (generalized linear model, p < 0.001) as well as age at surgery (generalized
linear model, p < 0.001), consistent with results described in subsection 2.3.2.
These results are consistent with those of reference [54], which reported an excess
of deletions with evidence of non-homologous end joining or microhomology-mediated
repair at their ends in radiation-exposed tumors. The same signature was observed in
[44] as well, primarily in tumors with DNA repair defects and concurrent evidence of
COSMIC SBS3. The REBC tumors lack evidence for high SBS3 activity. Reference [44]
also reported an association with age in some tissues. It is also important to note that
the total number of such indels per REBC sample is low, with a median of five per tumor
(range = [0, 40]), and that these indels also appear to be associated with age both in the
REBC sets and in [44]. A method for correcting for the e ect of age, like the indel to
substitution ratio, may be useful as a correlate to dose. This metric would still be unable
to attribute individual indels to radiation exposure, however. These results nonetheless
highlight a possible signature of radiation exposure and explain why radiation, while
a powerful carcinogen, does not appear to leave marked signatures in the single-base
substitution spectrum.
2.5 Germline variants
Germline variants can predispose individuals to higher risk of cancer [42, 37]. The germline
background also provides a genomic context that can explain cancer development in the
absence of a second recessive somatic hit or clear dominant somatic driver. Germline
variants in specific genes can predispose individuals to cancer after specific exposures.
Established radiosensitivity variants in genes such as ATM and RAD51C greatly increase
the risk of cancer development after exposure to ionizing radiation [206–209]. These
variants have largely been characterized from genome-wide association studies following
genotyping or exome sequencing of many thousands of individuals.
The REBC study is not of su cient size for discovery of novel predisposition variants.
At least several hundred more cases and controls would have been needed to detect
variants with even very large e ect sizes. It is however possible to accurately detect
established predisposition variants in each sample given that each normal was whole-
genome sequenced to su cient depth (Ø 40X for most normal samples). When overlayed
with information from somatic variant calling, a more complete picture of each tumor’s
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Sample Set Dose Category % of samples with T1 variant
REBC-Unexposed Unexposed 61%
THCA Unexposed 46%
REBC-Exposed 0-200 mGy 53%
REBC-Exposed 200-500 mGy 70%
REBC-Exposed 500-1000 mGy 57%
REBC-Exposed 1000+ mGy 35%
Table 2.4 Percentages of samples in each dose category that have at least one Tier 1
germline variant. Error bars are for a 95% confidence interval (binomal test).
life history emerges. In the REBC cohort, we also sought to explain the genesis of thyroid
cancer in some of the unexposed individuals, who are well below the median age of onset
yet still developed thyroid cancer in the absence of a known environmental exposure.
I called germline variants in these samples using a consensus calling mechanism. The
Strelka pipeline I implemented output germline SNV and indel calls along with the
somatic calls. I ran FreeBayes [210] in single-sample mode for every normal sample in our
dataset. I also ran GATK HaplotypeCaller for each sample and then performed joint
genotyping using GATK GenotypeGVCFs [92].
The results from these three callers were then normalized, combined, and annotated by
Dr. Hartley. Variants were all left-aligned and trimmed to normalize their representation.
Normalized variants were then merged into a single VCF with information about the
caller(s) of origin for each variant. This VCF was then annotated with population allele
frequency information as well as variant impact information from dbNSFP [211]. From
this information, the impact of a variant was calculated according to ACMG guidelines
[212] and with a custom tiering system. Only variants labeled Tier 1 (ACMG P/LP,
present in ClinVar [213], or SNPEFF high-impact [214]) were used in this analysis.
One hundred and sixty-six genes had at least one Tier 1 variant. Tier 1 germline
mutations included well-established cancer predisposition genes such as BRCA1/2 and
PTEN ; genes involved in DNA repair and microsatellite instability (ERCC2/6/8);
Fanconi Anemia predisposition genes (FANCA, etc.); and genes known to contribute to
radiation sensitivity (ATM , RAD51).
Across sample sets the number of samples with a Tier 1 germline variant was roughly
the same (REBC-Exposed: 55%; REBC-Unexposed: 61%; THCA:46%; pairwise Fisher
test p-values all > 0.1).
The proportion of samples with a Tier 1 variant varied across dose categories. This
variation was not significant, however. We hypothesized that the number of cases
















































































































































































Fig. 2.28 A waterfall plot of genes impacted by germline mutations.
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contributed by germline predisposition variants would decrease with increasing dose,
as more cases would be caused by mutagenic exposure to ionizing radiation. However,
neither dose nor the IREP POC 50th percentile estimate were significant predictors of
whether a sample had at least one Tier 1 variant (logistic glm, dose p = 0.13, IREP
p = 0.87; proportions per dose category with 95% confidence interval error bars for the
binomal test are shown in Figure 2.29). Our results suggest that there are not major
di erences in the rates of Tier 1 germline variants across groups. Proportions of samples

































































Fig. 2.29 Proportions of each sample set with at least one Tier 1 variant.
We observed some frequently mutated genes across samples sets, though we did not
have su cient power to find germline variants associated with radiation sensitivity even
at exceedingly high risk ratios (Figure 2.30). I restricted this analysis further to only
look at the missense, frameshift, or stop-gain mutations. POLQ was mutated across in
14 samples (1 THCA, 13 REBC) from all but the highest dose category. All of these
mutations were the same allele at the same position. It is possible that this mutations is
a germline polymorphism that is present at a higher frequency in the study population.
The next most-frequently observed mutated gene was CHEK1. CHEK1 mutations
were present in 7 of 381 REBC samples (1.8%). Two mutations were present in each of
these samples; based on local alignment of reads, these are likely to be false positives.
GJB2 was the next most frequently mutated gene. Seven samples (1 THCA, 6 REBC)
have mutations in GJB2. These variants were predicted to be pathogenic. Other genes
involved in DNA repair were repeatedly reported. The POLE and POLG genes were
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Fig. 2.30 Genes which are mutated by a frameshift, missense, or stop-gain mutation in at
least two samples.
One sample possessed two pathogenic loss-of-function germline mutations in ATM
and likely has clinical ataxia telangiectasia (AT). AT is characterized by neurological
symptoms, radiation sensitivity, and predisposition to various cancers [207]. This in-
dividual was not exposed to radiation and was diagnosed with PTC at age 16. This
was the only salient example of a clear predisposition disorder in the REBC-Unexposed
sample set. Further analysis beyond the scope of this work — including integration
with epigenetic data — is needed to better understand the germline-somatic interactions
within these sample sets.
2.6 Structural variation
In collaboration with Dr. Stewart, I analyzed the structural variant spectrum of the
REBC dataset using a consensus calling pipeline based on SvABA, dRanger, Manta, and
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snowman. Outputs from these programs were harmonized and merged to a common for-
mat, realigned around breakpoints by the Broad’s BreakPointer tool, and then annotated
with Oncotator to produce a MAF-like file.
Tumor BAM Normal BAM
dRanger SvABA Manta pcawg_snowman
1. Consensus filter
2. Tumor read count filter
3. Normal read count filter







Fig. 2.31 Structural variant calling pipeline.
The raw union SV callset contained roughly 86,000 variant calls. These were filtered
by a similar consensus scheme to small variants. Each caller recieved one vote, but
pcawg-snowman and SvABA could contribute a maximum of one vote together. Two
votes were required to pass a variant. Variants were then filtered to remove any with
fewer than 10 tumor supporting reads or 1 or more alt-supporting read in the normal.
All samples excluded from SSV analysis (i.e., those with low purity or failing quality
control) were excluded from SV analysis, except where explicitly noted.
2.6.1 Structural variants are common in papillary thyroid can-
cers
After filtering, 256 REBC-Exposed samples (84%), 57 REBC-Unexposed samples (73%)
and 31 THCA samples (62%) had at least one SV call. Most tumors harbored fewer than
three structural variants regardless of sample set (THCA median = 1; REBC-Exposed
median = 2; REBC-Unexposed median = 2).
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Fig. 2.32 Structural variant counts per sample, colored by SV type. Most tumors have
few SVs.
2.6.2 The number of rearrangements is associated with both
age and radiation dose
In the combined REBC and THCA dataset, age at surgery, radiation dose, and the number
of SSVs per sample were all associated with the total number of structural variants per
genome (Poisson generalized linear model; p = 8 ◊ 10≠8 for dose; p = 1.6 ◊ 10≠5 for age
at surgery; p = 0.006 for number of SSVs; SV and SSV hypermutator samples excluded).
The same was true when using dose category rather than continuous dose (poisson
generalized linear model; dose category p = 1.4 ◊ 10≠11; age at surgery p = 9.4 ◊ 10≠5;
number of SSVs p = 0.002). The number of structural variants generally increased
with increasing radiation dose category (Figure 2.33) It has been shown previously that
somatic structural variants accumulate with age in blood [215, 216].
Only the relationship between the number of structural events and dose was consis-
tently robust to stratification by age and sample set. For samples with a reported age at
surgery less than 25 only dose was still significant (n = 123; p = 8 ◊ 10≠8). This subset
of the data also had good class balance between exposed and unexposed samples and the
various dose groups. Between 25 and 45 years of age, all three predictors are significantly
associated with the number of SVs (Table 2.5). As only two REBC samples were older
than 45 years of age, we did not have su cient data to make inferences about associations























Fig. 2.33 Structural variant counts per sample, separated by dose category. The number
of structural variants generally increases with increasing dose.








REBC and THCA 429 p = 1.6 ◊
10≠5
p = 0.006 p = 8 ◊ 10≠8
REBC (Age < 25) 123 p = 0.07 p = 0.22 p = 8 ◊ 10≠5
REBC (25 < Age < 45) 269 p = 5 ◊ 10≠5 p = 9 ◊ 10≠9 p = 2.5 ◊ 10≠16
REBC (Dose > 0) 302 p = 9.5 ◊
10≠7
p = 0.28 p = 1.54 ◊
10≠14
Table 2.5 Table of p-values and sample sizes for GLM models, stratified by sample set
and age at surgery.
in this range. Among the 302 exposed samples (excluding any hypermutators), both age
at surgery and dose were associated with the number of structural events (Table 2.5).
These results suggest that radiation is inducing structural variant formation in exposed
samples. Structural variants also accumulate with age, as described above; however,
age-related accumulation is not significant across all age ranges. It is possible that the
same mechanism generating small deletions is responsible for generating large structural
variants. In subsection 2.6.7 I will explore whether gene fusions — the functional products
of certain structural variants — are also associated with increasing dose.
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2.6.3 Chromoplexy is frequent in papillary thyroid carcinomas
Three THCA samples and 20 REBC samples (6% of both sample sets) showed evidence
of chromoplexy. Chromoplexy was initially described in prostate cancer and has recently
been described in thyroid cancer as well as other neoplasms [69, 217]. It is thought that
chromoplexy is a result of DNA breakage and erroneous repair around spatially localized








































































































































Fig. 2.34 Overview of samples with chromoplexy. (A) Number of samples with apparent
chromoplexy, broken down by dose category. (B) Samples with apparent chromoplexy,
with age at surgery plotted on y-axis and dose category on the x-axis.
Similar rates of chromoplexy occur across dose categories (Figure 2.34A). Rates
of chromoplexy did not appear to be associated with either age at surgery or dose
(Figure 2.34B).
One REBC-Unexposed sample exhibited an SV hypermutator phenotype, with three
times more calls than any other tumor, caused by an apparent chromoplexy event
involving chromosomes 1, 2, 10, 13, and 18. The individual with this tumor was not
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exposed to radiation and had no clear germline predisposition variant that would explain
its high number of SV calls.
Fig. 2.35 Circos-style ideogram of chromosomes involved in structural variants in the SV
hypermutator sample. This sample had 141 reported structural events (82 interchromoso-
mal, 30 intrachromosomal deletions or translocations, 27 inversions and 2 duplications).
The large number of interchromosomal and inversion events on chromosome 10 (particular
the long arm) suggests a major chromoplexy event between chromosomes 1, 2, 10, 13,
and 18.
The SSV (small variant) hypermutator sample has the second highest number of
structural variants among all samples. This sample has lost portions of chromosomes
2, 3, 9, 11, 13, and 17. Chromosome 17 in this sample has 27 called structural variants
including tiled inversions and intrachromosomal translocations with occasional changes
in copy number. BreakPointer frequently reported microhomology at these breakpoints.
This sample also carries a somatic TP53R273C mutation, which may partially explain its
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genomic instability. The SSV hypermutator was exposed to radiation, though it had a
relatively low exposure of 160 mGy.
2.6.4 Whole genome CNA signatures
Two samples displayed a whole genome copy number aberration (CNA) signature similar
to one previously described in Hürthle cell carcinomas [218] (Figure 2.36). Hürthle cell
carcinoma (HCC) is generally considered a variant of the follicular subtype of thyroid
cancer and not a papillary carcinoma [219]. Reference [218] reported that more than half
of HCC tumors sequenced displayed a near-haploid state with consistent preservation of
both copies of chromosomes 5, 7, 12 and 20. These chromosomes are conserved at higher
copy number in both whole-genome copy number aberration cases we observed. Both
samples were female, received an estimated dose of 150 and 165 mGy, and had IREP
50th percentile values of approximately 50%.
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Fig. 2.36 Two samples showed whole genome copy number aberration signatures consistent
with previously reported signatures in Hürthle Cell Carcinoma. This signature has been
reported as a genome-halving event, where one copy of most chromosomes are entirely
lost with the exception of chromosomes 5, 7, 12 and 20, which are preserved in a diploid
state. (A) and (B) show total plots of copy number estimates (top) and allele fraction
(bottom). (A) A sample with significant allele ratio shifts for most chromosomes. Total
copy number estimates are shifted as well but appear to be confounded by sample purity,
which for this sample was less than 50%. (B) A second sample with clear loss of most
chromosomes except those canonically preserved in some Hürthle Cell Carcinoma samples.
This sample had an estimated tumor purity of greater than 85%.
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There is some debate about whether the copy number alterations observed in Hürthle
cell tumors is a genome-halving or genome-doubling event (private communication, Dr.
Chip Stewart and Dr. Gad Getz). The tumor copy number profile shown in Figure 2.36A
is for a tumor with less than 50% purity, making proper copy number determination
di cult. While the tumor profile shown in Figure 2.36B comes from a tumor with
estimated purity Ø 90% and is more stable, it appears to show an increase in the copy
number of the characteristic HCC chromosomes rather than a loss. Pathology data
from these tumors did not support a histologic classification as Hürthle cell carcinoma,
however the similarity of the genetic CNA profiles to those described in reference [218]
warrants further examination of Hürthle cell carcinoma CNA activity.
2.6.5 Inversions and translocations are common in thyroid car-
cinomas
Certain large variant classes were more common in specific sample sets. One hundred and
twenty-eight tumors (42%) in the REBC-Exposed sample set had at least one inversion
compared to 32% (25) of REBC-Unexposed samples and 25% (13) of THCA samples.































Fig. 2.37 Structural variant counts per sample broken down by variant class and sample
set. The SV hypermutator sample has been excluded. In general, tumors in the
REBC-Exposed set contain more interchromosomal and inversion variants. Deletion
and duplication counts per tumor are similar across sample sets. Intrachromosomal
translocations, which may actually represent inversions, non-tandem duplications, or
copy-neutral intrachromosomal exchanges but are not reported unambiguously by the
SV detection programs, are again elevated in the exposed group.
A higher proportion of REBC-Exposed tumors harbored an interchromosomal translo-
cation compared to unexposed tumors. Sixty-three percent (192 of 303) tumors harbored
at least one interchromosomal variant. Fifty-two percent of REBC-Unexposed samples
(41 of 78) had at least one interchromosomal variant compared to forty-six percent (23 of
50) of THCA samples.
Balanced inversions and translocations have previously been implicated as possible
signatures of radiation exposure [54]. Radiation induces single- and double-strand breaks
in the DNA [170]; this damage and subsequent repair has been hypothesized to cause
structural variant formation as well as formation of small deletions.
I tested the association between dose and the number of each SV class when correcting
for age at surgery, the number of SNVs and the number of small indels. Dose was not
associated with an increase in the number of deletions (poisson glm, REBC-Unexposed
and REBC-Exposed sample sets excluding SSV and SV hypermutators, number of SNVs
p = 0.28; number of indels p = 4.3 ◊ 10≠7; age at surgery p = 0.0005; dose truncated to
1000 mGy p = 0.45). Dose was significantly associated with the number of inversions
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(poisson glm, number of SNVs p = 7.8 ◊ 10≠8; number of indels p = 0.026; age at surgery
p < 2 ◊ 10≠16; dose truncated to 1000 mGy p < 2 ◊ 10≠16); it was also associated with
the number of interchromosomal variants (poisson glm, number of SNVs p < 2 ◊ 10≠16;
number of indels p < 2 ◊ 10≠16; age at surgery p < 2 ◊ 10≠16; dose truncated to 1000
mGy p = 4.6◊10≠5). While dose was associated with the number of tandem duplications
the low number of duplications both per sample and across the sample sets necessitates
skepticism about this result (poisson glm, number of SNVs p = 0.028; number of indels
p = 0.046; age at surgery p = 1.44 ◊ 10≠8; dose truncated to 1000 mGy p = 3.16 ◊ 10≠7).
As intrachromosomal translocations are ambiguously classified, we chose not to test their
association with dose. These results are in line with those described in subsection 2.6.2;
increased radiation dose appears to be associated with an increase in the number of
structural variants. It is di cult, however, to attribute any single genomic event to a
radiation strike. Reference [54] reported high levels of microhomology and balanced copy
number around structural variants in tumors that were exposed to radiation, as well the
increase in the indel to SNV ratio we observed in subsection 2.3.2. Work to characterize
the individual breakpoints and genomic contexts of the variants in this cohort is planned
as a followup to publications describing the overall mutational landscape.
2.6.6 Chromosome 10 is commonly involved in structural vari-
ants in PTC
Structural variants are not distributed evenly across the genome in PTC cases (‰2
goodness-of-fit test; p < 0.001). Chromosome 10 harbors a disproportionately high
number of events compared to all other chromosomes.
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Fig. 2.38 Counts of intrachromosomal structural variants per chromosome.
Chromosome 10 had the highest number of intrachromosomal events (Figure 2.38). It
also had many more inversions and intrachromosomal translocations. Figure 2.39 shows
the chord diagram of interchromosomal structural variants across all three sample sets.
Again, chromosome 10 is recurrently impacted by structural variants involving multiple
chromosomes, although chromosomes 1, 2 and 12 have similar numbers of interchromoso-
mal variants. Chromosome 12 and 15 were the most common interchromosomal partners,
most often resulting in a gene fusion between ETV 6 and NTRK3.































































Fig. 2.39 Chord diagram of chromosomes involved in interchromosomal structural variants.
Arc lengths and arc labels correspond to the number of structural events per chromosome.
There is great diversity in chromosome partners across the sample sets; variants pair
every autosome with at least three others. Chromosomes 1, 2, 10 and 12 are the most
impacted, though this is partially driven by chromoplexy events (including in the SV
hypermutator).
To correct for any samples with multiple events on chromosome 10 that might inflate
this number I also plotted the number of samples which reported an event on a given
chromosome (Figure 2.40).










Fig. 2.40 Counts of samples with at least one intrachromosomal event per chromosome.
Seventy samples (48 REBC-Exposed, 13 REBC-Unexposed, 9 THCA) had at least
one lesion on chromosome 10. There are several reasons for the prevalence of structural
variants on chromosome 10. In samples with at least one structural variant on chromosome
10, 32 REBC-Exposed (66%), 8 REBC-Unexposed (61%), and 7 THCA (77%) samples
had a structural variant that impacted RET . The RET proto-oncogene resides at position
10q11.2. RET is commonly rearranged in papillary thyroid carcinoma, especially among
cases that are exposed to radiation [220, 167]. RET fusions are potent drivers of papillary
thyroid carcinoma. There is some evidence that the 10q11.2 region of chromosome 10
may be more sensitive to radiation compared to the rest of the genome [221].

























Fig. 2.41 Counts of RET fusions in our sample sets.
RET -CCDC6 was the most common RET -PTC fusion across all sample sets. Also
called RET -PTC1, RET -CCDC6 is the most common RET fusion reported in studies
of papillary thyroid carcinoma [220]. RET -CCDC6 comprises up to 70% of the observed
RET rearrangements in some studies.
We observed other previously reported RET gene fusions as well as novel fusions.
RET -NCOA4 (RET -PTC3) was the second most common fusion in our study. RET -
TRIM24 and RET ≠ TRIM33 have been previously reported and we observe these in
our dataset. We observe a novel fusion between RET and TG. This fusion conserves the
kinase domain beginning at exon 11 like all other observed RET fusions, and it is likely
functional.







































































Fig. 2.42 Counts of all gene fusions in our sample sets.
2.6.7 Gene fusions are common in radiation-associated PTC
We corroborated DNA fusion calls with RNA calls where data was available. Our pipeline
showed very high concordance rates for gene fusion calls between RNA and DNA. Of
a total 168 RNA fusion calls, 137 (81.5%) were called as in-frame fusions by the DNA
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pipeline and an additional 10 (5.9%, total: 87.5%) were called but labeled out-frame-
fusion (not shown). The high concordance rates observed between the two orthogonal
sequencing strategies and pipelines suggest that our DNA data is of su cient sensitivity
and specificity for further analysis.
Although RET was the most common fusion partner many other gene fusions were
observed (Figure 2.42). [53] reported gene fusion drivers in 15.3% of their 484 whole-
exome sequenced samples. Gene fusions have been reported at much higher rates in
studies of children exposed to ionizing radiation, particularly the RET-PTC family of
fusions, which are present in 50-85% of samples in some studies [222, 223].
The REBC-Exposed sample set displayed a high proportion of gene fusions, many of
which are known drivers. Thirty-three percent (102 of 303) radiation-exposed samples
had at least one in-frame gene fusion. Twenty seven percent of REBC-Unexposed and
twenty-eight percent of THCA samples had at least one gene fusion. However, examining
exposure in a binary fashion obscures the fact that di erent dose groups showed much
larger di erences in the proportion of samples with at least one gene fusion.
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Fig. 2.43 Proportion of gene fusions by dose category. The proportion of observed gene
fusions tends to increase with increasing dose category. The proportion of gene fusions
ranges from roughly 25% in unexposed groups to roughly 75% in samples exposed to
between 500 and 1000 mGy.
There was a positive association between radiation dose and whether a sample had
at least one gene fusion when correcting for age at surgery, the number of SNVs, and the
number of indels (binomal logistic glm; restricted to REBC sample set; age at surgery
p = 0.0001; number of SNVs p = 0.27; number of indels p = 0.12; dose p = 0.0096). As
most samples had only one fusion, we were not able to test whether the number of fusions
per sample was associated with dose via Poisson regression. In line with the association
between fusion status and dose, the proportion of samples with at least one gene fusion
increases with categorical dose. At 0-200 mGy, roughly the same proportion (26.8%) of
samples in the REBC-Exposed set have a gene fusion compared to the REBC-Unexposed
and THCA sets. However, this proportion increases to 50% of samples in the higher dose
groups, with more than 75% of tumors in the 500-1000 mGy dose group possessing a gene
fusion. Reference [223] did not report the doses their samples received. Reference [222]
found RET rearrangments in 84% of observed irradiated thyroid carcinomas, compared
to 15% of sporadic tumors. These medically-irradiated tumors received significantly
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higher doses than tumors in our study. Overall, the proportions of tumors in each of the
REBC sample sets corroborates the results of past studies of radiation-associated thyroid
carcinomas as well as the association between dose and the number of rearrangements
described in subsection 2.6.2.
2.6.8 Breakpoints in fused genes are recurrent
We would expect structural variant breakpoints around a radiosensitive site to be highly
recurrent. Recurrent breakpoints will also occur where the gene fusion produced is
















































































Fig. 2.44 Genomic positions of gene fusion partners for the ten most fused genes. Each
bin is 1kb wide.
Breakpoints in RET were highly recurrent, with 32 breakpoints occuring within a
single 3kb span. This region falls immediately before the eleventh exon of RET. Active
RET fusions always occur in this region [224]. Transcribed fusions always include the
kinase domain but lack the transmembrane and extracellular domains [220].
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2.7 Papillary thyroid tumors tend to be driven by
one or few mutations
Figure 2.45 shows the overall driver landscape of REBC papillary thyroid carcinomas.
Most tumors have only one driver mutation. This is in line with patterns established
in pediatric tumors [45] and previous studies of papillary thyroid carcinoma [53]. Gene
fusions and SSV drivers are mutually exclusive, as are individual mutations in the MAPK
pathway.



























































































































Fig. 2.45 Drivers of raPTC broken down by sample set and radiation exposure group.
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Sample Set % BRAF driver % NRAS % HRAS % KRAS Total MAPK %
THCA 20 4 2 0 26
REBC-Unexposed 41 5.1 2.6 2.6 51.3
REBC, 0-200mGy 51.9 5.5 4.3 3.4 65.1
REBC, 200-500mGy 29.7 2.7 0 0 32.4
REBC, 500-1000mGy 14.3 0 0 0 14.3
REBC, 1000+mGy 29.4 0 5.9 0 35.3
Table 2.6 MAPK mutation rates across dose groups. Higher dose groups tend to have a
lower proportion of samples with MAPK SSV drivers.
Chromosome 22 loss, which has previously been implicated in thyroid carcinoma,
does not appear to be su cient to drive tumor progression. All samples with a reported
chromosome 22 CNA also had another driver mutation.
As described in subsection 2.2.3, the majority of our samples carry a BRAF , NRAS,
KRAS or HRAS mutations, all of which are well-established potent drivers of thyroid
carcinoma. 172 (56.7%) of exposed samples and 40 (51.2%) of unexposed REBC samples
had SSV drivers in the MAPK pathway. While only 26% (13 / 50) THCA samples had
an SSV MAPK driver, the rate of MAPK SSV drivers in the overall dataset described
in [53] was 61.7%.
The proportion of samples with a MAP SSV driver varied by radiation dose group
(Table 2.6). As dose increased the proportion of samples with a MAPK SSV driver
generally decreased, with a corresponding rise in the number of gene fusion drivers
(Figure 2.46).


































































Fig. 2.46 Proportion of samples with a putative SV-induced gene fusion driver. This
figure is essentially a reproduction of Figure 2.43, with the additional restriction that
fusions in this plot must be putative drivers and with the inclusion of error bars (binomial
test). Again, an increase in the proportion of gene fusions is observed with increasing dose
group. The unexposed groups (both REBC and THCA) as well as the lowest exposure
group (<200 mGy) have approximately the same proportion of gene fusions.
2.8 TERT promoter mutations are rare in pediatric
PTC
Mutations in the promoter of the TERT gene are associated with worse prognosis and
less-di erentiated tumors in thyroid cancer [225, 226]. TERT mutations are also typically
associated with greater age at diagnosis. I scanned our datasets for any mutations in
the TERT gene or promoter regions. We verified that we had su cient coverage to
call mutations in all REBC samples, and Dr. Stewart performed forced calling of the
TERT promoter region for all 381 REBC samples using Mutect; similar analyses were
performed for the THCA data in [53]. In our fifty THCA samples, 10 tumors (20%)
had canonical TERT promoter mutations. This rate is comparable to that found in
the entire THCA [53] dataset where TERT promoter mutations were found in 36% of
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samples. The youngest individual with a TERT mutation in THCA was 49 years of
age. Across all 381 REBC samples, only one sample had a canonical TERT promoter
mutation. This individual was 40 years old at surgery, among the oldest in our study. All

































Fig. 2.47 Mutations in the TERT promoter region are associated with age.
These results support previous results indicating that TERT promoter mutations
are associated with age. While we could not test for an association with dose, we note
that the single REBC sample with a TERT promoter mutation received an estimated
dose of 31 mGy, among the lowest in the dataset. The IREP 95% confidence interval of
probability of causation due to radiation exposure was [2.7, 31.8], indicating that this
individual’s cancer was unlikely to be caused by radiation.
2.9 Conclusions
Our study comprises the largest collection of whole-genome sequenced irradiated tumors
to date. Exposure to ionizing radiation is a well-established risk factor for development
of thyroid cancer. In 381 tumors from the Chernobyl Tissue bank and an additional
50 from The Cancer Genome Atlas, we find striking similarities between sporadic and
radiation-associated cases of papillary thyroid carcinoma. We also validate markers of
radiation exposure in the genome which were previously suggested but which could not
be verified without a study of this size.
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2.9.1 The genetic landscape of radiation-associated papillary
thyroid carcinoma
Papillary thyroid carcinoma has a low somatic mutation rate compared to all other adult
cancers. The median coding mutation count per tumor in our study is lower than that of
any other adult cancer in the original 12 TCGA cancer types. There is a clear association
between age at surgery and the number of SSVs. This association holds when looking
at substitution or indel SSVs alone. Papillary thyroid carcinomas have relatively low
mutation rates and are most often driven by a single driver mutation. Our data support
a model of thyroid cancer as an intermediate between adult and pediatric cases.
Constitutive activation of the MAPK pathway through either SSVs or gene fusions is
the primary mechanism of driver formation in papillary thyroid carcinoma. The MAPK
pathway contains the well-known BRAF , HRAS, NRAS, and KRAS genes as well as
the RET proto-oncogene that is often involved in gene fusions in radiation-associated
cases. While we observe other pancancer drivers in our dataset, these occur in tandem
with a MAPK mutation. MAPK mutations appear to be essential to papillary thyroid
carcinoma development.
TP53, the most commonly mutated gene across all cancer types, is rarely mutated
in papillary thyroid carcinoma. Only three tumors of 431 have a protein-altering TP53
mutation. TP53 mutations were mutually exclusive with BRAF V 600E mutations, the
most common driver in papillary thyroid carcinoma. BRAF mutation may alter TP53
expression via oncomiR-3151, and BRAF mutation alone may be su cient to alter
TP53 activity [227]. Unlike TERT , all TP53 mutants were thirty years old or less at
surgery. We did not have su cient information to test whether TP53 mutation was
associated with more aggressive disease, though our single SSV hypermutator was among
the three samples with a TP53 mutation. We did not observe any pathogenic TP53
germline mutations, either, though germline TP53 mutations in Li-Fraumeni syndrome
are associated with an increase risk of thyroid cancer.
No TERT promoter mutations were present in papillary thyroid carcinomas diagnosed
before age 40. This suggests that acquisition of TERT promoter mutations is neither
necessary nor su cient for development of PTC. Also missing from our REBC sample set
are any mutations in EIF1AX, previously reported as significantly mutated in sporadic
thyroid carcinoma.
Two genes essential to thyroid function, TG and TSHR, are significantly mutated in
the REBC sample set. Mutations in these genes always occurred in tumors which also
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possessed a driver mutation in one of the MAPK genes, indicating that such mutations
are not likely drivers on their own. TG mutations, many of which are indels, are likely
due to a previously-described lineage-specific hypermutational process [191].
DICER1, a gene essential in miRNA processing, was frequently mutated in tumors
in unexposed cases and was present exclusively in tumors which lacked a MAPK driver.
DICER1 is an established cancer predisposition gene. DICER1 syndrome requires only
one mutated allele to predispose one to cancer and cause miRNA dysregulation [228].
Our data indicate that somatic inactivation of one allele of DICER1 may predispose
one to papillary thyroid carcinoma.
The dominant mutational signatures of our dataset are the same as those of sporadic
papillary thyroid carcinoma. Signatures SBS2 and SBS13 mark the activity of the
APOBEC family of cytidine deaminases. APOBEC is widely active in tumors [229];
APOBEC-induced mutations are present across all three sample sets examined in this
thesis. APOBEC contributes to the mutational load of individual tumors but is not the
primary driver of carcinogenesis.
The majority of mutations in our dataset were attributable to signatures SBS1 and
SBS5. Mutations attributed to these two signatures occur in all human cancers and normal
cells, often at consistent rates with age [230]. While an underlying mutational process
has not been determined it is hypothesized that both are due to endogenous cellular
processes and not external exposures. The remaining signature predicted most resembled
signatures SBS22 and SBS25, two signatures thought to be related to chemotherapy
exposure [32]. Neither signature SBS22 nor signature SBS25 have previously been
reported in thyroid carcinoma, and to the best of our knowledge no patients in this
dataset received chemotherapy. The signature is ubiquitous across our samples but at
very low proportions of mutations. This signature may be a result of overfitting or an
exposure common to both exposed and unexposed individuals. The SSV hypermutator
shows evidence of defective DNA repair, possibly combined with mutations in DNA
polymerases, in its mutational context spectrum.
We did not see an association between radiation dose and the number of SSVs.
Substitution SSVs are strongly associated with age, and most of the SSVs in our dataset
are attributable to clock-like mutational signatures that accumulate mutations with age.
These facts together support the idea that radiation does not induce substitutions in the
genome at observable rates for the doses in our study.
Radiation exposure was associated with an increase in the proportion of indels,
particulary deletions. Deletions also accumulate with age, and ratios which corrected
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for the accumulation of somatic mutations with time were better response variables to
radiation dose than raw counts. The deletion:substitution ratio was significantly correlated
with radiation dose as well as IREP probability of causation. The deletion:substitution
ratio is a potential dose-sensitive genomic marker for radiation exposure.
We were able to fit two indel mutational signatures in the REBC dataset. One
of these signatures resembles COSMIC ID8, which has previously been reported as
a putative signature of radiation exposure. The indel features of this signature are
positively associated with radiation dose in the REBC dataset. The remaining signature
resembles COSMIC ID1, with some remaining convolution shared with the first signature.
ID1 is ubiquitous across samples and cancer types and likely represents a background
mutational process much like SBS1 or SBS5.
Structural variants are common in papillary thyroid carcinoma. Most tumors in our
sample sets have at least one structural variant. The burden of structural variants per
tumor is low, however, with a median of only one event per tumor. This event is often
the driver gene fusion. Structural variants of all classes are represented, though large
inversions and translocations, usually rare, are common in these data sets. Radiation dose
is associated with the number of structural variants within a sample, as is age at surgery.
The number of SSVs is sometimes associated with the number of structural variants,
though this association does not hold across all ages. Certain types of structural variants,
particularly inversions and interchromosomal translocations, were again associated with
increasing radiation dose. These associations provide more evidence for the hypothesis
that radiation is inducing double-strand breaks, some of which generate structural variants
when erroneously repaired.
Chromoplexy occurs in roughly 6% of papillary thyroid carcinomas. This rate is
consistent with that reported in the PCAWG study. Chromplexy often results in formation
of a fusion gene. There was no di erence in the proportion of samples with chromoplexy
between exposed and unexposed sample sets. We conclude that chromoplexy is most
likely not induced by radiation but is common in both sporadic and radiation-associated
papillary thyroid carcinomas.
Chromosome 10 is commonly involved in structural variation in PTC. This is likely
because of the presence of the RET proto-oncogene on Chromosome 10. RET is the
most common gene fusion partner in our dataset and a primary driver of constitutive
MAPK activation. Gene fusions were more common among radiation-exposed tumors,
with 25% of unexposed tumors and more than 50% of radiation exposed tumors having
at least one in-frame fusion. These fusions are formed primarily by balanced inversions
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and translocations. Cytogenetic data indicates the rate of inversions and translocations
increases with radiation dose [66]. A high proportion of gene fusion drivers (especially
RET ≠ PTC fusions) was reported previously in Chernobyl-associated PTC cases [222],
but the authors could not comment on whether the e ect was dose-dependent. We
find that the proportion of gene fusions generally increases with increasing exposure to
radionuclides and that this association reaches statistical significance.
Together, these results support previous results regarding the role of 131I in thyroid
carcinogenesis. Iodine radionuclides sequestered in the thyroid generate double-strand
breaks in the DNA in cells. These breaks can create driver mutations, especially gene
fusions, by misrepair. Errors in repair also lead to an excess of small deletions. The ratio
of deletions to substitutions provides a useful correlate to radiation exposure, one that
may one day act as a useful biomarker for measuring radiation exposure in next-generation
sequencing reads.
2.9.2 The REBC study as a possible model of multistage car-
cinogenesis and attributable risk
Certain aspects of the REBC study suggest it may be useful in deciphering the number of
mutations required for thyroid carcinoma formation and the e ects of external carcinogens,
particularly ionizing radiation. The number of drivers required for carcinogenesis has
been a matter of debate for decades, with Armitage and Doll describing a multi-stage
model of carcinogenesis in 1954 following previous studies conducted some years earlier
[231]. Armitage and Doll fit regression lines to log-transformed mortality rates on log-
transformed age for a number of cancers obtained from registries in England and Wales.
Based on work by Nordling [232], they hypothesized that the slope of these lines could be
attributed to the approximate number of successive steps required for cancer development,
with the additional complication of variable slope due to carcinogenic exposure. They
concluded that a multi-stage process consisting of six or seven stages (i.e., mutations)
could explain the patterns they observed, including the rapid increase with age, the
irregularity of this increase in some cancer types, the latent period between carcinogenic
exposure and tumor development, and that cancer incidence is often proportional to
carcinogenic exposure. Their work also established a mathematical link between age,
carcinogenic exposure, and mutation that has been continued by others [155, 233, 35].
Notably, Tomasetti et al. provided an extension of Armitage and Doll’s work in the
sequencing era [233]. Rather than death statistics, Tomasetti et al. used a mathematical
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model based on incidence, the number of drivers, and the number of mutations per year
to estimate the number of drivers required for tumor formation, leveraging the fact that
subtypes of certain cancers have both di erent risks and di erent mutation rates. The
use of the ratio of mutation rates means that this method is advantageously independent
of the strong dependence of cancer incidence on age. Their model predicted the number
of required driver mutations to be three for both lung adenocarcinoma and colorectal
cancers. An approach such as this based on the total number of mutations (in this case
in the exome) is only enabled by the ability of sequencing to capture the mutational
burden of a tumor, which was not assayable in the time of Armitage and Doll.
A determination of the number of drivers (or tumors) attributable to radiation is
beyond the scope of this thesis but certainly warrants investigation. The REBC dataset is
comprised of whole-genome sequenced samples with a defined, acute carcinogenic exposure,
including samples which received no radiation. There are notable genomic di erences
between exposed and unexposed samples, especially the proportion of gene fusion drivers.
These characteristics suggest it may be possible with additional data to estimate the
proportion of tumors attributable to radiation exposure. Many of the required variables
for analysis are present in the REBC dataset. Given that the time of the nuclear release
from Chernobyl is well-known, there are highly accurate estimates for age at exposure.
Dosimetry data provides a continuous measure of carcinogenic exposure. IREP values
give an integrated measure of probability of causation by radiation, accounting for age,
sex, latency, and specific background risk. Age at surgery is also available, though
this number is slightly confounded by intensive screening in the a ected areas after
the Chernobyl accident which likely brought many cases to the attention of medical
professionals years before they would otherwise have been detected. From these two ages
it is possible to derive the approximate latency between exposure and tumor detection
for this dataset.
Certain challenges prevent simply applying the model of reference [233], however. The
IREP values obtained in the study provide probability of causation but not estimates of
relative risk between the exposed and unexposed subgroups. While estimated di erences
in incidence between sporadic and radiation-exposed pediatric thyroid cancer range from
2 to 7-fold at 1 Gray [167, 234, 235], the per-year SSV mutation rates are nearly identical
in exposed and unexposed samples. As demonstrated in subsection 2.2.2, the number of
SSVs per tumor is predominantly determined by age. This evidence suggests that SSV
acquisition is not the rate limiting step in many of the REBC tumors. The structural
variant or small deletion rate may provide a more useful measure, though many samples
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have zero structural variants or indels. The small number of highly-exposed samples and
the di culty of determining whether a given tumor is attributable to radiation at low
dose further complicates such analyses.
We leave the calculation of the driver number mutations required for papillary thyroid
carcinoma formation to future studies as well, though note that it appears to be one or
two based on the somatic changes we observe. Most tumors in the dataset are driven by
activating SSVs or gene fusions in onocgenes. Integrated analysis of whole-genome data
with RNA sequencing and methylation will further inform this observation.
Chapter 3
Structural variation in variation
graphs
3.1 Introduction
In the previous chapter, I analyzed whole-genome data using algorithms which operate on
linear reference genomes. Structural variants were common in this dataset and frequently
generated gene fusion driver mutations.
In this chapter, I discuss how to perform comparable cancer-related analyses using
graph-based references with a particular focus on variants longer than fifty basepairs.
I first describe how structural variants are best represented in variation graphs and
why some representations are more advantageous than others. This requires discussing
strategies for selecting variants and constructing graphs. I then demonstrate how graphs
can improve long variant genotyping for previously discovered variants. I briefly introduce
methods for detecting structural variant breakpoints on variant graphs. Finally, I discuss
applications of variant graphs in cancer-specific contexts.
3.1.1 Publication and collaboration notes
GFAKluge, which is used here for calculating graph statistics and which makes up a core
part of the data interchange machinery of the variation graph toolkit, was published in
[236]. The construction logic and variant forms described in section 3.2 are implemented
in the variation graph toolkit, which was published in [99]. These have been extended in
the svaha variant graph constructor and [3]. [99] and [3] involved significant collaboration
with the authors of both papers.
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3.2 Representing structural variants in graphs
While there is a single straightforward method for representing simple substitution
variants in a graph (Figure 3.1), there are multiple ways to represent longer indels and
structural variants. Choosing a variant representation can have significant impacts on
















Fig. 3.1 A variation graph containing five substitution variants with two alleles each.
Each allele is represented by a single side of a bubble in the graph. Haplotypes would
trace paths through these in a directed fashion. vg represents all possible haplotypes
that could be generated from input variation. Graphs containing only substitutions are
naturally acyclic.
Variation graphs may be cyclic or acyclic, though in practice it is common to convert
cyclic structures to implicit directed acyclic ones to facilitate graph processing. In this
work I will refer only to acyclic graphs.
A common operation when in linear reference space is to left-align and trim variants
[92]. This produces a standardized representation of each variant and removes any
flanking sequence that is already represented in the reference, facilitating comparisons
between di erent variant callers. When operating on a variant graph, this process can
be generalized by aligning the variant sequence against the local graph sequence and
only incorporating bases which are not already represented in the graph. This minimizes
the amount of duplicated material in the graph and ensures that complex variants are
properly decomposed into their constituent variant bases. This representation in the
graph is referred to as "aligned alternates" (Figure 3.2.)
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Fig. 3.2 Aligned alternate representation of (A) a small deletion (B) a small insertion
and (C) a small inversion.
While the preferable representation for small variants, it presents major challenges
when working with longer or more complicated variation. Aligning complex, lengthy
alternative alleles is not always feasible or e cient. Significant increases in runtime are
seen when performing Smith-Waterman alignment between the graph and the variant
sequence. In practice, alignment of very large sequences requires significant amounts of
memory and the current implementation of vg often crashes when aligning very large
structural variant alleles.
Aligning alternate sequences produces a graph representation that does not always
obviously resemble the variant in VCF form. This is especially noticable for inversions,
which often decompose into complex intercalated runs of mismatches against the graph
backbone (Figure 3.2C). An alternative representation is to put the literal variant sequence
into the graph as-is (Figure 3.3). This representation, which I refer to as "flat alternates,"
has many advantages over aligned alternates.
Generating flat alternate graphs is e cient as no alignment is done. Variants also
clearly reflect their representation in VCF space, although inversions resemble substitution
variants and it requires further analysis to recognize the alternate sequence as the reverse
complement of the reference allele (Figure 3.3C). In a flat alternate representation every
allele is represented by at least one node, rather than some alleles being represented by
nodes and others by solely edges as in the aligned alternates representation. This greatly
simplifies working with the data structures of the graph for genotyping. It is possible to
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Fig. 3.3 Flat alternate representation of (A) a small deletion, (B) a small insertion, and
(C) a small inversion. All three variants have all of the possible alleles represented by at
least one node.
build flat alternate graphs with tens of thousands of structural variants on a personal
laptop using available approaches.
Flat alternates still have major drawbacks. Flat alternates can introduce duplicate
sequence in the graph. For deletions and insertions, the left flanking reference base is
used as the alternate allele node and the deleted sequence (plus the flanking base) is used
as the reference allele node. The single preceding base is therefore represented twice.
While this should have only a minor impact on alignment, it significantly increases the
number of nodes and edges in the graph without adding additional meaningful seqeunce.
For inversions and duplications, the entire variant sequence is represented at least
twice in the graph. When mapping reads, this causes the mapping quality for reads
aligned within the variant sequence to drop to zero, as duplicated sequence in the graph
makes it impossible to map a read unambiguously. This greatly complicates downstream
variant calling and genotyping. In addition, flat alternates often come directly from
the VCF reference and alternate allele fields. Files containing full structural variant
sequences can rapidly grow very large.
I use the term "graphical" to describe a more natural representation for structural
variants in the graph (Figure 3.4). This form combines aspects of both the flat and
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aligned alternates representations. Graphical variants are represented by at least one
node and/or edge, but care is taken during the construction process to add edges rather
than duplicating sequence in nodes. Graphical SVs only add sequence to the graph
when that sequence was not present in the reference. They also provide a clear mapping
between the VCF description and graph structures.
Fig. 3.4 Graphical alternate representation of (A) a small deletion, (B) a small insertion,
and (C) a small inversion. Graphical alternates look similar to aligned alternates for
deletions and insertions. Inversions are defined by edges rather than duplicate graph
sequence.
There are still some tradeo s that must be considered in implementations that create
graphs using this representation. Some variants (e.g. deletions) are represented only by
a single edge. This complicates the storage of paths in the graph, requiring them to be
defined by both nodes and edges. By default, vg paths are node-based, and variant alleles
that are defined only by an edge are not indexed as paths correctly. Properly indexing
these variants requires redefining paths as a series of nodes and/or edges or defining the
variants paths based on breakpoints and flanking reference nodes. Future designers of
variation graph implementations should consider this carefully. In addition, constructing
graphical alternates requires well-defined structural variant information tags (specifically
the SVTYPE and END tags) to be present in the input VCF. The VCF format was
designed primarily with small variants against the linear reference in mind, and these
SV-specific tags are not always consistently implemented across callers or well-defined in
the specification.
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Building structural variant graphs in linear time
All forms of alternate allele representation can be built in linear time with regards to the
number of breakpoints in the graph assuming that all incorporated variants are biallelic.
In practice, however, the aligned alternate representation takes significantly longer than
the other forms. I discuss why this form should be avoided for structural variation in
section 3.2.1.
I implemented an algorithm for building graphs from FASTA and VCF files in low
memory in the svaha package. This algorithm is able to construct graphs containing
deletions, insertions, inversions, and translocations. It could easily be extended to
included small variants. Graphs are output in GFA format and streamed to disk. A
similar algorithm is used in [99] and [3], although these construction algorithms do not
perform as well on large variants. An outline of the svaha graph construction procedure
follows.
Construction starts with set of structural variants V and a FASTA reference R.
Create an ordered set BPc for each contig c in R, intitializing it to contain 0 (the start
of the contig) and the last position on the contig. Initialize a map P which maps from
genomic position to variant v and a map N which maps from genomic position to node.
For each variant v ™ V , calculate the breakpoints [s, e] represented by the variant’s
position (vs) and its END (ve), CHR2, and SVTYPE info tags. Add s to BPchrom and e
to BPchr2. Store v in P at e.
Many variation graph implementations require nodes to be shorter than a certain
number of basepairs. When this is the case, perform the following. For each contig
c, retrieve its list of breakpoints BPc. Iterate from 0 to the length of the contig in
increments of the desired maximum node length, adding each of these values to BPc.
BPc now contains all of the positions on this contig where a node will start or end.
For each contig, perform the following. Create a pointer prev and initialize it to null.
This will hold the last node seen on the reference sequence. Iterate over each break b in
BPc, starting from index 1. Emit a new node node with the substring c[b, BPc[index≠1]].
Store node in N at both b and BPc[index ≠ 1]. If prev is not null, emit an edge between
prev and node. This links up contiguous reference sequences. Point prev to node. When
all breaks and all contigs have been processed the output file will contain a valid graph
of the reference sequence.
To process variants, iterate over the map P of genomic position to variant v. If b is
present in P , retrieve the variant v (which ends at b). Emit an edge from the node in N
at vs to node. If v is an inversion, this edge should point instead from node to N [vs].
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Once all contigs have been processed the output file will contain a valid graph.
Implementers must still handle interchromosomal variants so that both contigs of the
variant are constructed before the relevant nodes are queried.
The current implementation of this algorithm can construct the COSMIC graph
described in section 3.2.1 on a personal laptop with 8GB of RAM 1 in less than an hour.
This is largely limited by the write performance of the system’s disk. On a system with
a high-performance NVMe SSD2 this graph can be constructed in under ten minutes.
There is still room for improvement in this implementation. The two-pass algorithm for
construction (once over all breaks, then over all variants) described above can be reduced
to a single pass. A previous version of the program used a single-pass implementation.
This was changed to facilitate prototyping as the single-pass version requires considering
dependencies across contigs. It is also not necessary to store nodes which do not abut a
variant site; removing them from the map N could reduce the RAM usage significantly.
Certain steps in the algorithm could be parallelized as well. Generating BPc is
embarassingly parallel across contigs. Graph construction could be parallelized but with
significantly more di culty. Node IDs in the graph are coordinated by a single counter
to prevent having to properly namespace them later. However, a node ID space for each
contig could be precomputed given that the number of nodes and edges is known after
breakpoint sorting.
Using file-backed data structures could reduce the amount of RAM required to
construct graphs with svaha. I implemented file-backed random indices for sequences in
GFA files in the tinyGFA package but have not yet integrated these into svaha. Modern
SSDs have excellent random read performance compared to hard drives and have become
standard on even low-end personal computers. Integrating random-access indices reduce
RAM usage with very little cost in terms of runtime on these systems. Paths in the
graph are expensive to store in RAM and it is currently not possible to output them
in a streaming fashion to GFA format. Erik Garrison designed and I have implemented
a stream-compatible equivalent to GFA paths (the "W/Walk" line), but this is not a
standard GFA tag. With these changes it would be feasible for users without access to
high-performance or cloud computing systems to construct variation graphs in reasonable
time.
113" Apple MacBook Pro Early 2015, Intel Core i5-5287U, 8GB RAM, 512GB SSD
2Lenovo T480s, Intel Core i5-8350U, 24GB RAM, 1024GB NVMe SSD
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Dataset Variant Repre-
sentation










70 (s) 200826 296857 1,227,043
GGSV Simu-
lated Variation
flat alternates 0.32 (s) 43590 44588 1,337,866
GGSV Simu-
lated Variation
graphical 0.35 (s) 42947 43946 1,336,868
Table 3.1 Construction times and node / edge counts for graphs from simulated data.
3.2.1 Constructing structural variant graphs
I constructed graphs from a number of data sources to demonstrate the e ects of variant
representation on construction time and graph complexity.
Simulated random reference sequence
I first simulated a reference genome and associated structural variation using the ggsv
simulation package. Using truly random reference and insertion sequences ensure the
Smith-Waterman alignment process used in the aligned alternate variant representation
is able to align variants to the reference backbone and between alleles. I simulated a
reference genome 1 Mbp in length, then simulated a random assortment of approximately
1000 variants. I restricted these simulated variants to biallelic variants that do not overlap
and which are between 2 bp and 5 kbp in size. The final data set contained 327 deletions,
361 inversions, and 321 insertions of known size and sequence.
I then constructed graphs using each of the alternate allele representations for these
variants as well as constructing a graph containing only the reference sequence. All
graphs were limited to a maximum node size of 32. Because of this, even the reference
graph contains many nodes and edges despite incorporating no variation. I used vg to
perform graph construction then exported the graphs to GFA and calculated statistics
using GFAKluge. The time to construct the reference-only, flat, aligned alternates, and
graphical SV graphs as well as the number of nodes and edges in each is shown in
Table 3.1.
Constructing the reference-only graph, which has roughly 31,000 nodes and edges,
takes 0.195 seconds. The aligned alternates graph takes roughly 350 times longer to
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construct (70 seconds), and contains 200,000 nodes and almost 200,000 edges. Including
variation in flat alternate form imposes a much smaller penalty, taking only 0.32 seconds
and producing a graph that is not much larger than the reference graph and the variation
sequence. Constructing the graphical SV graph takes time comparable to the flat
alternates graph and produces a graph with roughly 600 fewer nodes and 640 fewer edges.
Constructing SV graphs in aligned alternates form rapidly becomes infeasible, and
it is hard to imagine a case where it would be the preferred representation for longer
variants. Even in a dataset without overlapping variation and using alignable sequence,
the penalty for aligning alleles against each other is apparent. In addition, the graph
contains nearly five times as many nodes/edges as the flat and graphical representations.
This has the e ect of increasing graph complexity rather than reducing it for large
variants.
The flat alternates representation contains roughly 100,000 more basepairs than
the aligned alternates representation but five times fewer nodes and edges. This is
an acceptable tradeo  as the penalty for increasing the number of basepairs in the
graph is much less than increasing the number of nodes and edges. While the single-
base reference nodes added for indel variants do not significantly impact mapping, the
duplicate sequences of inversion and duplication varaints introduced in flat alternate
representations would impact downstream mapping of reads. While it should be possible
to adjust for this type of duplication in the mapping algorithm this introduces additional
complexity.
The time required to construct the graphical SV representation is comparable to
the time to construct the flat alternate graph, imposing only a small penalty. The
graph produced is smaller in both sequence length and the number of nodes / edges. In
addition, the graphical SV representation does not require a VCF which contains the
variant sequences. The VCF used to construct the flat alternates graph was roughly
four times larger than that used to construct the graphical SV representation. While
the example used here is small and represents a best case scenario with low sequence
divergence, there is clearly an advantage to using graphical or flat alternates over aligned
representations.
The Catalog of Somatic Mutations in Cancer structural variant graph
I next performed similar construction experiments using a set of structural variants from
the Catalog of Somatic Mutations in Cancer. I downloaded the full set of structural
variants in the database (CosmicStructExport.tsv) for COSMIC v89 (hg38). I wrote
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Variants Allele Representation Nodes Edges
COSMIC reference-only (hg38) 96508420 96508444
COSMIC aligned alternates Not Feasible Not Feasible
COSMIC flat alternates Not Feasible Not Feasible
COSMIC graphical 96872672 96872477
Table 3.2 Build times and graph statistics for graphs built from structural variants in
the COSMIC database.
a python script to transform the description field of the file into a VCF record with
the proper SV tags; this is available in the COSMIC2VCF repository. The final VCF
contained roughly 288,000 variants of the original 294,270 included in the database
file, restricted to variants that are easily representable as a single event (e.g. excluding
complex events like fold-back inversions). I excluded duplications as they are not handled
well by current variation graph implementations and insertions because inserted sequence
data was not available. This left roughly 230,000 structural variants which were used to
build the graph.
Generating flat and aligned alternate representations of the COSMIC graph was not
feasible. Many of the variants in the database are large; adding the full sequences of them
to the VCF file created a file over 100 gigabytes in size. Reading this file and optionally
aligning all of these variants would have been prohibitively di cult for most users. It is
much easier to build the graphical SV representation. This graph takes roughly forty
minutes to build with vg or svaha and has 96 million nodes and edges.
Fig. 3.5 A variation graph of well-formed COSMIC deletions on chromosome 22.
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Variants Nodes Edges
hg19 (reference) 96739928 96739904
REBC (SV hypermutator) 96740200 96740343
REBC (all) 96872672 96872477
Table 3.3 Graph statistics for graphs built from structural variants in the REBC sample
set.
A structural variant graph from Chernobyl samples
To test the utility of variation graphs on real data, I constructed a graph of all structural
variant calls from our Chernobyl cohort. The calls used for construction included those
produced by any caller. In total, this set contained 86550 variants, significantly more
than our filtered set described in section 2.6. I also constructed a graph containing
variants from one of our samples with apparent chromoplexy to show that complex events
can be represented in variation graphs as long as they can be decomposed into a series of
simpler events.
I also generated a graph of the variants in the structural variant hypermutator
(Figure 3.6). This sample had multiple interchromosomal structural variants in a pattern
that resembled chromoplexy (Figure 2.35).
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Fig. 3.6 The whole genome variation graph of the SV hypermutator sample. Most
chromosomes are linear because they harbor no SVs. The chromosomes involved in
chromoplexy are condensed into a single subgraph.
Constructing the graph displayed in Figure 3.6 takes less than twenty seconds to
build on a 2015 MacBook Pro. A similar graph with nodes limited to 32 basepairs in
length takes roughly 40 minutes, roughly the same as the reference genome graph and
the pan-REBC graph with the same restriction.
Structural variant graphs
Using vg or svaha it is possible to construct structural variant graphs for simulated data,
personal genomes, and mutational catalogs. Graphs containing hundreds of thousands of
variants can be constructed on a standard personal laptop in minutes. In the following
sections, I will discuss how such graphs can be used and potential areas of improvement
in graph-based analysis.
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3.3 Typing structural variants in a variation graph
A primary benefit of graph-based representations of variation is the ability to map reads
and directly genotype variants without first going through the process of rediscovering
variants. I term this process variant typing to distinguish it from variant calling, in
which variants are discovered without a priori knowledge of their existence. While the
process cannot discover variants de novo it is significantly faster at recovering variants
which are recurrent across samples, as is common in cancer.
3.3.1 Existing approaches
Variant typing has been performed previously for both small and large variants. FreeBayes
allows force-calling of variants [210]. Many tools exist for genotyping structural variant
calls from a VCF and a matched set of mapped reads [88, 237, 86, 85]. These genotypers
often require that SV calls come from specific de novo callers, limiting the variants which
can be genotyped, and often perform poorly on insertions. Paragraph [238], a newer tool,
uses a graph-based genotyper that relies on the same graph Smith-Waterman algorithm
as [99] and performs much better on insertions.
3.3.2 Typing structural variants with vg recall
I implemented a graph-based structural variant typer, accessible via the recall sub-
command of vg. In vg, this process relies on storing the VCF variant calls as paths in
the graph. These calls may come from any variant caller which produces the standard
SVTYPE, SVLEN, and END tags. Insertion calling requires the SEQ tag or an external
FASTA file of insertion sequences.
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Fig. 3.7 An overview of the vg recall pipeline.
vg recall takes as input a VCF file of variants to genotype and a GAM alignment file
from the vg map commands. Variants must be in the graph and stored as paths to be
typed. In addition, the current implementation relies on the flat alternate representation
of SVs, though this could be extended to graphs utilizing graphical alternates if vg
supported paths that contain only edges.
The vg recall process works as follows. Iterate over the alignments in a GAM file.
For each alignment, check whether the alignment contains any nodes which correspond
to a variant in the graph path index and the VCF file. For any alignments that match a
known variant, check whether the alignment supports the reference or alternate allele
path. Each variant in the VCF is then annotated with the alignment counts for the
ref/alt alleles. The genotype likelihood formula from [239] is then used to calculate an
estimated genotype for the annotated variant alleles.
I demonstrated the performance of vg recall on a set of simulated variants from
ggsv (section 3.2.1). I compared these results to the calling and genotyping pipelines
implemented in delly [85] and lumpy [86], which uses the svtyper genotyper [239]. The
simulated variant set included deletions, insertions, and inversions Figure 3.8. vg recall
had the highest sensitivity of the three callers, correctly calling the genotypes of all
simulated homozygous alt sites.
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Fig. 3.8 Comparison of correctly-called structural variants from each caller across deletions,
insertions, and inversions. vg performs slightly better for deletions and inversions but
significantly outperforms both callers on insertions when the inserted sequence is known.
These results are for a VCF with no error in the position of variants.
In addition, the typing pipeline was much faster than the time required to call
and genotype variants using the traditional linear reference-based callers (Figure 3.9).
The mapping time however was much greater. Aligning reads to a graph introduces
additional complexity to the mapping process, and this has resulted in runtimes up to
ten times greater than for linear mappers [107]. As graph aligners become more common,
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Fig. 3.9 Runtimes of the three calling pipelines. While vg is much slower at mapping
reads, it is much fast than either DELLY or SVTYPER at genotyping variants.
In [3], we used an extended version of this approach to type variants from simulated
data as well as from The Human Genome Structural Variation Consortium (HGSVC)
[240]. This method allows variants to be typed when present in any form that can be
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represented by the snarl decomposition described in [241] (Figure 3.10A). We compared
the performance of vg to three existing SV genotypers (BayesTyper [242], DELLY [85],
and SVTYPER [239]) across variant classes (Figure 3.10B). BayesTyper is a graph-based
approach that uses exact matching of kmers across SV junctions to genotype reads while
DELLY and SVTYPER rely on alignments to a linear reference. Both graph-based
methods consistently outperformed the other tools when errors are not present; vg is
more robust to errors in variant position. At a depth of twenty reads, both graph-based
methods approach an F1 score of 1.
3.3 Typing structural variants in a variation graph 115
Fig. 3.10 Figure one reproduced from [3]. (a) vg uses read coverage information to
calculate support for an allele across a snarl in the graph. The algorithm for doing so is
described in the Methods section of the paper. (b) Performance (F1 score) at various
depths of variant genotypers for true VCF variants (left panel) and a VCF file with up to
ten bases of error in position (right panel). vg performs similarly to the best-performing
algorithm across all depths when no errors are present. When errors are present, vg
outperforms existing methods.
The HGSVC and Genome in a Bottle data used in [3] included both long reads from
short and long read platforms. Structural variants were called using ensemble methods
described in [91] and [243], respectively. The two graph-based methods again outper-
formed DELLY and SVTYPER (Figure 3.11). BayesTyper had the best overall F1 score,
although vg had comparable performance in non-repetitive regions. The performance
3.3 Typing structural variants in a variation graph 116
advantages of using a graph were consistent across all variant sizes (Figure 3.11B). The
distribution of variant sizes in the sample set is shown in Figure 3.11C.
Fig. 3.11 Figure two reproduced from [3]. We assessed the ability of each algorithm to
determine the presence of a variant (low alpha) and its genotype (solid) in both repetitive
and non-repetitive regions across simulated reads from HGSVC, real HGSVC Illumina
reads, and real Illumina reads from the Genome in a Bottle sample (a). (b) shows the
maximum F1 score for each variant class and read set across variant sizes in the genome.
(c) shows the variant size distributions in the HGSVC and Genome in a Bottle variant
calls.
Improvements are still needed to cover the full spectrum of variation. In [3] we only
extend our interrogation to variants that vary by up to ten basepairs in their position.
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While many breakpoints are recurrent in cancer samples (as shown in section 2.6, even
the most recurrent breakpoints can vary by hundreds of basepairs (Figure 2.44). Future
work should focus on being able to accurately type variants even when there is error in the
called breakpoints. In addition, the implementation in vg requires significant amounts of
RAM and requires splitting the genome into 2.5 Mbp bins. This will exclude some very
large but potentially relevant variants from analysis; it also means that interchromosomal
variants cannot yet be genotyped. Nonetheless, these results highlight the promise of
graph-based approaches in quickly and accurately genotyping recurrent variants.
3.4 Exploring detection of novel variants with graphs
In section 3.3 I demonstrate the utility of variation graphs in genotyping known structural
variants. However, this approach is restricted to variation that has been previously
discovered.
I explored several ways of calling structural variants de novo from graphs and graph-
relative alignments. Linear reference callers most often produce a VCF file which describes
variation relative to a reference genome. Section 3.4.1 describes a method for extracting
variant calls in VCF from bubbles in the graph relative to an embedded reference path.
Section 3.4.2 describes how structural variant mismapping signatures in graph alignments
could be used for structural variant calling.
3.4.1 Graph to VCF conversion
Graphs produced by alignment of long high-fidelity sequences contain bubbles that are
due mostly to variation rather than error. It is possible to call variants directly from these
without relying on aberrant read mapping signatures. Long reads also do not produce
the same signatures as short reads, as they are much more likely to span breakpoints of
even moderately-sized structural variants.
In the case that a graph contains a reference genome, or another spanning path, a
reference-relative VCF can be produced based on the bubbles within it. I implemented
this method, called graph deconstruction, in vg.
The procedure for deconstruction is as follows. Given a graph g and a reference path
P , compute a bubble decomposition of g. For each bubble, compute its bubble sides by
performing a depth-first search from the bubble’s entry vertex to its exit vertex. Test
whether any of these bubble sides are spanned by P . If so, the path formed by this
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bubble side is the reference allele. Compute the left-most coordinate in P touched by
any bubble side. This is the genomic coordinate of the VCF variant. Each alternate path
from the left-most coordinate to the next coordinate on the reference path constitutes
one allele of the variant.
Initially, deconstruction relied on a superbubbles decomposition according to [244].
A superbubble is a directed acyclic subgraph which has one entry and one exit vertex
with no edges between nodes inside the subgraph and those outside (except for the entry
and exit nodes). Deconstruct was significantly extended by Dr. Glenn Hickey, Dr. Adam
Novak, Dr. Benedict Paten, and Dr. Jordan Eizinga to utilize the snarl decomposition
described in [241]. Dr. Hickey also solved many of the scaling issues and enabled running
on whole genomes.
Deconstruct is designed for long, high-fidelity sequences such as PacBio CCS reads or
finished assemblies. Short read alignments will rarely span structural variant breakpoints
to produce a well-formed bubble. Because the total number of reads is much larger
for short read experiments than long read ones, many more paths are stored in the
graph’s path store at the same depth of sequencing. These factors make deconstruction
intractable on graphs of short reads data. Short read experiments are still common
due to their low cost and high per base accuracy, however, and a method for calling
structural variation on graphs from short reads would be an important addition to the
vg ecosystem.
3.4.2 Detection of structural variants from discordant read sig-
nals
Known structural variants that are already present in the graph can easily be typed in
short or long reads using the methods described in section 3.3. Novel variation, however,
cannot be typed and must be called de novo from the readset. While deconstruction can
call new variation, it is not practical or e ective with short read sets.
Modern structural variant callers that operate on the linear reference primarily detect
the presence of structural variation by their signatures in short read mappings.
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Fig. 3.12 (A) Simulated reads from a genome with a 1kbp deletion aligned to the HPV16
reference genome. Reads are colored by their mapping quality. Reads from the simulated
genome do not cover the deleted portion and low mapping quality reads (many of which
are soft clipped) appear at the breakpoint (B).
I implemented an analogous procedure on the graph that can extract common
structural variant signatures from graph-read alignments. This functionality is available
in the vg sift subcommand. This subcommand filters read alignments for specific
hallmarks of reads that span structural variant breakpoints. This information could be
used to produce structural putative variant calls for short read data aligned to the graph.
For each read pair in an alignment file, the pair is tested for SV signatures. This
includes whether the mates are mapped too close or far apart, whether one or both reads
are unmapped, whether either mate is soft-clipped, and whether mates are mapped in
the proper orientation. Reads are output into a separate file for each signature. This
essentially constitutes a multimap of SV signature to read pairs supporting that signature.
Soft-clipped reads can indicate that a read spans an SV breakpoint, especially if the
soft-clipped portion aligns to a distant portion of the genome. An example of this is
shown in Figure 3.12.
The soft-clipped reads extracted above could be used as the basis for de novo calling
of putative structural variants. Soft clipped reads which map near each other in the graph
can be used to stablish a putative breakpoint location. Reads that map near this position
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and which were extracted as representing possible SV signatures could then be used
to corroborate the breakpoint and establish a variant type. Lastly, a reference-relative
position would need to be generated from the putative breakpoint. The functionality for
this exists in vg but is not yet fully coordinated as an accessible framework.
3.5 Improving structural variant representations with
graphs
In the following sections, I discuss the tradeo s involved when selecting variants for
inclusion in a graph. While incorporating variants initially increases the possible sensi-
tivity of alignment, adding more variation can eventually lead to decreasing alignment
performance and increasing complexity. I then discuss a possible measure of read mapping
performance that is robust to variants that are not well-resolved in the graph. Finally, I
describe a procedure for refining breakpoints that demonstrates how the mutability of
variation graphs can be used to breakpoint-resolve structural variants.
3.5.1 Augmenting variation graphs
In vg, we rely on a process called graph augmentation to call structural variants in the
graph de novo. In graph augmentation, read alignments are compared to the graph and
any new sequence or path in the alignment is incorporated as a node or edge in the graph.
The read name and its alignment is also stored as a path in the graph’s path store.
Graph augmentation greatly increases the graph complexity, as variation and se-
quencing errors are incorporated as new graph sequence and a path is stored for each
read. Paths are expensive to store for variation graphs and this process rapidly generates
graphs that are hard to store and query. We removed the requirement that a graph be
augmented with read alignments in [3] to make typing analysess more tractable at the
cost of losing the ability to call such variants de novo.
A preferable approach would be to implement a method that maintains reads separate
from the graph. This prevents the computational complexity of operating on a graph
that contains significant amounts of incorporated read sequence. Operating out-of-graph
is analogous to how structural variants have previously been called on linear reference
genomes, where discordant signatures in read mappings are used to identify the presence
and type of structural variant.
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The error rate and total number of reads cause the computational blowup that impairs
graph augmentation. If the number of sequences to be incorporated were relatively few
and of high quality it would be feasible to operate on a graph composed of them. This is
essentially the case for graphs generated by aligning genome assemblies. Whole-genome
assembly graphs can be produced by vg, HAL [245], CACTUS [119], and seqwish. While
graph augmentation should be avoided in the case of noisy, high-error rate reads and
when many reads are present, it can be useful in cases where sequences come from
polished assemblies or high-fidelity reads.
3.5.2 Selecting variants to include in the graph
When implementing graph construction algorithms for structural variants it is important
to consider not only the choice of representation but also how specific variants impact
the graph topology. While naively one might assume that adding all possible variation
to a graph would yield the best alignment performance, this is not always the case. The
computational complexity of operating on the graph rapidly increases as more variation
is included. Runs of incorporated variants can also generate sequences that spuriously
match other regions of the graph, which can lead to decreased alignment performance.
How variants are selected for inclusion into variation graphs has been discussed
previously. We used an allele-frequency filter of 1% prevalence in the 1000 Genomes
VCF to balance graph complexity and alignment performance in [99]. As more variant
sites were added, read mappings improved at those sites when compared to the linear
reference. However, containing reference alleles sometimes received worse mappings, and
this e ect increase as more variation was added to the graph.
Algorithms operating on the graph tend to have computational complexity on the
order of nodes, edges, or paths in the graph. As more variation is included in a graph,
the number of nodes, edges, and paths can increase significantly.
Reference [102] thoroughly examined various strategies for balancing the tradeo 
between improved alignment sensitivity and increasing computational complexity when
incorporating more small variants in the graph. These models incorporated both popula-
tion frequency information and a measure of computational complexity. Alignment was
performed using HiSat2 [104] (a graph-based variation-aware aligner) or the Enhanced
Reference Genome [101], which adds alternate allele sequence to a known reference and
aligns reads to the modified linear sequence. Previous studies had relied on filtering
strategies based on allele frequency, database inclusion, or ethnicity. For most models
the best performance occurred when 8-15% of the total variants were included, though
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some models performed best when including up to 30% of variants. Significant decreases
in the percentage of reads aligned (both correctly and incorrectly) and increases in
computational complexity were seen above these levels. Only the simplest models were
able to scale to the entire human genome.
In cancer, deciding whether a variant is included in the graph requires considering
more than its allele frequency and whether it increases graph complexity. Factors such
as a variant’s penetrance or e ect on treatment can outweigh the cost of adding it to
the graph. Missing variants that significantly increase lifetime cancer risk or which can
inform personalized treatment can impose a major cost on both the patient and the
healthcare system.
Fig. 3.13 A Bandage plot of the a graph constructed from all simple COSMIC intrachro-
mosomal structural variants.
Structural variants present additional challenges when constructing graphs. Inter-
chromosomal variants are common in disease. The best practices for genome graphs
encourage parallelizing construction and indexing by disjoint subgraph, often by contig or
chromosome. Adding interchromosomal variants to the graph entangles these subgraphs
(Figure 3.14), creating a graph that is much more complicated than one containing
only intrachromosomal variants (Figure 3.13). If small variants are also included in the
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subgraphs, or if many structural variants are present, such graphs can quickly become
intractable.
Fig. 3.14 Bandage visualization of COSMIC structural variants, including interchro-
mosomal variants. Variants that have breakpoints on multiple chromosomes entangle
the subgraphs containing these chromosomes. For COSMIC structural variants, all
chromosomes become entangled into a single subgraph.
Because interchromosomal variants entangle subgraphs, I recommend not adding
them to graphs already containing significant amounts of variation. Instead, analysis
should be split across multiple graphs and a common, stable reference system (such
as the reference genome) can be used to map all variation into a common coordinate
system. As graph coordinate systems become more developed this process should become
practical [246].
3.5.3 Common coordinate systems will facilitate alignment to
multiple graphs
The naive approach to assaying the full spectrum of variants is to align reads once
to a single graph containing all variants of interest. For the reasons described in
subsection 3.5.2 this approach is suboptimal when the graph contains many complex or
adjacent variants. Common graph coordinate systems will facilitate the joint analysis
3.5 Improving structural variant representations with graphs 124
of reads mapped to di erent graphs. This means that reads from the same experiment
could be mapped to multiple graphs containing di erent variant sets and then collated
for downstream analysis.
There are notable advantages to such an approach. The majority of reads in human
resequencing experiments will exactly match the reference genome or points of common
variation. These reads do not need to be realigned further as their alignments cannot
be improved. Common variants can then be quickly typed from these alignments. This
would save significant amounts of work compared to performing alignment on a complex
graph and then variant calling the entire readset.
Reads which do not exactly match a graph of common variants may contain rare
variation, structural variant signatures, or sequencing errors. This subset of reads should
be a significantly smaller percentage of total reads than those that map perfectly. The
reason a read or pair did not exactly map can sometimes be determined by its alignment.
For example, reads which contain soft clips may fall at structural variant breakpoints
and reads with mismatches at their tail end may contain sequencing errors rather than
true polymorphisms.
This subset of reads can be aligned to more complex graphs containing variants of
interest such as one composed of known disease predisposition variants. In the case of
cancer, this may be known pathogenic germline variants (e.g. in the BRCA1/BRCA2
genes) or somatic variation from COSMIC. Reads which map to the reference allele at
these positions can be pulled from the initial alignments to support accurate genotyping.
Improved alignments combined with low-pass whole genome sequencing could one day
replace custom gene panels and microarrays in genetic testing to provide a more complete
genomic picture.
Finally, reads containing structural variant signatures can be aligned to graphs
containing structural variants of interest. While the tools for construction of graphs
and read alignment already exist, it will take the development of a stable, common
graph coordinate system and translation machinery to make the analysis described above
practical.
3.5.4 Measuring concordance between imperfect alignments and
the graph
Mapping quality and percent identity are not well-suited for assessing the quality of
alignments to graphs containing structural variants. Modern short-read sequencers
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produce reads that are 100-150bp in length, though reads from specific contexts such as
ancient samples may be as short as 30 bp. Many aligners do not produce full or proper
read alignments for short reads which span structural variant breakpoints.
One measure that I started to explore was an alignment concordance score calculated
for a pair of reads as follows:
Ca Ã ≠(S + 2P ) + E + C
where S is the total number soft-clipped bases, P is the z-normalized insert size of
the pair, E is a fixed penalty for one-end-anchored read pairs, and C is a fixed reward for
reads being on a contiguous sequence. This score is proportional to these values and not
exactly defined because it may be useful to scale it to a specific range such as PHRED
or the interval [0, 1]. Incorporating these values into a single metric allows one to more
accurately score alignments which may be perfect at the per-base level but which map
to repetitive regions of the genome as well as those that support a variant that is not
well-represented in the graph. This measure may can be combined with percent identity /
mapping quality to provide further information about how well a read or pair is mapped.
Because no graph-specific information is contained in this score it is useful as a means of
comparison to linear mappings.
For single-end or long reads, there is no information about insert size or one-end-
anchoredness. In this case information about the mapping position of the soft-clipped
portion can be used to generate a similar measure. Having a measure of graph-read
concordance that does not rely on alignment identity allows one to compare read mappings
even when reads map inexactly or variation is not represented perfectly in the graph.
3.5.5 Homogenizing breakpoints in an SV graph
As previously discussed, it is rare that structural variants reoccur at exactly the same
breakpoints. There is significant interest in determining the breakpoint-exact location
of structural variants. Regions of recurrent structural variants may constitute fragile
sites in the genome, which are susceptible to illegitimate recombination or sensitive to
break-inducing mutagens such as ionizing radiation.
The process of determining exact breakpoints from inexact locations is termed
"breakpoint refinement." Traditionally, this has been performed by local assembly, though
this approach is computationally expensive and can be confounded by microhomology,
which is common at SV breakpoints. Variation graphs can be modified to include more
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variation without losing information about the core reference. This property suggests
that a process for breakpoint refinement could easily be defined on mutable variation
graphs.
I implemented a procedure for refining breakpoints on variation graphs based on
augmenting the graph with read mappings and generating candidate alleles by realigning
graph tips, which represent possible structural variant breakpoints. I call this procedure
homogenization, as the many alleles introduced by graph augmentation are homogenized
to one or few best representations. While graph augmentation is expensive and in general
should be avoided it is particularly useful in breakpoint refinement. This process could
be improved by iteratively realigning tips, scoring alignments, and regenerating the
candidate allele set. It is possible to avoid augmentation when performing breakpoint
refinement; however, I have not implemented such an out-of-graph approach.
Breakpoint homogenization of a given variant proceeds as follows. The graph is first
augmented with a set of alignments. Alignments which are softclipped are collected. The
softclipped portions are remapped to the graph, generating a set of edges between the last
anchored portion of the read and the softclipped portion’s new alignment. These edges
are the candidate alleles of the structural variant. It is important that the soft-clipped
portion be of su cient length and uniqueness within the genome to map accurately.
Reads can then be realigned to the graph containing the newly-generated candidate
alleles.
Breakpoint homogenization su ers from many of the same challenges as assembly-
based refinement. Repetitive regions or microhomology near the breakpoint can impair
local alignment of the clipped sequence. Alignment of longer clipped portions should
be slighty more robust than deBruijn graph based assembly methods, which are highly-
sensitive to repetitive sequence, but less robust than methods relying on string or overlap
graphs. Homogenization is also computationally expensive, requiring mutliple rounds of
read alignment and graph indexing. The procedure could likely be parallelized across allele
candidates though no such implementation yet exists. Adding rounds of approximately
scoring the candidate alleles and removing low scoring ones could make the process both
more accurate and more e cient.
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3.6 Potential applications for variation graphs in can-
cer genomics
The main purpose of variation graphs is to improve sequence alignment by reducing
reference bias. Better alignments have been shown to improve downstream variant calling
and other processes that rely on accurate sequence-sequence alignment [247, 109]. While
previous work has established these e ects for small variants the same had not yet been
done for structural variants.
In this chapter I have discussed how to construct variation graphs containing structural
variation and use them to genotype variants. I also discussed potential methods for
calling novel variation and improving graph-based structural variant analysis.
There remain many areas in cancer genomics that could benefit from graph-based
analyses. Graphs composed of germline variation could improve the sensititivity of
detecting cancer predisposition variants, especially indels. Early and accurate detection
of such variants is a major goal of consumer genetic testing. While I briefly discuss a
potential method for doing so, to date there is little work in this area. Graphs may one
day function as digital gene panels, providing increased sensitivity to detect consequential
variation by algorithmic improvement rather than laboratory technique.
Somatic analysis may also benefit from graph-based approaches. vg includes many
haplotype-aware methods for alignment, variant calling and phasing. These could be
extended to create tumor-normal graphs for individuals or cohorts. Reads could then be
mapped to germline and somatic variation simultaneously. The integration of somatic
and germline variation calling into a unified framework mirrors the biological phenomena
proposed in Knudson’s two-hit hypothesis. Such joint mappings could also improve our
ability to assess tumor purity and subclonality, both of which rely on accurate allele
frequency estimates of somatic variants and the germline background.
In the special case where tumor reads from a single individual are mapped to a
graph containing private variation from that patient’s normal sample the process of
mapping reads and calling variants is directly analogous to contemporary single-sample
somatic variant calling methods. A graph coloring approach (like those used in [248]
and [118]) could be applied to indicate which nodes were incorporated from tumor or
normal variation. The addition of normal variation from other samples to the graph
is analogous to comparison of the tumor sample against a panel of normals. Graphs
generated in this manner contain both germline and somatic variation and rely on
annotations to distinguish the origin of a variant. Graph-based somatic filtering can
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then be performed based on the graph annotations and measures of read depth in the
tumor and normal. An alternative approach is to map reads from a normal sample to a
graph of patient-specific tumor variation, then perform a bubble-popping procedure to
remove any nodes supported by the normal genome but not the reference (essentially
removing the germline background from the graph). The remaining graph structures
represent a patient-specific tumor genome graph. Such graphs present the most exciting
opportunities for exploring new approaches for analyzing tumor subclonality, but creating
such structures will require new algorithms for performing the bubble-popping step and
careful tuning of variation discovery pipelines to improve sensitivity to tumor variation
while minimizing the incorporation of errors.
Lastly, graphs can play a role in better assessing repetitive elements in the genome.
Short tandem repeats (STRs) are frequently mutated in cancer, can be hallmarks of
mutations in specific DNA repair genes, and may function as driver events [249]. They
have also been implicated as possible markers of radiation exposure in both germline and
somatic cells [250, 251]. Reference [249] used global alignment to assess STR variation
in tumor genomes. A variation graph could be used to represent the reference allele,
alternate alleles, as well as established variation in these regions. Reads could then be
aligned exactly to these sequences.
Variation graphs provide demonstrated benefits for working with small variants and
structural variation. As our catalog of known variation expands there are ample oppor-
tunities to improve upon existing analytical pipelines using variation-aware algorithms
such as variation graphs.
Chapter 4
Further algorithms for examining
genetic heterogeneity
4.1 Introduction
In Chapter 3 I explored how variation graphs can improve genomic inference. Graphs
are variation-aware because they incorporate previously-observed or putative variation.
The advantages of variation graphs come from their abilities to improve read alignment
where the genome di ers from the reference.
However, graphs are not the only variation-aware data structures or algorithms. In this
chapter I explore alignment-free variation-aware algorithms. Alignment-free algorithms
perform genome inference without performing alignment, relying instead on information
theoretic methods or subsequences such as kmers or minimizers. In certain applications
this can lead to significant improvements in e ciency.
Alignment-free algorithms are considered the state-of-the-art in RNA-seq transcript
quantification [252, 253] and have been applied extensively in metagenomics [110]. In
this chapter I present a toolkit for viral coinfection analysis using MinHash. MinHash is
a kmer-based method that can calculate approximate Jaccard similarity by comparing
only a representative subset of full data. This gives it performance that is sublinear to
the total sequence length.
I developed a software package, rkmh, to calculate MinHash-based similarities and
classify individual reads. I apply this toolkit to analyze highly-similar HPV16 sequences.
HPV16 is the primary cause of cervical cancer. Specific genomic variants confer sigificantly
di erent risks for cancer progression upon infection. I first show that this toolkit is
robust to varying read lengths and error rates. The toolkit I developed is able to classify
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individual reads at the HPV16 lineage and sublineage level across multiple sequencing
technologies. Coinfections can then be detected based on the classifications of individual
reads.
I then discuss future applications of similar kmer-based approaches. I show how kmers
spanning heterozygous sites can be used to bin long reads from di erent haplotypes
before genome assembly. Kmer-based methods have been used previously to remove
duplicated portions after assembly [128, 127]. They have also been combined with trio
data to separate maternal and paternal haplotypes in assembly [254, 126]. My approach
for haplotype separation does not require sequencing the full trio but does require
orthogonal read data from both short and long read technologies. Read classification
using rkmh (including for HPV16 analysis) does not require both long and short reads;
any contemporary long or short read technology may be used alone or in combination.
4.1.1 Publication and collaboration notes
The work in section 4.2 has been published in [96]. I performed all of the analysis in this
paper with guidance and data from the other authors. I would also like to acknowledge
members of the Durbin lab (particularly Shane McCarthy, Haynes Heaton, Dengfeng
Guan, Erik Garrison, Markus Klarqvist, and Shilpa Garg) for discussions about using
this method for genome assembly. This work has not yet been published; the software is
available on https://github.com/edawson/fanthasm.
4.2 A MinHash toolkit for analyzing HPV coinfec-
tions
4.2.1 A MinHash toolkit for viral coinfection analysis
rkmh is a toolkit developed to help characterize HPV coinfections at the type and lineage
level. rkmh makes use of the MinHash locality-sensitive hashing scheme, a technique
developed for detecting similarity in webpages that has been previously applied in
metagenomics [95]. Tools are included for classifying reads and removing contaminating
sequences. A pipeline specifically for analyzing HPV16 lineage coinfections is also
included. rkmh can classify a deep-sequenced HPV16 sample in minutes on a laptop
computer. While all results here are from rkmh as applied to HPV, the tools are genome
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agnostic and could be applied to other genomes of interest and read technologies without
requiring any modifications.
4.2.2 Implementation
I developed rkmh based on methods introduced in [95], extending their algorithm to use
various filters at the per-read level which improve classification performance (described
in section 4.2.2). rkmh maintains information about type and lineage assignment on a
per-read basis to enable estimation of relative abundances in a mixed infection.
rkmh is written in C++ and is threaded with OpenMP. It is freely available under
the MIT open source software license at github.com/edawson/rkmh.
Hashing reads with rkmh
Much like Mash [95] and sourmash [255], rkmh relies on MinHash to transform reads
for similarity comparison. Briefly, the algorithm works by generating all consecutive
overlapping kmers of the read and hashing them with MurmurHash3 (Austin Appleby,
https://github.com/aappleby/smhasher) to 64-bit integers. These integers are then
sorted. A subset of size N of these hashes, usually the lowest N according to standard
numerical ordering, are then chosen as a signature or "sketch" of the read. This e ectively
represents a sample of the kmers present in a read.
MinHash is locality-sensitive at the sketch level: reads which are more similar will
share more kmers. By comparing only N integers, the number of comparisons per
reference is reduced by L ≠ k ≠ N where L is the length of the genome and k is the kmer
size.
Classifying reads
Reads are classified by first generating the MinHash sketches for the reference sequences.
A MinHash sketch is then generated for each read. All sketches use a single, fixed kmer
size k and sketch size N . Abundance and uniqueness filters are optionally applied at this
stage. Each read’s sketch is then compared to each reference sketch. The intersection of
the two sketches is calculated in O(N) time where N is the sketch size. The read is then
labeled as the reference with which the read shares the largest number of hashes.
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Filtering kmers to improve classifications of individual reads
To improve specificity I implemented a set of kmer- and read-level filters in rkmh that
are not o ered by other MinHash-based classifiers. The classify, stream, and filter
commands support four filters. The first is a floor for kmer abundance in reads (≠M).
As the reads are hashed the number of times each hash is seen is stored. Any hashes
that do not meet the threshold for abundance are then excluded from a read’s MinHash
sketch. Reference [95] implemented this filter to remove sequencing errors in sketches of
read sets. Here I have simply extended it to remove them in individual read sketches.
The second available filter is a ceiling on the number of times a hash may occur in
the reference sequence set (≠I). This filter is designed to remove repetitive kmers or
those shared among many references, making them uninformative.
I also implemented a minimum di erence filter (≠D) that flags read sketches if
the di erence between the first- and second-best classifications is less than the desired
threshold. This removes reads that cannot be given a unique classification because they
come from genomic regions shared among references. Finally, a minimum number of
shared hashes may be set so that reads that do not match well to any reference are
flagged (≠N).
Filtering reads
I initially tried assessing the performance of our type classifier on raw data but found that
its performance was very poor, with high rates of supposedly false negatives. I performed
a BLASTN [133] search on some of these reads to find that many of their top hits were
in the human genome. I implemented a filter to deal with this at the classification level.
Such a feature is also useful in filtering a FASTQ file to find only reads which come
from the organism of interest. The rkmh filter command implements the filters used
in classification to filter reads. The rkmh stream command also implements an option
for this, allowing real-time filtering of FASTQ reads during analysis.
Quantifying lineage and sublineage prevalence within a sample
Lineage and sublineage strains are di erentiated mostly by SNVs and small INDELs.
These polymorphisms alter the kmers of the sequence. If these kmers are unique among
the reference sequence they can be used as a way of quantifying the strain they define.
I implemented an exact kmer matching strategy in rkmh by removing all kmers that
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appear in multiple references. This creates a minimal sketch that contains kmers unique
to each reference sequence.
Each read is kmerized, hashed, and then compared against these reduced sketches.
Reads that match well to a given reference sketch can be used to estimate the reference
strain’s abundance in that set of reads. This process has been wrapped in the rkmh
hpv16 command. When run in the rkmh directory, all reads in a fastq file can be labeled
with their HPV type and HPV16 lineage/sublineage by running:
rkmh hpv16 -f <fastq.fq> > out.rk
The read classifications can be converted to lineage/sublineage prevalence estimates
by running:
python scripts/score_real_classification.py < out.rk > out.cls
This will produce a file that contains a single line listing the estimated lineage and
sublineage frequencies.
Run time performance of rkmh
rkmh was designed to scale to millions of reads and genomes megabases in size. Classifying
over 400,000 Ion Torrent reads against all 182 HPV type references in PAVE requires less
than one gigabyte of RAM and runs on a quad-core Intel desktop in 1 minute 16 seconds.
In general, rkmh can process around 250,000 basepairs per core-second and scales well to
increasing numbers of cores. Run times are dominated by sketch size and the number
of reads as these two parameters a ect the total number of comparisons to be made.
Memory usage is dominated by the size and number of the reference genomes, meaning
that there is not a major penalty for using long reads and that memory usage remains
relatively constant over time. I have tested rkmh on ONT minION reads from genomes
as large as 4.5 Mbp (Escherichia coli strain K-12) in under 16 GB of RAM using sketch
sizes in the tens of thousands (data not shown).
rkmh output formats
There are three main output formats produced by rkmh. The outputs of the stream
and classify commands are a tab-separated classification description similar to that
produced by [95]. This format is easily manipulated using command line tools such
as grep, cut, and sed, making analysis on any Unix system simple and portable.
Additionally, the rkmh hash command can output sketches in JSON or the vowpal-
wabbit vector format, a tab-separated format used by the vowpal-wabbit machine
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learning package [256]. The version used by rkmh needs only to be labeled with its correct
class by replacing a single sentinel string using sed. Sketches and vw-vectors may be
computed for individual reads in a FASTA/FASTQ file or for the entire file.
Generation of simulated data
To assess the performance of rkmh I generated simulated read sets of coinfected and non-
coinfected samples at known mixture proportions. I simulated reads at extremely high
depth from 62 manually-prepared HPV16 sublineage reference genomes using DWGSIM
(Nils Homer, https://github.com/nh13/DWGSIM). I set DWGSIM to create 225 basepair
reads using the Ion Torrent error profile and flow order. This produced a set of large
FASTQ files, one for each sublineage.
I generated random coinfections using the scripts at https://github.com/edawson/siminf.
Briefly, siminf randomly selects an overall coverage to simulate along with a list of
infecting strains and their relative proportion. A minimum of 5% strain abundance is
required. siminf then samples our large sublineage FASTQ files to generate a FASTQ
containing reads from the chosen sublineages in the desired proportions. Fifty of these
simulated coinfections are available in https://github.com/edawson/rkmh_sim_data.
4.2.3 HPV typing performance across sequencing technologies
is sensitive to kmer and sketch size
I assessed the HPV typing performance of rkmh on three datasets: simulated 100bp
paired end Illumina reads based on the PAVE database of HPV reference genomes [257];
a real HPV16 sample sequenced on the Ion Torrent Proton platform (typical read length
250bp); and a set of 3,660 Oxford Nanopore minION reads generated from two HPV16
reference strains (typical read length over 6500bp). The minION reads typically cover
the majority of the 7-8kb HPV genome, but have a relatively high error rate of 10% or
more, comparable to the di erence between HPV types and greater than that between
lineages (they were collected in 2015 using the R7 pore).
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Fig. 4.1 Sensitivity of rkmh with respect to sketch size (A) and kmer size (B). There are
diminishing returns to increasing sketch size above roughly 4000, regardless of read length.
(B) shows that kmers are not su ciently unique to classify reads with k Æ 10. Above
k = 18, sensitivity begins to drop, likely due to the e ects of incorporating sequencing
errors into kmers. This is especially noticeable for ONT minION reads, which have a
much higher error rate (above 12% per base for the R7.4 pore) compared to ION Torrent
and Illumina (< 0.1% per base).
MinHash-based methods depend on a “sketch" which is a characteristic subset of
kmers from a set of input sequences. Even at a low sketch size of 1000, rkmh correctly
classifies more than 99% of the short reads and more than 90% of the nanopore reads
(Figure 4.1A). As sketch size increases to 4000, per-read accuracy approaches 100% for
short reads and 96% for ONT minION reads, with negligible improvements for sketch
sizes higher than 4000. Sketch sizes below 1000 are not su ciently sensitive for classifying
HPV types, showing per-read accuracies well below 90%.
Kmer size is the main determinant of MinHash classification performance when errors
are present. For HPV type classification we find that performance is diminished above k =
18 for our Ion Torrent reads and above k = 14 for our ONT minION reads (Figure 4.1B).
This is due to the introduction of kmers containing one or more sequencing errors. The
high per-base error rate of the ONT minION R7.4 pore (12% total per base [258]) means
that as kmer size increases there is a rapid accumulation of kmers that do not match the
reference because of incorporated errors, to the extent that for some reads no diagnostic
kmer is found.
I compared the performance of rkmh to Taxonomer [259], a tool commonly used for
metagenomic classification but which is not specifically designed for viral classification.
On the set of 3,660 HPV16 minION reads, Taxonomer reported that 42.4% were of viral
origin and 8.3% were from HPV16. It also reported 1,177 bacterial reads and 304 human
reads; 398 reads were unclassified. rkmh reported 3,381 (92.4%) as HPV16. When I ran
Taxonomer on a simulated 250bp ION Torrent HPV16 coinfection data set (discussed
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further below), it reported that 29.2% of reads were HPV16, whereas rkmh reported
that 94% of reads came from HPV16. In summary, Taxonomer has substantially lower
sensitivity and specificity than rkmh for this type of data and analysis – this is not
surprising since taxonomer is a general purpose metagenomics classification tool, which
is not designed for medium to long read length viral sequence analysis.
4.2.4 Kmer pruning improves classification performance
It is possible to increase the type classification rate for minION reads by decreasing
the kmer size, at the cost of introducing false positive assignments to other HPV types.
However, this e ect can be counteracted by removing kmers that are rare in the read set
or enriching for those that distinguish between reference genomes. Such filters have been
previously applied across read sets but not for individual reads.
I call this sketch modification process "pruning" and describe the individual filters in
more detail in the section 4.2.2. Figure 4.2 shows the e ect of pruning readset kmers on
the ability of rkmh to classify Ion Torrent and minION reads. Increasing read pruning
via the M parameter has a negligible e ect on Ion Torrent reads as they have a low error
rate (<< 1%) and are relatively short; the majority of information available in them is
acquired using just the default rkmh settings. MinION reads, while possessing a higher
error rate, also possess many more kmers, meaning that dropping an erroneous kmer
from the read sketch makes room for a possibly informative one. By dropping the kmer
size from k = 16 to k = 10 and increasing the readset pruning threshold, both precision
and recall of read classification improve by roughly 2% (Figure 4.2C).





























































Fig. 4.2 Precision/recall plots for type classification of 70,000 Ion Torrent reads from an
HPV16 amplicon sequencing reaction (A) and 3,660 ONT minION reads derived from
two HPV16 isolates (B, C) at various read sketch pruning levels M indicated by the
label attached to each point. Read sketch pruning removes rare kmers in the read sketch
which might be random sequencing errors. (A, B) were classified using a kmer size of 16
and (C) was classified using a kmer size of 10. Ion Torrent reads have low substitution
error rates, so pruning removes few kmers and the precision boost is small (<0.001%)
(A). ONT minION reads have a much higher error rate approaching 10% per-base. For
minION reads, pruning is able to improve precision to roughly 99.8% when using a kmer
size of 16 (B). A smaller kmer size of 10 combined with high levels of pruning lead to an
increase in both precision and recall, with precision and recall increasing from slightly
more than 97.0% to over 99% (C).
These results demonstrate that rkmh is suitable for HPV typing. More than 90% of the
individual reads match their known correct HPV type across Ion Torrent, ONT minION,
and simulated Illumina datasets. Kmer pruning can further improve classification
performance for long, noisy reads. From these per-read classifications one can determine
the proportions of the infecting types by tallying the number of reads that support each
type.
4.2.5 Accurate read classifications enable accurate percent com-
position estimates of HPV types
I next simulated a coinfection of HPV16, 18, and 31 by combining at equal proportions
Ion Torrent reads from known samples of a single HPV type. I also examined the same
sample after removing reads which did not map to the HPV genome(s), of which there
are many (Figure 4.3A).
I summed the number of reads classified by rkmh to each HPV type with more than
5 kmers and divided each sum by the total number of reads classified to estimate the
percent prevalence. rkmh is able to detect all three HPV types, though their proportions
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are o  by 5-15% (Figure 4.3B). Most of the reads are unclassified. It is to be expected
that many of the unclassified reads may contain bits of human sequence and that our
HPV18 sample appears over-reported simply because it had the most HPV DNA of the
three. When restricting to reads that map to the HPV16, HPV18 or HPV31 genomes,
rkmh accurately classifies over 99% of the reads into the correct type at the default
settings (Figure 4.7). rkmh produces essentially perfect estimates of percent composition






























































Fig. 4.3 (A) The performance of rkmh on a simulated HPV type coinfection. Summing
the rows of this matrix gives percent prevalence estimates for each type (B).
I then applied rkmh to ten real samples amplified using a universal HPV primer
scheme, sequenced on the ION Torrent and annotated with infecting HPV types by
manual review. In eight out of the ten samples, rkmh correctly identified all of the
manually annotated types using the default parameters (k = 16, s = 1000, threshold
Ø 1% or Ø 1000 reads) (Supplementary Table 1).
The two samples where the classifications di er involved marginal decisions. For one
sample, a type that had not been previously annotated was reported with 1.4% of reads
assigned to it. For another sample a previously annotated type only received 942 reads,
just below the reporting threshold of 1000. This was still greater than 20 times more
than the next highest type (41 reads), and so could have been examined as a borderline
case without generating noise. Based on the performance of rkmh on both our simulated
set and ten real samples, we believe it is providing reliable type estimates in line with
previous annotations.
4.2.6 Classification and quantification of HPV16 lineage coin-
fections
HPV16 lineages and sublineages di er by less than 10% of L1 sequence. HPV16A
and HPV16D di er the most among HPV16’s lineages but still share more than 97%
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identity. Within the A lineage the A1, A2, A3, and A4 sublineages di er by less than 1%
(Figure 4.4). MinHash similarity estimates and nucleotide similarity are highly correlated
(r = 0.9947), but MinHash estimates show a bigger spread than nucleotide similarity
because a single base change a ects the k adjacent kmers. In essence, MinHash (and
kmer-based methods in general) exaggerate di erences between sequences, compared to
direct string comparison.
100 94.52 95.53 93.8 86.93 86.72 83.81 84.86 83.71 83.9
100 95.23 93.14 85.96 85.44 83.02 84.07 83.19 83.55
100 94.86 87.18 86.51 84.25 85.15 84.39 84.48
100 86.12 86.05 83.86 84.41 83.24 83.66
100 95.04 90.13 90.44 89.08 88.53
100 90.44 90.72 89.26 88.66











































































Fig. 4.4 Percent similarity for HPV sublineage; numbers above the diagonal are nucleotide
similarity. Numbers under the diagonal are similarity estimates based on the number of
shared hashes from rkmh .
To assess rkmh’s ability to discriminate coinfecting lineages using sketch pruning,
I simulated a coinfection of HPV16 A4 / C / D3 in a 54:26:20 ratio. The per read
performance as well as rkmh’s estimated percent composition of our sample at various
parameterizations are shown in Figure 4.5. At the default settings (i.e. the standard
MinHash algorithm, k = 16, s = 1000) there is a large amount of noise in the lineage
classifications and the estimated percent compositions are similarly a ected. Sublineage
A1 is estimated to be the dominant sublineage even though no reads from sublineage A1
are present.














































































































































































Fig. 4.5 (A) The percentage of reads from a simulated coinfection classified by rkmh to
each of the HPV16 sublineages, at default settings (k = 16, s = 1000, no pruning, no
di erence filter). Summing each row of (A), with the exception of reads that couldn’t be
classified, gives the percent prevalence estimate of each sublineage (B). (C) The percent
of reads classified to each sublineage by rkmh at pruning level M = 100 and I = 1. This
significantly improves the prevalence estimates (D).
I applied sketch pruning to remove kmers that are shared among sublineages (see
section 4.2.2 for details). At I = 1 each kmer in a reference sketch will be unique to a
single sublineage. This e ectively removes shared portions of the genome and reduces
the MinHash procedure to exact kmer matching.
Raising the pruning level to I = 1 is su cient to reduce erroneous read classifications
from approximately 30% of reads misclassified to less than 5%; this comes at the expense
of 60-90% of reads from each sublineage being removed from analysis (Figure 4.5C).
This leads to much better estimates of sublineage prevalence (Figure 4.5D). Pruning is
more e ective at removing false classifications than simply requiring a minimum number
of di erences between a read’s two best classifications (a filter implemented in other
MinHash packages) ( s = 8000, D = 20; not shown). Sketch pruning at I = 1 does not
meaningfully a ect type classification (not shown).
For the HPV16 specific workflow, I use the set di erences of sublineage hashes to
strictly remove kmers that appear across multiple sublineages. This enforces that each
kmer appears in only one sublineage sketch; this provides only a minor improvement
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over the standard pruning implementation (Figure 4.6), which is much faster. These
results are representative of repeated tests on simulated coinfections (data available at
https://github.com/edawson/rkmh_sim_data). The overall correlation between rkmh


















































































































































































































































































































Fig. 4.6 Sublineage classification of simulated reads and corresponding prevalence esti-
mates using di erent rkmh runtime parameters. (A) Per-read classification rates at the
default settings (s = 1000, k = 16, no pruning) are poor, with many o -target matches.
(B) This is reflected in the prevalence estimates, where a high proportion of sublineage A1
is reported though no A1 reads were present. (C, D) Read classifications and prevalence
estimates at (s = 8000, k = 16, I = 1 and M = 5) are significantly improved, though
still somewhat noisy. (E, F) Performance at (s = 8000, k = 16, I = 1, M = 100) is
further improved; pruning of the read sketches leads to better read classifications. (G, H)
Classifications using the hpv16 pipeline, which is equivalent (s = 8000, k = 16, I = 1, M
= 5) but using a strategy that removes all kmers shared across references, rather than
the approximate technique used by the sketch command.
I next performed a systematic analysis of the e ects of divergence, read length, and
error rate on read classification performance. I simulated three lineage references A, B, C
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with random divergence rates 0.5%, 1%, 2.5% from the HPV reference. Then I simulated
3 sublineages A1, A2, A3, B1, B2 etc. at random divergence distances 0.05%, 0.1%, 0.25%
from each of their lineage references. Then, for each reference set I simulated a million
reads, selected evenly from these sublineages for each of the following sequence mod-
els, chosen to reflect the range of di erent read lengths and error rates available in practice:
75bp 0.1% error (short Illumina)
150bp 0.5% error (long Illumina)
250bp 1% error (IonTorrent)
5000bp 10% error (long read single pass)
5000bp 1% error (long read multi-pass)
The design of three potential references at both lineage and sublineage level facilitates
evaluating false positive rates in terms of assignment to the lineage and sublineage not
present in the data, as well as sensitivity in terms of correct assignment. For reads 250bp
or longer, > 80% of reads are correctly classified to their known lineage, and pruning
could reduce false positive assignments to almost zero (Figure 4.7). We therefore expect
rkmh to produce accurate lineage quantifications for ION Torrent data.
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Fig. 4.7 Per-read lineage classification performance on di erent simulated HPV16 sub-
lineage read sets. Lineage classification performance increases with read length and
divergence. Short (75bp) Illumina reads show the worst classification performance,
likely because a read may not be long enough to capture a lineage-defining SNP (A).
Performance on 150bp reads is much better, and false-positive assignments are almost
completely removed using kmer pruning (B). For simulated 250bp ION Torrent reads,
rkmh correctly assigns over 80% of reads to their lineage at all parameter combinations
tested (C). For 5000bp reads, rkmh is 100% accurate at lineage classifications across the
spectrum of genome divergence and error rates (D, E). For 250bp and longer reads, we
expect relatively accurate quantifications of infecting lineages given that most reads are
correctly classified.
At the sublineage level, rkmh performed poorly at default parameters across read types
(as expected) but kmer pruning could reduce the false-positive sublineage assignments
to less than 0.1% of reads (Figure 4.8). Sublineage sensitivity was largely determined
by divergence from the reference, with two-fold di erences in the percentage of reads
correctly classified between 0.05% and 0.25% divergence. While this can bias estimated
proportions for sublineages, individual read classifications using kmer pruning are highly
specific, indicating that rkmh can still detect the presence or absence of sublineages based
on the presence of high-confidence read assignments.
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Fig. 4.8
Since rkmh can characterize simulated coinfections adequately, I assessed its perfor-
mance on real coinfections identified in samples from Mirabello et al. 2016 [4].







Primary Lineage 32 2 95%
Primary Sublineage 31 3 91%
Secondary Lineage 24 10 71%







Table 4.1 Performance of rkmh on samples from [4] which were manually reviewed for
their infecting sublineages and coinfection status.
In roughly 90% of real cases I examined rkmh agreed with the manually annotated
predominant infecting lineage and sublineage (Table 4.1). There was good concordance
(70% or more) with manual annotations for coinfection status, where I consider a sample
coinfected if a second lineages/sublineage is represented in at least 1% of reads. rkmh
can identify a coinfected secondary lineage with similar accuracy.
However, the performance of rkmh to identify any secondary sublineage(s) is only 35%.
Further review of samples for which rkmh did not agree with the manual annotations
indicated that many had characteristics which make them di cult or impossible to
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correctly classify. In some samples, the two dominant sublineages had frequencies that
were close to equal and rkmh correctly predicted the infecting sublineages but not their
order. When a sample possessed a sublineage not in the reference set, rkmh often predicted
the correct lineage but assigned reads evenly among the sublineages in the family. This
sometimes falsely indicated a coinfection was present at the sublineage level. Lastly, a
small proportion of samples I examined were of low coverage or quality and had no reads
that could be used for classification.
4.2.7 Pitfalls and improvements
There are various factors that can lead to biases or incompleteness in the application
of rkmh . In the unique kmer matching sketches, each sublineage is defined by between
145 and 440 unique kmers. HPV sublineages with more available unique kmers may be
more detectable, biasing results toward more divergent sublineages. It is also important
to note that the amplicon sequencing scheme used to sequence the Ion Torrent samples
does not produce consistent depth across the genome. If mutations are not randomly
distributed, and regions of diversity are not evenly sequenced, this di erence in depth
could reduce the correlation between kmer prevalence and strain prevalence.
All of the real data used in this work were produced by amplicon approaches, and so
should not include fusions with host DNA. However, if such sequences were present due
to other enrichment approaches, they might increase noise and reduce signal for some
reads. Fusions should not lead to biases, assuming multiple integration sites. Long reads
from single-molecule sequencing should provide more specific per-read classifications and
therefore better estimates of sublineage prevalence once the technology becomes cost
e cient. MinHash, while a viable method when strain prevalences are high, may not be
a viable estimator of very low-prevalence (Æ5%) coinfecting lineages and sublineages.
It can be expected that not all HPV16 sublineage isolates to perfectly match our
reference genomes as the virus continues to evolve, albeit slowly. Many of the secondary
sublineage classifications which were labeled "incorrect" may well be isolates harboring
mutations present in multiple sublineages. This highlights the fact that classifications
are only as good as the reference panel. In an early run of the pipeline, the sequence for
sublineage A2 was mistakenly left out. This had a significant impact on sensitivity for
non-A lineage reads as many reads were discarded in A2-infected samples. The upside of
this is that future domain knowledge may yield even better classifications. Accounting for
the phylogenetic nesting of sublineages within lineages can somewhat improve results in
such situations. While rkmh incorrectly labeled reads from the A2 sublineage, it was able
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to accurately label the reads as originating from the HPV16A lineage. In general, rkmh
is better able to assign lineages than sublineages because the amount of discriminating
information is greater. A postprocessing script is included in the repository for scrubbing
incorrect sublineage labels based on lineage assignments.
It should also be noted that our reference set is based on annotations that were
performed by hand in IGV and may contain mistakes and di erences in opinion. In
particular, some of the errors at the level of secondary lineage / sublineage may be
a ected by variation in reference classification. As each read is independently classified,
this may indicate that some of samples require further manual review.
With respect to possible future improvements to rkmh , Ondov et al. discuss possible
performance improvements to the MinHash scheme in [95]. Sequence Bloom Trees are
data structures that would allow MinHash sketch comparison in logarithmic rather than
linear time. This could make rkmh both more time- and energy-e cient.
An alternative to the Sequence Bloom Tree would be to use the minimizer database
described in [110] to assign genus-level labels to reads in metagenomic samples, though
the kmer sizes we use for HPV16 classification may be too small to make this sensible.
Additionally, many existing packages support pre-hashing sequences, which amortizes
the expense of this procedure over later comparisons. rkmh will implement this in a
future release. rkmh also removes the p-value defined in [95], which becomes harder to
interpret on a per-read basis and which is a ected in complex ways by the various filters
in rkmh .
Several modifications to the sketching procedure might improve classification per-
formance. Skip-grams (kmers generated from genomic substrings length k2 separated
by a small, fixed distance) would improve classification if genomes share rearrangement
patterns. Using minimizers, where sketches are composed of hashes sampled from rolling
genomic windows (rather than randomly sampling the entire sequence as in MinHash)
would provide more even coverage of the reference sequences, possibly improving the
chances of a read matching. Dynamic sketch sizes based on the length of the query
sequence (rather than a fixed sketch size) might provide a slight improvement in runtime.
Classification might be improved by introducing machine learning techniques trained on
full sketches, as the current supervised approach may overlook cryptic but important
features. Finally, improvements in data quality from long, high-fidelity reads should
yield a large improvement in results when such data becomes available, and could be
instrumental in advancing scientific inquiry and eventually developing e ective public
health measures to address HPV infection.
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4.2.8 Summary and future directions
HPV is a common sexually-transmitted agent, and a small subset of HPV infections
become chronic and can lead to cervical, anogenital or oropharyngeal cancer. Twelve
of at least 170 known HPV viral types are currently associated with cancer risk, and
sublineages within these carcinogenic types are further associated with variable risks.
Confounding proper classification of HPV infections is the prevalence of multiple
types, lineages, and sublineages in individual infections. Thus, the accurate detection of
HPV types, as well as HPV16 lineages and sublineages, could have important pleiotropic
implications for public health measures.
I developed a computational toolkit to classify coinfected HPV samples, as in [4]. This
method, rkmh, is a collection of tools that addresses some of the challenges associated
with analyzing mixtures of biological sequences.
To implement rkmh I extended existing work utilizing the MinHash locality-sensitive
hashing scheme [95], resulting in a tool that provides accurate classifications of individual
reads. Accurate classification of the infecting viral types, lineages and sublineages is
critical given the vast di erences in disease risk between HPV types and even closely
related HPV16 sublineages. The toolset demonstrates that accurate classification of
individual reads and estimation of type and lineage prevalence is possible with current
sequencing practices, but that sensitive sublineage detection may require improvements
in technique.
While applied here to HPV, rkmh could be used in any context where quantification of
specific sequences within a mixture and selection for or removal of such sequences might
be useful. MinHash has previously been applied to larger metagenomic datasets with
striking success. Ondov et al. demonstrate MinHash’s ability to work on genomes several
megabases in size and scale to billions of reads in [95]. Other viruses show significantly
more intra-host variation than HPV; notably, Human Immunodeficiency Virus (HIV)
evolves during infection and in response to treatment [260]. Zika and Ebola are urgent
public health threats, have been shown to evolve over the course of outbreaks, and have
been successfully sequenced in the field on the ONT minION [261–263]. The ability
to generate per-read classifications using rkmh on a standard laptop could be a useful
addition to the current pipelines employed by these studies. Lightweight algorithms such
as rkmh may also be of interest in areas with strict computing power limitations such as
space genomics or developing nations.
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4.3 Potential frontiers for lightweight algorithms and
long reads
Reference [252] provides a clear definition of lightweight algorithms as those that use
data sparingly, consider and attempt to reduce constant factors in algorithmic com-
plexity, and utilize parallel computing hardware e ectively. rkmh is able to deconvolute
individual reads from HPV16 coinfections because the core algorithms are aware of
lineage-distinguishing variants a priori. As only 1-2% of the genome is su cient to
distinguish subtypes, the total amount of information that must be processed is signifi-
cantly reduced compared to performing alignment. From individual read classifications,
a picture of the overall mixture of many components can be gleaned. Kmers are selected
for HPV16 classifications based upon their uniqueness across strains. The same approach
used in rkmh has potential applications in the field of genome assembly, especially in the
separation of reads from di erent haplotypes.
4.3.1 Separating haplotypes for individual assembly using kmer
methods
There are strong similarities between genome assembly and metagenomic classification.
Reads which are much shorter than the chromosomes are mixed together and must be
separated to reconstruct the original genomic sequence. The extra overlap information
contained in long reads is useful in both.
Linear references are haploid, but most eukaryotes have a ploidy of at least two. For
most non-asexual organisms, each copy of the genome will di er from the other due
to mutations accumulated since their last common ancestor. For humans, this percent
di erence (i.e., the heterozygosity rate) is approximately 0.1, meaning that on average
every 1000 basepairs there is a single di erence in the genome.
To produce a haploid reference assembly the two (or more) slightly di erent haplotypic
sequences should be separated.
However, assembly algorithms typically merge haplotypes together. When they do this
they can arbitrarily switch between haplotypes (i.e., incorrectly phase the haplotypes),
or, if the haplotypes are su ciently di erent, incorporate them both into the primary
assembly as duplicate sequence. This e ectively introduces repetitive structures with
minor variations into the reference where none are present. It can also greatly increase
the size of the final assembly.
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Unique kmers which span heterozygous sites in the genome are present at one-half
the frequency of kmers which span homozygous sites because one kmer comes from each
of the two alleles. We can extract kmers that span heterozygous sites then by counting
all kmers in the genome and selecting those which are present at a frequency 12 of the
homozygous frequency. This approach is analogous to the one used in [254] to bin reads
by parental haplotype; their approach required data from both parents, however, which
is not always available.
Fig. 4.9 Kmer frequency spectra from GenomeScope for deep Illumina data of a Heliconius
sara specimen. (A) Raw frequencies show the two clear frequency peaks of kmers at
heterozygous (app. 100X) and homozygous (app. 200X) sites. (B) Shows the same data
with log-transformed frequencies, showing that kmers below approximately 50X are likely
due to errors.
We examined the kmer spectra of deep Illumina reads from a Heliconius sara specimen,
a butterfly that lacks a reference genome and for which we did not have parental sequencing
data (Figure 4.9). Heliconius sara has an estimated heterozygosity rate of 1.73%, nearly
twenty times that in humans. A clear kmer frequency peak is seen at 200X, representing
kmers spanning homozygous regions, and another peak is seen at 100X (kmers spanning
heterozygous sites).
To generate normalized representative kmers of heterozygous sites, we assembled
unitigs for 21-mers with a frequency between 50X and 150X using BCALM2 [264]. Kmer
frequencies were calculated with jellyfish [265]. For any heterozygous site, there will
be two separate unitigs, one containing each of the two alleles. Any heterozygous sites
within 21bp of each other will be merged into a single pair of unitigs.
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I next labeled a deep PacBio read set with these unitigs using fanthasm. fanthasm
takes a file containing unitigs and a set of PacBio reads. Unitigs are stored in a map of
their constituent 21-mers (hashed to an integer) to the unitig identifier. Each read is then
kmerized, hashed, and labeled with any unitigs with which it shares kmers. A MinHash
sketch of each read is produced as well since the sorted list of kmer hashes is required
for the heterozygous kmer search. MinHash has been used previously for pre-assembly
overlapping of reads in MashMap [134]. Manual review of several of the longest reads
showed that they contained mutually exclusive heterozygous unitigs. Ideally, reads would
next be examined for overlap by MinHash and haplotype of origin by heterozygous unitigs
before being assembled, however I did not implement these processes.
4.3.2 Assembly of individual tumor subclones
We are able to locate putative haplotig-defining kmers in the Heliconius sara genome
because they are present at an allele fraction of fifty percent. This makes sentinel kmers
for heterozygous sites observable as a lower-peaked distribution in Figure 4.9. Tumors
often have a more complex allele frequency spectra confounded by alternative ploidies,
loss of heterozygosity, and heterogeneity in the form of subclonal mutations and normal
cell contamination.
Reference [46] demonstrated the ability to detect subclones in tumor samples by ultra-
deep (300X) whole genome sequencing using the SciClone algorithm [266]. This algorithm
was initially validated on a 188X whole genome sequenced multiple myeloma sample.
Such sequencing is financially impractical but demonstrates that it is possible to partition
subclonal mutations by variant allele frequency. A list of such mutations, combined with
long reads from the tumor, should be su cient to generate kmer frequencies and unitigs
to partition long reads by tumor subclone as was performed in subsection 4.3.1.
4.3.3 Point-of-care testing
A major advantage of both alignment-free and variant-aware algorithms is their speed.
Because much less information needs to be processed, relevant results are available more
quickly. These algorithms tend to also make e cient use of computational hardware. In
the case of rkmh , as little as 1% of the genome is su cient to classify HPV sublineages.
The data structures necessary to perform classification can fit in well under one Gigabyte
of RAM.
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There were two primary datasets that motivated the development of rkmh . The first
was a large sample set of over 200,000 Pap smear samples, some of which we examined
in [96]. While we have not yet applied rkmh to the full dataset we did calculate read
classifications for 700 of these samples and 2,000 in-silico simulated coinfections (data
not shown). In general, rkmh can classify a single sample using one core in less than
five minutes. This reduced the estimated cost of analyzing these samples significantly
compared to the existing pipline, making processing of all 200,000 feasible and a ordable.
The second dataset was the National Cancer Institute’s HPV vaccination and point-of-
care testing initiatives in Costa Rica. While there are still many steps before clinical
sequencing of HPV infections is routine, rkmh could provide real-time o ine analysis at
point of care in this setting.
4.3.4 Lightweight algorithms improve analysis
References [267] and [252] revolutionized RNA sequencing analysis by greatly reducing
the cost of the associated bioinformatics using lightweight algorithms. Combined with a
drop in sequencing cost, this has greatly expanded the number of labs that can a ord to
sequence large numbers of samples. Sequencing has become increasingly portable as well,
enabling applications such as real-time Ebola and Zika outbreak observation [268, 269].
As our catalog of known variation and reference-quality assemblies grows, these tools
will further improve. Improvements in DNA sequencing analysis are following similar
patterns. Reference [267] uses pseudoalignment of RNA reads to a transcriptome de
Bruijn graph. vg and [98] provide graph-based alignment of reads to graph genomes for
DNA. Alignment of DNA sequencing reads has long relied on sparse seeds, and research
into better seeding strategies is ongoing. MiniMap2 [270] uses a seeding index based
on minimizers (rather than maximal exact matches as in [271]) to align both long and
short reads in much less time and with comparable accuracy to previous approaches.
These approaches are being actively explored for graph alignment as well (Jouni Síren
and the vgteam, github). The application of lightweight principles to graph genome
implementations will make these approaches practical, greatly expanding our ability to
interrogate genomic variation using more sensitive approaches.
Chapter 5
Conclusions
In this thesis, I describe an analysis of several hundred radiation-exposed tumors from
the Chernobyl Tissue Bank (CTB). I also present new tools for variation-aware analysis
using graphs and lightweight algorithms. Such algorithms can improve both the speed
and sensitivity with which we find variants by incorporating information from previous
studies.
Tumors from the Chernobyl Tissue Bank show dose-dependent signs of radiation
exposure in their genomes. Erroneous repair of radiation-induced double strand breaks
leads to an excess of small deletions and large, balanced inversions and translocations.
These findings are significant in that they describe a genomic marker for radiation
exposure as well as evidence for the mechanism by which 131I exposure increases the risk
of thyroid cancer development.
These tumors are driven exclusively by activating mutations in genes involved in the
MAPK signaling pathway, highlighting its role in thyroid tumorigenesis. Genes essential
to normal thyroid function (TG and TSHR) are mutated above background frequency
but only occur in the presence of mutations in MAPK. The number of gene fusion
driven tumors increases with increasing exposure to radiation. The genes involved in
these fusions are MAPK signaling genes (especially RET ) which become constitutively
active. Fusion breakpoints are highly recurrent. This is most likely attributable to the
need for these fusions to preserve specific domains in the fusion product. RET fusions
always begin at the eleventh exon because they must preserve the kinase domain to be
functional.
While we will always require algorithms that can find novel variants, we can save
significant amounts of time by utilizing variation aware algorithms. This is especially true
when we are interested in specific variants such as driver mutations or the lineage-defining
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sites of HPV16. In the CTB dataset, just five mutations — BRAF V 600E, RET -CCDC6,
ETV 6-NTRK3, NRASQ61R, and HRASQ61R — account for 67% of the driver mutations
found, with BRAF V 600E alone acting as the primary driver in 47% of tumors. Combining
low-pass sequencing and variation-aware algorithms in a digital gene panel may one day
provide sensitive genotyping at lower cost and with less bias than current state-of-the-art
targeted sequencing approaches.
Genome graphs provide a powerful variation-aware implementation for genotyping
both small and large variants. Graph-based approaches consistently outperform structural
variant genotypers which rely on the linear reference. Their supremacy in genotyping
inversions makes them especially promising in cancer genome analysis. Though such
variants are rare in the general population they are common and clinically important in
cancer, particuarly radiation-associated papillary thyroid carcinoma cases.
vg provides methods for calling structural variants de novo, but such approaches
are still nascent. Graph deconstruction and snarl-based variant calling have relied on
augmenting the graph with reads, though there is active work to remove this limitation.
In subsection 3.4.2 I describe methods for locating structural variant signatures in reads
mapped to a graph. I hope that these approaches will enable development of downstream
variant callers analogous to those developed a decade ago for linear reference alignments.
With further development, breakpoint homogenization may be used to further refine
these calls. Graphs hold significant promise to improve our knowledge of structural
variation in healthy and morbid populations.
While our variant calling pipelines used in analyzing the CTB samples should benefit
from the application of graph-based regenotyping, doing so is prohibitively expensive with
current techniques. Many studies have avoided realigning to updated linear references for
this reason, and read-to-graph alignment currently takes 3-5 times as long as alignment
to a linear reference. As graph alignment algorithms continue to improve it will become
a ordable to reanalyze our data. I describe areas for improvement in graph-based
structural variant calling and genotyping in Chapter 3, but even with these changes
alignment will remain the most expensive operation. Improvements in alignment speed
will be necessary to make graph-based analysis routine, and research in this area is highly
active.
MinHash and other lightweight algorithms can significantly speed up specific tasks and
reduce costs. Sparse seeds, particularly minimizers, are used extensively in alignment and
are one method being explored for improving graph-based alignment. I show in Chapter
4 how a MinHash-based toolkit for viral analysis improved HPV16 coinfection detection
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while simultaneously making analysis practical on any modern compute hardware. This
approach generalizes well to data from other species, new reference panels, and reads
from many modern sequencing platforms. Adaptations may one day be useful in genome
assembly and analysis of subclonal architecture.
Both graph genomes and the MinHash toolkit rkmh are examples of variation-aware
algorithms. These have been applied extensively in population studies but much less often
in cancer genomics. Notable exceptions to this generalization include the extensive use of
previously-observed mutations for annotation and the use of panel-of-normals filtering to
remove germline and passenger mutations from somatic variant calls. In this thesis I have
demonstrated the power of variation-aware algorithms, both graph- and MinHash-based,
for structural variant genotyping and HPV16 coinfection analysis. However many more
applications can be imagined, some of which I have described in Chapters 3 and 4. The
recurrent nature of mutations in cancer and the relatively small number of mutations
of interest (compared to the total number often analyzed in population studies) make
variation-aware approaches especially promising for cancer genome analysis. This is
especially important as study sizes approach two orders of magnitude larger size than
those of just a decade ago. The use of lightweight, variation-aware algorithms will help
bring genomics into the era of million-genome studies and provide invaluable insights
into human genetics and disease.
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